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ABSTRACT 
In a comparative evaluation of several techniques, c:; mmercial 
modifications of equilibrium dialysis and uLtrafiltration were found to give 
satisfactory values of ligand binding to albumin. However, continuous 
ultrafiltration yielded anomalously high estimates of binding. The fluorescent 
probe properties of warfarin and phenprocoumon were found to be useful for 
examination of the drugs' binding sites and particularly suitable for the 
monitoring of Llgand competition for albumin binding. 
Bovine Serum Albumin binding of medium chain fatty. - acids was Investigated 
using ultrafiltration and computerised analysis of experimental data. The 
primary association constants increased smoothly, with chain length, up to 
heptanoate but the step to eight carbons was found to produce a particularly 
large increase in affinity. A model based upon two piimary, chain length 
specific, fatty acid binding sites is proposed. Other --ý! -ýservations s+_; ggest 
that a 'break point' at eight carbons may be a common feature of alkyl chain 
Interactions with macromolecules. Thermodynamic d&: -i suggests tha,: both 
electrostatic and hydrophobic bonding is involved in primary fatty acid 
complexes with albumin. Secondary binding increased linearly with chain 
length and was suggested to be purely hydrophobic in nature. The primary 
fatty acid binding sites on albumin have been shown to be dissimilar to those 
for coumarins and for carbamates whilst all of the Ligands share some 
secondary sites. 
Circular dichroism studies of a series of coumarin drugs has shown that 
they bind to album ins at the same sites, but in differ ing orientations. 
Lipophilicity was shown to be an important determinant of binding affinity, but 
ionic interactions seemed to be of little importance . Albumin binding of 
phenprocoumon and warfarin enantiomers was examined by dialysis and 
spectroscopic methods. The isomers were h . und differently to albumin 
which was thought to be due to the spatial relationships of the coumarin rings 
and sidegroups to the binding sites. Bovine and Human albumins showed 
disparate stereos pec if ic ities for the coumarin drugs. 
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CHAPTER ONE 
AN INTRODUCTION TO DRUG-PROTEIN INTERACTIONS 
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1: 1 FOREWORDS 
1: 1: 1 BIOPOLYMER-SMALL MOLECULE INTERACTIONS 
In living systems, biopolymer-small molecule interactions are 
ubiquitous and are of paramount importance to innumerable biological 
reactions. Such interactions cover the whole field of biology, ranging 
from the mechanisms of respiration through the action of receptors and 
repressors, the combination of enzyme and substrate to the subtle influence 
of electrolytes on proteins. 
The discipline of Pharmacology is one which is inevitably, deeply 
concerned with the interaction of active small molecule:; with biopolymers . 
It was in the early years of the twentieth century that Ehrlich (1909) first 
proposed that drugs must combine with tissue constituents in order to 
exert any profound influence upon body function. The study of those 
macromolecules with which a drug Interacts to produce its characteristic 
biological effects, the receptors, is therefore at the heat of Pharmacology. 
Not only is a drug-receptor protein interaction necessary for the 
manifestation of pharmacological activity, but the combination of drugs 
with other tissue and plasma proteins profoundly influences the drug's 
fate in the body. It is to be hoped that studies of drug-protein interactions 
which have direct relevance in Pharmacology may also hold some relevant 
information for the wider field of small molecule-biopolymer interactions. 
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1: 1: 2 DRUG-PLASMA PROTEIN INTERACTIONS 
Blood is the medium by which drugs are transported ir: twoen the 
site of administration and their sites of action, metabolism and excretion. 
Drugs are carried either as free solution or suspension in the plasma 
water or bound to one of the components of blood. It is a fundamental, 
and often tacit, assumption, in all plasma binding studies, that lt is 
only the free portion of drug which is able to exert a pharmacological 
effect or is available for metabolism and excretion. The inter-relation- 
ship of free and bound drug with these processes may be illustrated as 
in figure 1: 1. 
Modern study of plasma binding was, perhaps, initiated by Benhold 
(1938) who suggested that plasma proteins had the function of transporting 
small molecules around the body. Whilst it is difficult to visualise the 
plasma proteins as a regimented or regulated transport system, they never- 
theless do combine with a remarkable number of xenobiotic and natural 
substances. Goldstein's excellent review of 1949 served to emphasise 
the growing realisation of the importance of drug-plasma protein interactions. 
The increased interest in such Interactions since that time Is reflected In 
the amount of research published in the field, and a tabular presentation 
of all available data, such as Goldstein (1949) and later Meyer and Guttman 
(1968) provided, would now produce a most weighty volume. It is beyond 
the scope of a treatise such as this to consider more than a mere fraction 
of the information available to date, however several good reviews have 
been published, in addition to the two already mentioned, which cover most 
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Figure 1: 1 The Fate of a Drug in the Body 
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aspects of drug-plasma protein interactions; Scatchard (1949), Brodie and 
Hogben (1957), Thorp (1964), Brodie (1965), Desgrez and De Traverse 
(1966), Goldstein et al. (1968), Kreiglstein (1969), Sett: Ir:: et al. (1971), 
Davison (1971), Westphal and Knoefel (1972), Anton and Solomon (1973), 
Steinhardtand Reynolds (1969), Wilson (1974), Bridges and Wilson (1976) 
and Sellers and Koch-Wesser (1976a, b). 
It Is Important to realise that the plasma proteins are most important 
In the binding of endogenous substances as well as drugs. Often the 
term drug-protein could equally well be anutrient-protein or endogenous 
molecule-protein, however the phrase will be used throughout this work, 
rather than , some more cumbersome 
term, with the rtýalisation that 
the ligand involved need not necessarily be a pharmacologically active 
agent. 
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1: 2 BLOOD COMPONENTS 
1: 2: 1 INTRODUCTION 
Blood is a complex mixture of proteins and cells, with a diversity in 
structure as manifold as their diversity in-function. Excluding peptide 
hormones, erythrocytes and other cellular components, and tissue derived 
enzymes, plasma contains more than one hundred distinct proteins. With 
the exception of serum albumin only brief mention will be made of the 
constituents of blood where there is relevance to the binding of drugs. 
Further information on the structure and function of blood components can 
be obtained from the following articles: Putnam (19LLO) , Neurath 
(1965), 
Schultze and Heremans (1966), Turner and Hutme (1971), Rothschild and 
Waldman (1970), Scanu and Wisdan (1972), Putnam (1975). 
1: 2: 2 BLOOD CELLS 
Human blood contains some 2- 20 x 1012 cells.. litre-l (Bennhold, 
1966) comprising erythrocytes, platelets and the various leukocytes. 
Platelets are known to accumulate monoamines, a phenomenon which 
can be inhibited by phenothiazines and tricyclic antidepressants (Ahtee, et al., 
1974), but otherwise little is known of the binding of compounds to 
platelets or leukocytes. Relatively few drugs are known to bind 
significantly to erythrocytes, and whilst such an interaction may be 
important in these specific cases it is generally considered to contribute 
Little to the total blood binding. The lack of binding may simply be due 
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to the far smaller surface area presented by erythrocytes: 3,200 m2 in 
the blood of an adult man compared to 130,000 - 725,000 º-1i2 for the 
plasma proteins (Bernhold, 1966). Compounds which have been reported 
to bind to the erythrocytes of various species Include: promazine and 
chlorpromazine (Jähnchen et al., 1971; Girl and Peoples, 1975; Manian 
at at., 1974), pentazocine (Ehrnebo et A[., 1974), steroids (Brinkman and 
van der MoLen, 1972), sulphonamides (Maren, 1967), salicylate and pheno- 
barbital (McArthur et al ., 1971) and Phenprocoumon (Neider et al. , 1975). 
Cruze and Meyer (1976) recently reported the binding of salicylate to bovine 
erythrocytes and the effects of haemolysis upon binding. 
1: 2: 3 GLOBU LINS, LIPOPROTEINS AND OTHER NON-ALBU MIN PLASMA 
PROTEINS 
A List of some of the major non-albumin plasma proteins is presented 
In Table 1: 1 . 
Thyroxin Binding Pre Albumin (TBPA) is the first pta iia protein for 
which the complete amino acid sequence (Kanda et al., 1974) and three 
dimensional structure (Blake et al., 1974) were elucidated. One molecule 
of TBPA binds one motecu[e of Retinol Binding Protein (RBV), the vitamin A 
carrier of plasma, as well as combining with thyroxine . Thyroxine 
Binding Globulin (TBG) and albumin are the other carriers of thyroxine in 
plasma. 
Lauren (1960) has reviewed the metal binding proteins, including 
Ceruloplasmin which binds more than 90% of plasma copper (Poulik and 
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Table 1: 1 Some parameters of the major non-albumin plasma proteins 
from human plasma* 
Protein Molecular 
weight 
Amount in 
plasma 
mg/100 mi 
Substances 
transported 
(if any) 
Prea lbum in (thyroxin 54 ,9 80 10-40 Thyroxin, retino l binding) binding protein 
al Globulins: - 
Retinol binding protein 21,000 3-6 RetinoL (vitamin 
A) 
aI acid glycoprotein 40,000 55-140 - 
Transcortin 55,700 7 Steroid hormones 
a1 antitrypsin 54,000 200-400 - 
Transcobalbumin ? ? Vitamin B12 
a2 Globulins: - 
Ceruloplasmin 151,000 15-60 Copper 
HaptogLobtn 100,000-400,000 100-300 Hemoglobin 
a2 Macrog lobu I in 725,000 150-420 Hormones 
Thyroxine Binding 58,000 1-2 Thyroxin 
globulin 
ß Globulins: - 
Hemopexin 57,000 50-100 Haem 
Transferrin 76,500 200-320 Iron 
Complement system 86,000-400,000 1-160 - 
Immunoglobulins 160,000 and above Up to 1800 Antigens (drugs? ) 
lipoprotein a +a 1 .5x 106 to Variable Phospholipid, fatty 1 2 ß lipoprotein greater than acid, cholesterol 8 4x 10 + ester 
Coagulation proteins various Up to 450 - 
*Data taken from Putnam 1975. 
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Weiss, 1975), and Transferrin the specific iron binding protein of plasma 
(Putnam, 1975). A great deal of literature is available concerning the 
binding of corticosteroids to plasma proteins, much of which has been 
reviewed by Westphal (1971) including the roles of Transcortin and 
Corticosteroid Binding Globulin (CBG). Transcobalbumin is a minor 
plasma protein with high affinity for vitamin B12 (Hippe and Olsen, 1971), 
the binding of other vitamins to plasma proteins has been reviewed by 
Raoul (1966) . 
Haptoglobin and Hemopexin bind, in equimolar stoichiometry, hemo- 
globin and heure respectively (Jayle, 1962; Aisen, 1975) and together with 
Transferrin form a triumvirate of proteins Involved In the conservation of 
hemoglobin and its metabolites. 
The plasma lipoproteins form an extremely heterogen:; ous group of 
proteins, compiexed in variable proportions with lipid atid carbohydrate. 
The majority of plasma lipid, in the form of mono, di and triglycerides, 
phospholipids, cholesterol and cholesterol esters is transported in complex 
with lipoproteins (Scanu et al., 1975). Under conditions of high plasma 
free fatty acid concentrations these also may be carried in association with 
lipoprotein (Mora, et a[. , 1955; Po lonovski, 1966). hilirubin and prosta- 
glandins, normally associated with albumin in plasma, can combine with 
lipoproteins at high ligand concentrations (Cooke and Roberts, 1969; Raz, 
1972). The drugs tetra hydrocannab ino I (Wahlquist et al., 1970; Widman et al., 
1973) and recently quinidine (Nilsen , 1976) have been reported to bind to a 
small degree to plasma lipoprotein. 
The proteins of the complement and coagulation systems have not been 
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reported to interact with drugs, and whilst the same can be said of the 
immunoglobulins it is important to realise that drugs may act as haptens 
or even antigens resulting in the production of specific antibodies capable 
of binding avidly to the drug. This is a possibility which is often Ignored 
In drug binding studies. 
1: 2: 4 ALBUMIN - GENERAL ASPECTS 
Albumin is the most plentiful of the plasma proteins, accounting for 
more than 50% of total protein in human plasma. It is the principle agent 
responsible for the osmotic pressure of blood and for the sequestration and 
transport of many endogenous compounds: fatty acids, bitirubin, amino 
acids, various hormones etc. etc. The concentration of albumin In plasma 
is generally a good measure of health, or as Peters (1975) has it; "Happiness 
is a normal albumin level". 
The ability of albumin to enter into reversible combination with an 
enormous range of compounds with differing chemical structure and physical 
characteristics is unrivalled throughout all biological systems. The relative 
ease of Isolation and purification of albumin, coupled with the fact that lt 
makes the predominant contribution to plasma binding for the majority of 
drugs has made it particularly suitable and popular for use in studies of 
drug-plasma binding and as a model for general ligand-protein interactions. 
The literature on albumin is so extensive as to have promoted several 
reviews, those of Foster (1960), Putnam (1965) and Peters (1975) concern 
mainly structural aspects whilst the biosynthesis, metabolism and physio- 
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Logical role of albumin have been covered by Anker (1960); Burke (1969); 
Rothschild and Waldman (1970) and Peters (1970). Most. of the next 
three sections will be concerned with Human Serum Albumin (HSA, syn. 
Human Plasma Albumin, HPA) with reference to other albumins, particularly 
that of the major commercial source, the cow; Bovine Serum Albumin (BSA), 
where pertinent. 
The figures 35g. 1- 1 to 45 -1 g. l (Marks, 1972) are now generally 
accepted as the limits of albumin concentration in the plasma of normal, 
healthy male adults, giving a total intravascular mass of about 140 g 
for a 75 kg man. Intravascular albumin accounts for oaLy 30% to 40% of 
total body albumin and is In continuous, free exchange with other body 
fluids. The half Life of albumin in the body is about J days, with a 
turnover of about 14 g. da -I y (Schulze and Heremans, 1966; Peters, 1970). 
The liver is the major site of synthesis, with the thyroid gland producing 
minor quantities (Rothschild et at., 1972). Catabolism seems to be a 
general phenomenon, being faster in organs of high metcibolic rate such 
as liver, kidney, spleen and lymph nodes. Muscle, however, with its 
large mass, contributes much to the overall rate (Hawkhis, 1961; 
MacFarlane, 1963). Changes In albumin levels with acre and disease, 
and the influence upon plasma protein binding will be discussed in a later 
section. The plasma concentration of albumin is subject to some diurnal 
variations, mainly under the influence of the nutritional status, exercise 
and posture. 
It has already been mentioned that albumin may be a useful model 
to mirror general ligand-protein or enzyme-substrate interactions, but it 
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is not generally appreciated that albumin may actually have some inherent 
enzymatic activity. Most enzymatic activity associated with albumin 
preparations can be removed by rigorous purification, such activities include 
acid protease (Wilson and Foster, 1971); nuclease (Arai et al., 1972) and 
phospholipase (Eisbach and Pettis, 1973). However purified albumin has 
been reported to catalyse the breakdown of ferrihaems (Brown et at., 
1974); the Messenheimer complex (Taylor and Chau, 1975); S-lauroyl- 
mercaptoethanol (Kurooka and Yoshimura, 1973); p-nitrophenyt acetate 
(Titdon and Ogilvie, 1972) and several other esters (see previous citation 
for references). Additionally, albumin is thought to possess some thyroid 
hormone synthesising ability (Thomas-Morvan, 1976) and has been reported 
to catalyse the oxidative dimerisation of a synthetic derivative of trinitro- 
benzene (Chavez and Benjamin, 1975). The significance of such catalytic 
activities is at present unknown, but the phenomena must merit further 
study. 
1: 2: 5 ALBUMIN - STRUCTURE 
Serum albumin is a simple protein, being a polypeptide chain of about 
580 residues, with small interspecies variations. It is alone among the 
plasma proteins in having no associated carbohydrate, a criterion which is 
used to demonstrate its purity (Cohn, 1947). The molecular weights of 
albumins have been variously reported to be between 66,000 and 69,000. 
The molecular weight of HSA, calculated from the amino acid composition 
Is 66,500 (Meloun et al. , 1975), the best estimate from physical measure- 
ments is 66,700 obtained using the ultracentrifuge by Squire et al., 1968. 
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Albumin is characterised by smaller size, but greater solubility, total 
charge, net negative charge, stability and flexibility thý', n other proteins. 
According to hydrodynamic data, albumin is a prolate ei.. it. ),, -, oLd with major 
and minor axes of 14 nm and 4 nm. 
Albumin has more than 200 positive and negative charges, distributed 
throughout the molecule, giving a hydrophilic character and leading to a 
high solubility in aqueous media. The isotonic point of albumin is about 
pH 5.2 which is also the point of maximum total charge with 101 positive 
and negative charges (Hughes, 1954). At pH 7.4, albumin has a net 
negative charge of 18 (White et aL., 1968). 
The complete amino acid sequences of Bovine and Human Serum 
Albumins have recent, y been elucidated, largely by the efforts of Brown 
and his co-workers (Brown, 1974,1975; Behrens et a,, 1975). This 
group have also partially sequenced Ovine and Porcine: 'llbumins. Many 
other workers, from various laboratories have contributed significantly to 
the deciphering of these sequences. Peters (1975) has recently reviewed 
the relevant literature. The amino acid sequences of Bovine and Human 
Albumins are shown in figures 1: 2 and 1: 3 as determined by Brown and 
colleagues, and in the configuration proposed by therr, (Brown, 1975; 
Behrens et al ., 1975). The group of Meloun has also published the 
complete sequence of HSA (Meloun et at., 1975) and considerable differences 
exist between these two reports. Perhaps the most important discrepancy 
is the deletidn of Phe 157 from the structure of HSA determined by Behrens 
et at. (1975) resulting in one too few residues in their sequence. It is 
likely that the sequence of Meloun and co-workers is the more accurate, 
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Figure 1: 2 The amino acid sequence of Bovine Serum Albumin 
t 
2 
3 
4 
5 
6 
7 
8 
9 
The sequence is displayed in a model showing the proposed linking of 
cystines to form multiple double loops. From Brown (1975). 
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Figure 1: 3 The amino acid sequence of Human Serum Albumin 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Residues assigned by analogy with BSA are shown in lower case letters. 
From Behrens et at. (1975) . 
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since their data agrees well with that of other groups and also much of 
the sequence of HSA proposed by Behrens et at. , was from analogy 
with that of BSA. 
Both albumin molecules are composed of 9 major loops, each being 
made up of two minor loops, which are bonded by disulphide linkages. 
There are six long major loops and three short in each case, occurring in 
the repeating sequence long short long - long short long - long short long. 
This arrangement was proposed by Brown (1975) from the primary sequence 
for reasons which may be summarised as follows: - There are seven 
Cys-Cys pairs in each molecule (loops 2,3,4,6,7,8) each of which is 
situated 7 to 10 residues from a tone Cys and a greater distance from a 
second lone Cys. Take for instance, major loop 9 of BSA (residues 504- 
581, isolated independently by Peters and Hawn, 1967, and designated 
The'). The peptide contains two lone Cys residues, 513 and 566 and a 
pair 557-558. The conformational rigidity of the backbone prevents a 
disulphide link being formed between Cys 557 and Cys 558. Of the two 
other possible permutations of disulphide bonds the pairing 513-558 and 
566-557 was chosen to increase the length of the shore: minor loop, thus 
decreasing its conformational restrictions. 
There are two departures from the typical disulphide pairing structure, 
short loop 5 has its Cys pair separated by three residues rather than 
adjacent and loop 1 has no tone Cys in the region 8-11 and only a single 
Cys at 53-54 rather than the expected pair. The residues 8-52 are never- 
theless represented as the long minor loop of major loop 1, even though 
they are not held by a disulphide link. 
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The existence of independent double loops, as proposed here, is 
supported by the various peptide fragments which have been formed by 
digestion of the albumin molecule. The relation hip of many of the 
fragments, reported by various workers, to the model of Brown (1975) is 
shown in figure 1: 4. Further reference to these peptides and to the 
distribution of amino acids with regard to function will be made In the 
next section. 
The secondary structure of albumin has been reported to contain 
50-55% a helix, about 15-20% ß pleated sheet and the remainder random 
coll. (Sjoholm and Ljungstedt, 1973; Sogami and Foster, 1968; Reed 
et al. , 1975), but recently, Chen (1976) could find no evidence of ý sheet 
in BSA using the technique of laser-Raman spectroscopy. The effects of 
the many S-S bridges upon helical content is difficult to assess but the 
two sets of data are not incompatible. Little is known of the tertiary 
structure of albumin, but some predictions can be made from what Is 
known of the primary and secondary structure. These predictions will 
remain unproven until X-ray crystalographic studies, now in their infancy 
(McClure and Craven, 1974) reach a more mature state. 
The observed compactness of the molecule at neutral pH can be assumed 
to be a consequence of associations between the Loops. Brown (1975) has 
suggested that BSA Is in the form of a pentahedrat cylinder formed by five 
helices. It is likely that association of loops form globular portions of 
the molecule, or domains. The existence of a series of domains, linearly 
arranged with transverse clefts was proposed by Anderson and Weber (1969) 
from fluorescence polarisation data of the Interaction of ANS with BSA. 
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Figure 1: 4 The peptides of albumin which have been used in small molecule 
binding studies 
HUMAN 
1 124 297 584 
(a) BCA CNBr 
BOVINE 
Phe 
1 24 49 185 306 405 453 503 51 
(b) 1II ---"----{ i_. _i"______ý Peps 
1 405 
(c) ' Peps 
1 306 581 
(d) 1BIA1 Peps 
loop no. 123456789 
ALL fragments were isolated without breaking S-S bonds. 
CNBr and Peps signify cleavage by cyanogen bromide and pepsin respectively. 
The fragments are named according to the workers who isolated them. 
References are: (a) McMenamy et al. (1971); (b) Peters and Hawn (1967), 
and Feldhoff and Peters (1975); (c) Feldhoff and Peters (1975); (d) King (1973). 
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Peters (1975) has proposed a system of domains for albumin which divide 
the molecule into four portions; loops 123, loops 4 and 5, loop 6 and 
loops 789, based upon the net charge of each loop and h susceptibility 
of linkages to peptic or tryptic attack. The division between loops 4, 
5 and loop 6 was the least clearly defined. 
The theory of domains has been invoked to explain the transition which 
albumin undergoes below pH 4. A lowering of pH from 4 to 2 is followed 
by the transition of albumin from a normal (N) form to a faster (F) migrating 
form. Further lowering of the pH causes continued acid unfolding 
(Foster, 1960). This acid expansion has been explained by a separation 
of the domains such as those proposed by Peters (1975), The separation 
has variously been suggested to produce 2,3 or 4 sections (Foster, 1960; 
Bloomfield, 1966; Weber and Young, 1964). 
A commercial preparation of albumin is generally a heterogeneous mix, 
containing simple contaminants such as a and ß Globulins or endonucleases 
but also many more subtle additions which manifest themselves by producing 
a range of apparently different albumins . One class of 
impurities are those 
which are complexed with the single free suiphydryl group of albumin 
(Cysteine 34). About 20% of crystalline albumin is coniplexed with half 
cysteine and about 5% with half glutathione (King, 1961; Andersson, 1966). 
Albumin which contains one free suiphydryl group per niolecule is termed 
m erca pta lbum in . 
Foster et at. (1965) reported a form of microheterogeneity of albumin 
associated with differences in the pH at which the species undergo the 
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N->F transition. These differences are not due to sulphvdryl inter- 
actions, but may be explained by the presence of tightly bound fatty acids 
(McMenamy, 1967; Wong and Foster, 1969). Other poisible explanations 
Include the presence of dimers or polymers, differences in amide content 
or location (Spencer and King, 1973) or so called molecular ageing. 
The ageing of circulating Human Albumin is thought to include such 
processes as the acetylation of e amino groups by aspirin (see next section) . 
The optical properties of albumin including ultraviolet and visible 
light absorption, fluorescence and circular dichroism characteristics will 
be covered in subsequent chapters. 
1: 2.6 ALBUMIN - NATURE OF BINDING SITES 
Albumin has some 200 charged residues, equally divided between 
negative and positive groups with a net negative charge at pH 7.4. 
In the absence of any other evidence lt would seem likely that these 
charged residues would provide a multitude of sites for interaction with 
charged small molecules. One would also expect a disposition toward 
the binding of cations at neutral PH, due to the net negative charge. In 
reality this Is far from the truth, for most small molecules the number of 
primary binding sites on albumin total less than ten, often only one or two. 
Also, albumin generally shows a greater affinity for anionic compounds 
rather than those with a positive charge. These surprising findings have 
led to much Interest in the nature and location of binding sites in albumin. 
The binding of some metallic cations is well documented, but generally 
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little is known of the binding sites for positively charged molecules. 
The amino terminal nitrogen along with the first two peptide nitrogens and 
the nitrogen of the imidazole ring His 3 form a square planar chelate ring 
for both Cu 
2+ 
and Ni 
2+ (Bradshaw, 1968). The suiphydryl. group of Cys 34 
forms covalent bonds with Ag+, Hg2+ and RHg+, and, as was mentioned 
prevlously, can form an S-S bond with other sulphur containing ligands. 
The metal ions already listed, plus manganese which is bound at a single 
site (Mildvan and Cohn, 1963), are examples of elemenrcdl ions which 
have specific binding sites on albumin. Manyother such ions have a large 
number of weaker Interactions with the protein e .g. Cot+, Zn2+, Cut+ 
Cat+, F-, Br-, and I-. Thorpe (1964) considered that the N-terminal 
region acts as a binding site for pyridoxal phosphate, fatty acids, thyroxine 
and various other ligands, but recent evidence Largely contradicts this 
theory. Affinity LabeLling has suggested that pyridoxal. phosphate is 
attached at Lys 223 of BSA, at the tip of loop 4 (Anders son et al . , 1971) . 
Acetyl salicylic acid (Aspirin) is known to acetylate a specific lysine 
amino group in albumin, although it may bind to other sites with equal or 
greater avidity but without any chemical modification resulting. Hawkins 
et at. (1969) isolated an acetylated peptide from HSA, after aspirin pre- 
treatment, with the sequence ! eu-Lys*-ser (glu, ala, leu) tys, Gambhir et at. 
(1975) have recently sequenced a 107 residue fragment of HSA, incLuding 
the acetylated Lys and the Lone trypto Phan . From the sequence of HSA by 
Me Loun et at. (1975) the acetylated lysine can be placed at position 199 
in the sequence leu-Lys* - cys-aLa-ser-Leu-gln-lys, which lies in the cleft 
between loops 3 and 4 in the model of Behrens et at. (1975). 
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The binding sites already mentioned have been single amino acids, 
it Is very likely however that most interactions cannot be considered to 
involve just one residue, but larger regions of the protein, 
Further work on the nature of drug binding sites has been largely 
concerned with the binding of organic anions to albumin. It has been 
suggested many times that such binding sites would contain a cationic 
head group(s) and a pocket of non polar amino acids. The structure of 
albumin seems to provide many such sites, with the clefts between the 
Loops providing areas of hydrophobicity and several charged amino acids 
at the tips of the loops, particularly on the 'right side` of the molecule 
e. g. Arg 81,143,144,334,335,410 etc. etc. Lys 223,272,293 etc. 
(all residues refer to BSA) . Brown (1975) has suggested that the binding 
site for anionic compounds is a right side hole In the cylinder structure 
which he also postulated for BSA. Swaney and Klotz (1970) sequenced 
a short peptide containing the Lone tryptophan of HSA and suggested that 
certain cationic groups surrounding a cluster of non polar residues forms 
an ideal binding site. Their sequence of lys-ala -tr p--a la-va l-a la-arg 
fits into the HSA sequence of Meloun et at. (1975) as residues 212-218, 
and, in the scheme of Behrens et at. (1975), between loops 3 and 4 (see 
fig. 1: 3. A similar region Is present in the BSA molecule. As evidence 
for the presence of tryptophan at a binding site of HSA Swaney and Klotz 
cited the findings that tryptophan is perturbed by the binding of sodium 
dodecyl sulphate (SDS) (Herskovits and Laskowski, 1962; Williams et al., 
1965) and the steroids testosterone, progesterone and cortisol (Ryan, 1968; 
Ryan and Gibbs, 1970). Further reference will be made to the perturbation 
of tryptophan and its possible involvement in binding. 
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The area around the 'reactive' tyrosine of albumin (Sanger, 1960, 
cited by Steinhardt et a[. , 1971) also meets the requ iromont for an organic 
anion binding site. The sequences of arg-tyr--thr-arc:; La BSA and arq--trp- 
thr--lys in HSA can be found around residues 407-413 between the loops 6 
and 7. 
Anderson and Weber (1969) postulated the existence of clefts perpen- 
dicular to the major axis of albumin which would bind ANS, in order to 
explain the fluorescence polarisation of ANS when bound to BSA. The 
areas between loops 3 and 4 (including the tryptophan containing site of 
Swaney and Klotz) and loops 6 and 7 (Including the rc. xcý: ive tyrosine: of 
Sanger) are two possible clefts. The facts that ANS strongly quenches 
the fluorescence of HSA (Santos and Spector, 1974) anal BSA (Jun et aL 
1975) and that modification of the Arg residues of BSA causes a 100 fold 
diminishing of ANS binding (Jonas and Weber, 1971) give further weight 
to this argument. Reed et at. (1975) found ANS to bind mostly to large 
fragments of BSA and to loop 3. The same workers reported the bilirubin 
binding site to be located in residues 186-238 of BSA., I: his area is much 
of loop 4 and again contains the tryptophan site of Swaney and Klotz They 
also suggested that salicylate was bound in a similar region. These 
observations are consistent with the pronounced quenching of the fluorescence 
of BSA and HSA by bilirubin (Chen, 1971, quoted by Ckiignell, 1972), and the 
competition of salicylate and bilirubin for binding sites; (Odell, 1973). 
The site of binding of acetyl salicylic acid (residue 1.99 of HSA) and the 
findings of Jacobsen (1972,1975) that histidyl, tyrosyt, arginyl and Lysyl 
residues are involved in the binding of bilirubin to HSA 
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are also quite compatible with these views. Studies Involving Tryptophan, 
the only amino acid bound with plasma albumins to any extent, have yielded 
some interesting results. Using three cyanogen bromide tagments of HSA 
A (residues 299-585, Loops 6,7,8,9) B (residues 1-124, loops 1 and 2) and 
C (residues 125-298, loops 3,4,5) two groups have studied the tryptophan 
binding site. Sjöholm and Lungstedt (1973) reported that fragment C 
contained the main tryptophan binding site, whilst A did have some affinity 
for tryptophan. They also found the drugs phenylbutazo. ne, Librium and 
Propiomazine (a phenothiazine) bound to fragments A and C but not B. 
The group of McMenamy (McMenamy et at., 1971; Gambhir and McMenamy, 
1973; Gambhir et al. , 1975) localised the primary tryptophan binding site 
near His 146 by affinity labeLLing with bromoacety. l-L-tryptophan. They 
also reported Lys 190 (189 in Behren's sequence) to be involved, and that 
a tyrosyl. hydroxyl of fragment A could also be irripl. Icated i. t) tryptophan 
binding. These observations place the primary tYyptophan binding site 
between loops 3 and 4. This group considered that within fragments C 
(loops 3,4,5) and A-phe (a section of A probably containing loops 6+ 7) 
exist the major binding sites of HSA, a conclusion which fits well with 
the previous discussion. 
Albumin binding sites for fatty acids are of particular interest in this 
thesis, and have received much attention from other workers. The influence 
of chain length and conformational changes upon binding sites will be 
discussed In Chapter 4. King (1973) studied the binding of octanoate to 
two fragments of BSA equivalent to loops 1,2,3,4,5 (named B) and 6,7,8,9 
(A) . He re ported too p 6,7,8,9 to contain one high affinity site with two 
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Lower affinity sites on the remainder of the molecule. King (1973) also 
reported D and L tryptophan to compete for the high affinity site, this is 
possibly the same site reported for secondary binding o T, «-tryptophan. 
The binding of fatty acids to fragments of BSA produced by limited proteo- 
lysis has recently been reported by Reed et at. (1975). The three strongest 
binding sites for palmitate were found to be in the carboxy terminal two 
thirds of the molecule as follows; site 1 within residues 377 to 503 (loops 
7 and 8) site 2 239-306 (loops 4 and 5) and site 3 within 307-377 (loop 6). 
In studies using trinitrobenzene sulphonic acid, a peptide was isolated 
TNP 
labelled with TNP which had the sequence Leu-ala-"glu--Lys-tyr (Andersson 
et al ., 1971). It was found that this site In BSA was not Included In the 
primary binding site for caprylate or pa lrn state but was irwo lved in secondary 
binding. This sequence does not occur In the sequence of BSA proposed by 
Brown (1975) but may well be equivalent to residues 346 to 3 51: leu-ala- lys- 
glu-tyr in loop 6 which would be consistent with site 3 proposed by Reed 
et al. (1975). Lysine has also been reported to be involved in fatty acid 
binding by Green (1963). 
Noel and Hunter (1972) considered that at least some of the binding of 
fatty acid to BSA was to a cleft which contained the si. ncile sulphhydryl 
group (residue 34) since the binding of unsaturated fatty acid potentiated 
the oxidation of the sutphhydryl group. They also suggested that a 
tryptophanyl residue was near this binding site, this Is probably Trp 134 
of loop 3 (not that of Swaney and Klotz) which Is brought Into close proximity 
to CYs 34 by a folding together of loops 1 and 3. It is interesting that 
L-thyroxine is thought to bind near Cys34 (Ohkubo, 1969) and that 
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L-thyroxine competes for a secondary fatty acid binding site (Tabachnick, 
1964). 
It is likely that the area around the exposed Trp of HSA (214) and 
BSA (212) does not provide a primary binding site for fatty acid, since the 
addition of 2 or 3 moles of long chain fatty acid does not cause any change 
in the fluorescence or absorption of HSA tryptophan. (Spector and john, 
1968). Palmitate can reduce the quenching of HSAtrp caused by iodide, 
but this is probably due to a conformational change (Spector et al., 1973). 
This site probably does constitute a secondary site since a high concentration 
of paimitate will displace ANS (Santos and Spector 1972,1974) and L- 
tryptophan (McMenamy and Oncley, 1958) both thought to bind to this region 
and will alter the transitions of Trp at high concentrations (Steinhardt 
et at., 1972). Conclusions are much the same with BSA, however, 
fluorescence data is confused by the presence of a second tryptophan 
residue . The free trypto Phan , which is quenched by iodine and is not near 
the free -SH group (Noel and Hunter, 1972) is not a primary binding site. 
The second tryptophan, which is not quenched by Iodine but is affected by 
oxidation of the lone--SH group seems to be involved (Noel and Hunter, 1972) 
and probably accounts for the 45% quenching of BSA fluorescence upon the 
addition of fatty acid (Spector and john, 1968). The involvement of tyrosine 
residues in the binding of fatty acid, as reported by several groups is 
confirmed by a perturbation of tyrosine absorption with fatty acid binding 
(Zakrzewski and Goch, 1968; Steinhardt et at., 1972). 
Figure 1: 6 is an attempt to summarise the postulated locations of 
binding sites on the albumin molecule. Some other locations may be 
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Figure 1: 6 The location of some binding sites on albumin 
a) Specific amino acids 
3 
4 
6 
7 
9 
1 
3 
4 
6 
7 
9 
N term in.: dt (1,2,3): 
Cut+, Nit+. 
Lone Cys (34): R. SH, R. S-S. R, 
heavy metals. 
Lys 199 (HSA): acetyl 
salicylic acid. 
Tr p 212 (214, HSA) : binding site 
isolated by Swaney and Klotz 
(1970). 
Lys 223: pyridoxal phosphate. 
Tyr 408 (411, HSA): the reactive 
tyrosinki of Sanger (1960) . 
Around the lone Cys and buried 
Trp: secondary fatty acid, 
Thyroxin. 
Around the exposed Trp: ANS, 
Balirubin, Salicylate, 
L-Trypto phan . 
r acid binding sites of Reed et at. 
Site 2, '39-306 
(1975) 
Site 3,307-377 
Site 1,307-377 
Around the react the Tyr: ANS, 
D and L Tryptophan secondary. 
Residues refer to BSA, unless otherwise stated. All these binding sites 
are fully discussed in the text. "= Cys 34 "= Trp 134 (BSA only) 
"= Trp 212 (214 in HSA). 
b) Larger binding areas 
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inferred from competition studies. 
and warfarin will be discussed later, 
and 5). 
Those involving fatty acids 
in the relevant chapters (4 
Having considered the information available pertaining to binding sites 
it must be said that some workers believe that it may be a misconception 
to think of binding sites in terms of specific areas of the molecule. 
Karush (1950) first proposed the idea of 'conformational adaptability' 
which includes the concept that binding sites may be very flexible, moulding 
to suit the ligand involved, and that the binding of a ligand can induce 
conformational changes which create or destroy bindiiicj sites. There is 
considerable evidence to support the idea that albumin undergoes some 
conformational changes with the binding of Ligands, reflected by changes 
in physical properties such as viscosity, light absorption, stability etc. 
Conformational changes may also explain the interference of one ligand's 
binding by a second ligand in a 'non competitive' fashion (see section 
and chapter 3). We must be careful, then, not to apply a too rigid approach 
to the allocation of drug binding sites to portions of the albumin model. 
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1: 3 BONDS INVOLVED IN DRUG-PROTEIN INTERACTIONS 
The original concept of the molecular nature of drug-albumin interactions 
was one of electrostatic attraction and bonding by ionic bonds. When the 
ionic nature of many drugs, and the number of charged groups on the protein 
are considered it is not surprising that this view was taken. It has however 
become increasingly evident that ionic Interactions play only a minor role in 
most associations with albumin. It is pertinent, then, to consider the various 
types of bond which may be formed between protein and Ligand. 
1: 3: 1 COVALENT BONDS 
Covalent bonds are formed when two molecules share a pair of electrons,. 
This type of interaction is a chemical combination rather than an association 
and is generally not important In drug-protein Interactions. Covalent bonds 
are very stable, with a bond energy of i 100 kcal. M-f and are thus 
essentially irreversible. 
There are only a few examples of covalent bonds being formed 
between albumin and drugs, probably the best known Eexciinples are the 
Interaction of acetylsalicylic acid and TNBS with the £ amino groups of 
lysine in albumin (see section 1: 2: 6). There may be many more covalent 
Interactions between drugs and albumin than are generally recognised, 
since few binding experiments are designed to display the presence of 
this type of binding. There are certain groups of drugs which, either in 
their native form, or after metabolic conversion, are known to bind covalently 
to macromolecules. The alkylating agents are one such group which have 
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the carbonium ion as the reactive species and which bind to nucleic acids 
and various cellular and tissue proteins. Compounds which form epoxides 
as metabolic Intermediates are also known to bind covalently to macro- 
molecules. The study of reactive species binding to macromolecules is 
a separate and fast expanding field which is beyond the scope of this 
introduction. It should be pointed out, however, that the covalent binding 
of a drug to albumin may produce a molecule which acts as an antigen, 
ILLiciting an immumological response. 
Albumin contains a single free cysteine residue which may be available 
for oxidation and mercaptide formation. This residue is normally present 
in the reduced state or complexed with either half cysteine orhalf glutathione. 
However, the formation of a covalent link with exogenous compounds is a 
distinct possibility. Heavy metals and compounds which contain sulphydryl 
groups are just two types of molecule which can react with free cyste[ne. 
The coordinate bond is a particular form of covalent bond in which both 
electrons are donated from one atom. The elements nitrogen, oxygen and 
sulphur, when bonded normally have an unshared pair of s orbital electrons 
which are available for coordinate bond formation. Often bonds are formed 
with metal ions such as Na+, Mg, 
+, K+, Cat+, Cu+ or Zn 
2+ 
and also the 
transition metals e. g. Co, Mn, Fe have a peculiar ability to accept electrons 
In unfilled Inner orbitals. 
1: 3: 2 THE IONIC BOND 
The ionic bond is the result of coulombic forces (electrostatic attraction) 
between oppositely charged Ions. The bond has an average energy of 
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5k cal. mole-1 and the attraction diminishes with the square root of the 
separating distance. The ionisable amino acids are listed in table 1: 2 
with the numbers present in Bovine and Human Albumins. The mere presence 
of an ionisable amino acid does not mean that it is necessarily available 
for ionic interactions with a ligand. The surrounding structure of the protein 
may make it inaccessible the ion may be involved in intra-molecular 
bonding or the amino acid may be predominantly in the unionised form. 
Many drugs contain charged groups which are capable of forming Ionic bonds 
with the protein. The charged groupOneed not necessarily be totally ionisable, 
the carbonyl group for example R-C- has a small negative charge on the 
oxygen and the opposite charge on the carbon atom. 
1: 3: 3 THE HYDROGEN BOND 
The hydrogen bond may be considered as a particui. r r. type of tonic bond, 
despite the fact that both contributors to the bond may be uncharged when 
apart . The bond is formed between a hydrogen atom, which Is covalently 
bound, and an electronegative receptor atom. The average hydrogen bond 
bridges approximately A and has a strength of 2-5k cal mole-1. Despite 
the rather weak nature of the bond, many such Interact. ons can be formed 
between two Ligands giving considerable stability to the complex. The 
most common forms of hydrogen bond in [igand-protein interactions occur 
between the hydroxyl groups of the protein and terminal sulphur, nitrogen 
or oxygen atoms of the ligand. Hydrogen bonds are highly directional, 
the electronegative centre must lie in line with the hydrogen covalent link 
before a bond can be formed. 
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Table 1: 2 The ionizable groups present on albumin 
Amino acid residues Ionic group pK a 
(25°C) 
Number of residues b 
present on albumin 
HSA BSA 
C-terminal a -carboxyl 2.09 1 1 
N-terminal a-amino 9.65 1 1 
Aspartic acid 0-carboxyl 3.86 39 41 
Glutamic acid y-carboxyl 4.25 60 59 
Tyrosine phenolic 10.35 18 19 
Lysine e-amino 10.53 58 59 
Arginine guanidino 12.48 23 23 
Histidine imidazole 6.00 16 17 
a. From Lehninger (1970) 
b. Based upon the sequences shown in figures 1: 2 and 1; 3 
-36- 
1: 3: 4 WEAK ELECTROSTATIC ATTRACTIONS 
Van der Waals forces are a group of weak electrostatic interactions 
including attractions between dipoles and induced dipoles and the repulsion 
between similar atoms. The repulsion is known as the Born force and Is 
due to the repulsion of the electron clouds which surround atoms and molecules. 
The Born force is only important when atoms are in close proximity and the 
electron clouds overlap. Keesom and Debye attractive forces require a 
permanent dipole and are thus not often important in drucj-"protein interactions. 
Permanent dipoles occur In electrically neutral molecules due to the uneven 
distribution of charge around covalently linked atoms of different electro- 
negativity. Keesom forces are due to the attraction of Savo permanent 
dipoles whilst Debye forces occur between permanent and induced dipoles. 
London forces occur between neutral atoms with no pormnnent dipole and 
are the most important of the Van der Waals forces involved In ligand-protein 
interactions. The electrons surrounding a neutral atom are not fixed and 
can move from orbital to orbital producing transitory asymmetries is the charge 
distribution, i. e. a dipole. Although such a dipole is very short lived, it 
can induce a second dipole In a close, second electric field which results 
in an attraction. Such attractions are continuously formed and are responsible 
for the permanent attraction between two atoms, in the absence of any other 
electrical processes. Van der Waal's forces are very short ranged, 
diminishing with the s? xth power of the distance between participating atoms 
and have a very small bond energy. Complexes of considerable stability 
can be formed, however, since Van der Waal's forces are additive and 
molecules can participate in many such interactions, a good example of 
'strength in numbers'. 
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1: 3: 5 HYDROPHOBIC BONDING 
The term 'hydrophobic bond' is much used in the jargon of protein-- 
binding researchers, but it is a somewhat misleading title and requires 
clarification. Hydrophobic bonding has been defined as the tendency for 
non-polar groups to aggregate together in aqueous solution. This process 
does of course occur, but is not due to some special type of bond, 
rather due to a maxim isation of Van der Waal',,., and ionic interactions. 
Thus, if a hydrocarbon is mixed with water, the water molecules will 
associate to form the maximum number of hydrogen bonds and the hydrocarbon 
molecules will associate to give the maximum number of London-Van der 
Waal's interactions. Even in a system as simple as hydrocarbon in water 
the preceding explanation is, however, only an approximation of the processes 
involved. The precise nature of hydrocarbon-water Inteiactlons is an area 
of contention at the present time (Hermann, 1971; 1972). The term hydro- 
phobic bond is then a convenient short hand phrase to describe a complex 
mixture of Interactions. 
As a postscript to this section it Is Informative to consider the order 
of reactions as a ligand is introduced into a protein solution. Providing 
the ligand is soluble, it will be taken up into solution, in other words will 
be surrounded by water molecules. (The surface of the protein is already 
coated with water and consequently binding must involve the squeezing out 
of some of these water molecules). Once diffusion processes have brought 
the ligand into the vicinity of the protein, thermal agitations will ensure 
that the llgand and protein will collide. If the Ligand is ionised the first 
attachment to the protein will be via ionic bonds, since other attractive 
-38- 
forces are effective only over a short range. Once in very close proximity 
to the binding site a combination of hydrogen, Van der Waat's and hydro- 
phobic bonds will determine the strength of the interact. n.. In most cases 
the binding will not be so tight as to preclude dissociation and an equili- 
brium will be set up which will obey the laws of mass action. 
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1: 4 THE INFLUENCE OF DRUG PROPERTIES ON PROTEIN BINDING 
One of the main goals of protein binding research is to reach a stage 
at which it will be possible to predict the affinity of a new drug for albumin 
solely from its structure. Whilst this stage is still many years in the 
future, which is perhaps not surprising considering the number of bond 
types and the multiplicity of sites involved in binding, certain general 
conclusions have been made concerning the influence of drug structure on 
binding 
. These conclusions concern three broad types of modification in 
drug structure which may affect protein binding, the three types are Illustrated 
in an early piece of work by Klotz et at. '(1952). Ms s report concerned the 
binding to albumin of the dye methyl orange and its derivatives. 
Methyl pi. ýjti e 
CH 
3 
\ON 
CH 3 
0 
(O =N 
JO 
O- 
The affinity of albumin for the compound was found to change if 
a) the dimethyl amino group was lengthened to diethyl, dipropyl, or dibutyl, 
there was in fact a reduction in affinity with increasiugi chain length. 
b) the anionic residue sulphate was modified to carboxylate, phosphate or 
arsonate and c) if the position of the anionic group on the phenyl ring was 
changed. The three types of modification are, then: changes in the hydro- 
phobicity of the molecule, changes in the ionisable group and steric or 
isomeric changes. Of these three, the first category is by far the most 
studied. 
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There have been many reports of a correlation between lipophilic 
character of a ligand and its degree of binding, virtually all of which have 
reported increased binding with increasing lipophilicity, in contrast to the 
findings of Klotz et at. (1952). Bridges and Wilson (1976) have recently 
reviewed the literature in this field, with reference to the albumin binding 
of steroid hormones, cardenolides, penicillins, other antibiotics and 
particularly phenothiazines and sulphonamides. In such studies, ilpophillcity 
is often measured as the partition coefficient (P, usually quoted as log. P) 
of the compound between octanol and water. The correlation between 
log, p and affinity of binding to albumin was first noted by Hanch and co- 
workers (see Leo et al., 1971) for a series of neutral molecules. Wilson 
(1974) showed a similar correlation between log. P and the 'total binding 
constant' nK, for a series of aliphatic carbamates. In a detailed account 
of a[kane binding to BSA, Wishina (1964; Wishina and Finder, 1964) 
concluded that the binding was akin to gas in liquid solubility and that 
a(kane binding was a good test for the presence of hydrophobic areas on 
the surface of proteins. 
Similar relationships between binding and lipophilic, ity have also been 
reported for ampiphilic compounds, i. e. those with ionic and hydrophobic 
portions. The acidic sulphates and suiphonates (Karush and Sonenburg, 
1949; Ray et al. , 1966; Reynolds et al., 1967) are two examples and the 
fatty acids are also well studledýbut will be discussed in chapter 4. For 
the basic phenothiazines (KriegLstein et aL., 1972a, b; Nambu and Nagai, 
1972) a correlation has been found whilst there was no relationship for 
tricyclic antidepressant binding (Jorgensen. et al ., 1973). 
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The overwhelming volume of data leads to the conclusion that lipophilic 
character is a prime determinant of the strength of binding for a wide range 
of compounds. There are however deviations from the norm . The binding 
of methyl orange derivatives (Klotz et al ., 1952) has already been reported 
as one such exception. Dunn (1973) reported a parabolic relationship 
between log. P and binding for carboxylic acids, p-amino benzene sulphonamides, 
anti-inflammatory and uricouric agents. The binding of uncharged ligands, 
such as alkenes, alcohols and carbamates are typified by a larger number 
of binding sites (often greater than 5) and a tower affinity (often Ka <1x 104M 
1) 
than the equivalent charged molecuLe, which suggests some involvement of 
Ionic interactions in the binding reaction of charged compounds. 
The nature of ionisable groups in a Ligand can profuundLy affect the 
binding to albumin . Klotz et at. (1952) found the carboxyl derivative of 
methyl orange had a similar binding whilst the phosphate and arsonate 
derivatives had much reduced binding compared to the parent molecule. 
For a straight, hydrocarbon chain the affinity of binding is increased as the 
polar head is modified In the order OH < COO < SO3 ;< 
SO4 (Steinhard 
and Reynolds, 1969). Generally, anionic compounds bind more avidly to 
albumin than cationic molecules, the addition of amino or N-heterocyclic 
groups to a ligand frequently diminishes binding. Any modification of an 
Ionic ligand which affects the degree of dissociation may affect the ligand's 
binding characteristics. 
The arrangement of functional groups In a llgand is often as Important 
as the nature of the groups In determining binding characteristics. 
Generalisations are hard to make in this area because of the diverse 
structural nature of drugs, but for aromatic compounds Klotz et at., (1948) has 
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suggested ortho substituents may affect binding more than the meta or 
para equivalents because the latter two can interact with solvent molecules 
to a greater extent. Ortho aminobenzoate and ortho hydroxypheny[acetate 
are both more highly bound than their para counterparts (Klotz, 1946; Luck 
and Schmidt, 1948). The binding of various hydroxylated warfarin derivatives 
is also consistent with the theory of Klotz et al. (1.948) . 
Warfarin 
7OO 0H 
6CO4. 
S4l 
OH C 
1 
H2 
C=O 
I 
um 3 
Hydroxylation in positions 4', 6,7 or 8, where interaction with water 
molecules is likely, produces a diminution of binding whilst 5-hydroxylation 
increases binding. O'Reilly (1973) suggests that a hydrogen bonded ring, 
Involving the 5 and 4 hydroxyl's may account for this increased binding. 
Optical isomers, as well as structural isomers, may also have dissimilar 
binding characteristics. Müller and Wollert (1975) reported a stereo specific 
binding of D and L oxazepam hemisuccinate. L tryptophan is known to bind 
to HSA with a higher affinity than the D isomer (McMenamy and Oncley, 1958) 
Koga et at. (1975) studied the binding of dansyl alanine and dansyl glycine 
and found the D isomer to have a higher affinity for BSA in each case. 
Stereo specific binding in general, and more specifically the binding of the 
enantiomers of warfarin and phenprocoumon will be discussed in chapter 6. 
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15 PHARMACOLOGICAL AND CLINICAL IMPLICATIONS OF 
DRUG-PROTEIN INTERACTIONS 
Despite the wealth of information available concem. y.:; i7 drug-albumin 
Interactions, the significance of binding in drug mediated therapy is still 
poorly understood. Several authors have reveiwed the field of plasma 
protein binding with reference to pharmacodynamics and 
pharmacokinetics: Goldstein, 1949; Brodie, 1966; Meyor and Guttman, 
1968; Keen, 1971; Anton and Solomon, 1973; Gillette, 1975; Shand et at. , 
1975; Wilson and Bridges, 1976. 
1: 5: 1 ABSORPTION 
Little is known of the influence of protein binding on the absorption of 
drugs administered enterally or parenterally. Indeed, iateraction with plasma 
or interstitial proteins is seldom considered in drug absorption studies. 
Brodie (1966) has suggested that aqueous Insoluble drugs will precipitate 
in the gastrointestinal tract giving a situation where the limiting factor of 
absorption Is the rate of solution of the drug crystals. If the drug Is highly 
bound to plasma proteins, freshly dissolved drug is c : Ltkly removed and the. 
rate of solutions is enhanced. Brodie asserts, furthermore, that without 
a high affinity for plasma proteins, highly [Ipophilic drugs such as dicoumerol 
would not be absorbed. There have however, been no definitive experiments 
to establish the role of plasma binding in absorption from the G. I. tract. 
The rate of absorption of a series of barbituric acids has been correlated 
with their plasma protein binding, but the authors (Kakemi et al., 1969) 
concluded that binding to the mucosal membrane was far more important. 
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It is possible that the parenteral administration of aqueous insoluble drugs 
would be impractical if they were not bound to plasma proteins since the 
drug would precipitate in small blood vessels. 
1: 5: 2 DISTRIBUTION AND ACTIVITY 
After administration to the body, a drug will distribute, down a 
concentration gradient, throughout the body, just as if it were a volume of 
water providing that the drug can pass freely across cellular membranes 
and that it Is not associated with any body components. This situation 
rarely occurs in practice since most drugs associate to some degree with 
the macromolecules of plasma and tissue limiting their availability to other 
compartments of the body which may include the receptor sites. An 
equilibrium between compartments is set up which may bo illustrated simply 
as below or more comprehensively as in figure 1: 1 . 
PLASMA TISSUES 
Bound drug Bound drug 
Iý 1ý 
Drug receptor complex Unbound drug Unbound drug 
It is a fundamental, and often tacit, assumption of pharmacology and 
pharmacokinetics that the activity of a drug is related to the free concen- 
tratlon in plasma. The bound drug does not contribute directly to activity 
since only the free form is in equilibrium with the receptor (Goldstein, 1949; 
Brodie, 1966; Goldstein et al., 1968). 
Whilst this premise is certainly correct for the majority of drugs and 
is supported by the many observations of reduced potency with high plasma 
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protein binding (for example sulphonamides, Kruger-Th iem er et al., 1965; 
or Penicillins, Rol inson and Sutherland, 1965) the possibility that bound 
drugs may still retain some activity should not be ignored. Many small 
molecules and drugs, when covalently linked to albumin, can elicit an 
antigenic response and thus the bound molecule must be available to 
receptors of the immunological system . There Is no firm evidence to prove 
that other receptors cannot interact with bound drugs in a similar manner. 
Benhold (1938) hypothesised that drugs would have to be bound to plasma 
proteins in order to pass into cells. This view is now largely discounted, 
but it may actually have some foundation. Fatty acids must be bound to 
albumin for efficient uptake and removal from adipose tissue in vivo and 
adipose cells in culture (Spector, 1975). Drugs which are otherwise unable 
to cross the cell membrane may be taken up bound to albumin by pinocytosis. 
The binding of the drugs phalloidin (Barbanti-Brodano et al., 1974) and 
amanitin (Derenzini et al., 1973) causes a much enhanced toxicity of the 
compounds due to this phenomenon. It must be remembered in this context 
that albumin is available to cells as a source of amino acids via pinocytosis. 
As much as 10% of protein metabolism may be carried on in this manner 
(Peters, 1975) . 
Drug bound to plasma or tissue proteins should not be considered as 
lost, but in storage. Metabolism and excretion will reduce the free plasma 
concentration which promotes the dissociation of the drug-protein complex 
thus replenishing the free drug. In this way protein binding prolongs the 
action of many drugs at a reasonably constant free plasma concentration. 
Without this effect, drugs which are rapidly metabolised or excreted would 
have to be given with great frequency in order to maintain therapeutic levels. 
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In addition, protein binding can act as a buffer to prevent Large fluctuations 
in free drug concentrations with the administration of a dose which might 
otherwise lead to toxic levels. 
It is interesting to observe at this point that the clini. cal estimation of 
plasma drug concentrations is almost always one of total drug (unless 
bioassay is used in which case only free drug may be measured). It should 
be obvious from preceding comments that total plasma levels of drug may 
bear little relation to the availability of drug at the rec(, pi: or site. Even 
bioassay or other free drug estimation may give misleading results if diluted 
plasma is used in the assay since drug binding is not nncessarily independant 
of protein concentration. 
Several workers have produced mathematical model; to mimic the effects 
of plasma protein binding upon drug distribution: Mart: '1i 19 6 5a , b; Keen, 
1971; Shoenemann et at. , 1973; Wagner, 1973; Gittet. ý. e, 1975; Shand 
et al., 1975; Julkunen et at., 1976. Most of these reports include complex 
pharmacokinetic models beyond the scope of this thesis, but the conclusions 
of Martin provide some simple generalisations: plasma protein binding will 
only have an appreciable effect upon distribution If the association constant 
of the drug-protein complex is greater than 104 M-1 . Drugs with a high 
affinity will be localised mainly in the plasma compartiu nt at low concentrations, 
but the fraction in plasma will be markedly reduced at higher concentrations. 
Such drugs will also have a narrow dosage range above which a small 
addition of drug wiLl result in a large increase in free concentration. The 
treatment of Martin (1965a, b) is oversimplified, ignoring such important 
factors as metabolism and excretion, but the final statement that plasma 
protein binding is an Important modifier of drug distribut: Ion only for drugs 
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with high affinity at high concentrations Is a good rule-of-thumb. 
Little mention has been made of the influence of tissue binding upon 
drug distribution. Despite the fact that the mass 
of extravascular protein available to drugs easily outweighs the plasma 
proteins, the balance of research into the two areas is tipped firmly away 
from tissue binding . Because tissue protein is so abundant, it is quite 
likely to be a more important binding component than plasma, at least for 
some drugs. Experimental data is, however, scarce; Burns et al. (1953) 
found drug levels in a patient who had been receiving phenylbutazone for 
some time to be high in several extravascular sites. The concentrations 
of drug in heart, lung and muscle were 32,24 and 19 times higher than the 
total plasma concentration. Brodie (1952) reported the concentration of 
thiopentane to be 10 times higher in adipose tissue that in plasma, three 
hours after intravenous Injection. 
A number of body compartments are separated from the circulation by 
membranes dissimilar to the normal plasma membrane. Areas such as the 
brain, the eye, the mammary gland and the foetus have very slow equlli- 
bration with plasma free drug because of the need to pass across several 
membranes. The final concentration of drug on the extravascular side of 
the membrane will depend largely upon the local protein concentration and 
its affinity for the drug in question. The brain, for exam ple, generally attains 
only low concentrations of highly plasma protein bound drugs. 
The transfer of small molecules across the placenta is being closely 
studied, due to concern over the chemical teratogenicity of environmental 
agents. Drugs can normally pass through the placenta but equilibration 
-48- 
is slow, since only the free drug of maternal plasma is available for 
transfer (Goldstein et al ., 1968). The binding of drugs iii fetal plasma 
will be covered in section 1: 6-1. 
1: 5: 3 METABOLISM 
just as it is assumed that only the free fraction of a drug is biologically 
active, it is also generally thought that it is the same: i: &'«ction which is 
available for metabolism. However, from the few studies which have been 
made of the rate of dissociation of a drug-albumin complex it seems likely 
that this process would not be rate limiting in metabolism (Thorp , 1964; 
Meyer and Gutman, 1968). A theoretical approach to the influence of 
plasma protein binding on the rate of drug metabolism in the Liver has been 
made by Gillette (1971,1973,1975) and also Shand ý-, nci c otLeague s (1975). 
They conclude that binding can have diverse effects dopcnding upon the KA 
of the interaction, the KM and Vmax of the metabolising system, the degree 
of tissue binding and the dose of the drug. To illustrate this diversity in 
effect consider two drugs, one which has a 'first pass' type metabolism, 
the other being only slowly transformed. Plasma binding will enhance the 
rate of metabolism for the first drug, since it is effectiz, oly transportir(g drug 
to the liver, whilst for the second, slowly metabolised compound, binding 
will act as a storage mechanism, increasing the half life of the drug (Gillette, 
1975). The situation is further complicated by tissue binding, where plasma 
binding may act to transfer drug from the tissues to the site of metabolism. 
The rate of diffusion of a drug into hepatocytes may be limiting for highly 
active liver enzymes systems. It has been suggested (Gillette, 1973) that 
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the hepatic cytoplasmic proteins Y (Ligandin) and Z (FABP or amino azo dye 
BPA) may be involved in the binding of drugs, thus maintaining a concentration 
gradient and possibly increasing the availability of drugs to enzymes in 
the centre of cells. Y and Z proteins have been shown to bind bilirubin, 
bromosulphophthatein, indocyanine green (Levi et at., 1969), corticosterolds 
(Litwack et at., 1972), haem (Meuwlssen et al., 1972), fatty acids, steroids, 
and various carcinogens (Tipping et al. , 1976). These proteins may also 
be involved in the flux of molecules from liver cells into the bile (Litwack 
et al., 1971). 
There have been relatively few experimental studies of the effects of 
plasma protein binding upon metabolism, Newbold and Kilpatrick (1960), 
showed a decreased rate of acetylation of two sulphonamides In rabbit 
perfused liver with the addition of plasma to the perfusate. Later work 
also showed correlations between the protein binding and metabolism of 
sulphonamides both in vitro (Anton and Boyle, 1964) and in vivo (Wiseman 
and Nelson, 1964). Levy (1973) has suggested that the rate of metabolism 
of d icoumero t is regulated by protein binding determining the distribution of 
the drug to the liver. 
One interesting aspect of the metabolism-binding relationship is that 
metabolites may compete with the native compound for binding sites. This 
could result In a displacement of the drug and possibly an Increase in 
metabolism leading to more metabolite being formed. 
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1: 5: 4 EXCRETION 
The removal of drugs from the body is usually accompTlished either 
by renal elimination and disposal in the urine, or biliary elimination and 
excretion in the faeces. Three processes contribute to renal excretion: 
glomerular filtration, tubular secretion and tubular resorption. The pores 
of the glomerulus allow free passage of small molecules but not proteins, 
therefore if no secretion or resorption of a drug takes then rencip 
elimination will be a function of the free drug concentration. The elimination 
of tetracyclines is an example of such a situation, with an inverse relation- 
ship between protein binding and rate of renal excretion (Kun in et al., 1959; 
Fabre et al. , 1971). Drugs which are subject to tubular secretion are 
rapidly and continuously removed from the tubules and thus protein binding 
is prcbably not important unless it is considered that by 'protein biuviing 
acts to transport the drug to the site of elimination (Keen, 1971). The 
opposing view has been put forward by Kruger-Theimer (1968) who suggested 
that tubular secretion is a function of free drug. The findings that penicillins 
are rapidly secreted via tubular secretion, independent of their high protein 
binding (Rolinson, 1967; Notari, 1973) lends support to the former theory. 
Tubular resorption takes place passively through the IrLtact tubular nvc. rrbrane 
and is a function only of the hydrophobicity and ionisation of the drug . The 
three processes can interact to produce a complex pattern of elimination 
which is well illustrated by the excretion of sulphonamides via the kidneys 
which some workers have found unconnected with protein binding (Newbold 
and Kilpatrick, 1960; Rieder, 1963) whilst others have shown a positive 
correlation (Arita et al ., 1971). 
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Since bile is secreted from liver cells those factors, including protein 
binding, which influence drug uptake into liver cells may also affect: biliary 
elimination. The biiiary excretion of several compounds this been correlated 
with protein binding, Including steroids (Sandberg and Slaiznwhite, 1956), 
organic, carboxylic acids (Brauer, 1959) and azo dyes (Preistly and O`ReiLLy, 
1966). However all these compounds are known to bind to l igand in (or 
aminoazodye binding protein A) and it may actually be a correlation between 
ligandin binding and biliary excretion which was obsE? rvnJ by these authors. 
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1: 6 MODIFIERS OF DRUG-PLASMA PROTEIN BINDING 
1: 6: 1 AGE 
The plasma protein binding of many drugs is reduced both in the very 
young and in senior citizens. This trend is at least partially a reflection 
of the plasma albumin levels at various stages of maturity. The human, 
foetal plasma albumin level at 26 weeks is 18 g. L-f rising to 35.7 g. L-I 
immediately before birth (Gitlin and Boesman, 1966). The normal adult 
level of about 35 g. L-f falls off after the age of 50 to as little as 22 g. L-l 
in septuagenarians. (Weber and Cohen, 1975). 
Many workers have reported a reduced binding of thugs in foetal, 
neonatal or cord human plasma compared to adult plas., i. These drugs 
Include sulphonamides and saticylate (Ganshorn and kurz, 1968), dtphenyl- 
hydantoin, phenobarbitone, ampicillin and benzytpenicillin (Ehrnebo et al ., 
1971), sulphaphenazole (Chignell et al ., 1971). These workers suggested 
that the binding differences were due to reduced albumin concentration in 
immature plasma and a higher concentration of competing ligands such as 
bilirubin. However Krasner and co-workers (Krasner ! i: al., 1973) found 
purified foetal albumin bound salicylate less strongly, but bilirubin more 
avidly, than adult albumin. Similar findings were reported by Windorfer 
et al ., (1974) for neonatal and adult plasmas which had been diluted to the 
same albumin concentration and adjusted to the same bilirubin level. 
Salicylate was bound less strongly in neonatal plasma and was more easily 
displaced by bilirubin. It seems, then, that there is a genuine discrepancy 
between the binding abilities of immature albumin and adult albumin, but 
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the origin of the difference is unknown. 
The preceding results suggest that drug concentrations on the foetal. 
side of the placenta will be lower than the maternal side due to the reduced 
binding. This is based upon an adult neonatal or foetal comparison, recent 
findings have suggested that foetal binding should be compared with the 
corresponding maternal parameter. Garrettson et at. (1975) found a 
maternal: foetal saLicylate ratio of 1: 1.6 in the case of a mother who had 
taken large daily doses of salicylate throughout pregnancy. Later work 
(Levy et al., 1975) has shown salicylate to be more extensively bound 
in foetal plasma than the corresponding maternal plasma, and lt was 
postulated that the difference was because of reduced Lnaternal albumin 
levels, and higher maternal plasma free fatty acid concentration. 
1: 6: 2 DISEASE 
The most obvious way In which disease can affect protein binding Is 
by altering the plasma concentration of the binding mac; omolecule. Hypo- 
albuminaemia is a rare genetic disorder but a similar condition can arise in 
a variety of clinical conditions Including hepatitis and. cirrhosis of the liver 
and impaired renal function. Diseases of the liver and kidneys have been 
well studied in recent years with relevance to the effect on protein binding. 
Reidenberg (1974) has reviewed the field whilst Black and Arias (1975) have 
covered the implications of chronic renal failure. 
It has been reported that most organic, anionic, drugs normally associated 
with plasma proteins, show reduced binding in uremic plasma, whereas basic 
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or neutral compounds are less affected (Reidenburg, 1974; Reidenburg and 
Affrime, 1973). This is probably explained by the increase in nitrogenous 
and acidic waste products in uremia as well as the reduced albumin levels. 
Whether the binding properties of albumin are actually altered in uremia is 
a contentious matter, some groups have concluded that the albumin of 
uremic plasma is intrinsically different to that of normal plasma (Anton and 
Corey, 1971; Gohneim and Pandya, 1975). Phenytoin (syn diphenyihydantoin, 
DPH) is bound less In uremic plasma than normal (Reidenburg et a[., 1971, 
Odar-Cederlof and Borga, 1976) and Shoeman et at. (1973) have suggested 
that this may be due to qualitative differences In the respective albumins. 
It is interesting to note that uremia is often treated by haemodialysis which 
entails the administration of large amounts of heparin '3 the patient. 
Storste: n and jannsen (1976) have shown that heparin given to both normal 
and uremic subjects causes a significant reduction in the binding of digoxin 
and digitoxin, due to the release of free fatty acids. 
Many drugs have been reported to be less bound in the plasma of patients 
with hepatic failure. The binding of DPH in acute viral hepatitis (Blaschke 
et at. , 1975) and thiopental in hepatic cirrhosis (Gohneim and Pandya, 1975) 
are both reduced, probably due to lower albumin levels and a higher bilirubin 
concentration. Hepatic failure not only affects albumin synthesis but may 
Influence drug metabolism which may in turn affect protein binding by 
alteration of metabolite levels. 
1: 6: 3 COMPETITION 
It has been shown, from a consideration of the nature of albumin 
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(see 1: 2: 6) that there are only a limited number of binding sites available 
on the molecule. It is inevitable, there, that drugs or endogenous substances 
will compete for binding sites under some circumstances. Competition can 
also occur for binding sites on other proteins or on tissues but these are 
Less well documented. Co-administered drugs may compete with each other 
or a drug may compete with an endogenous compound, or more unusually 
two endogenous compounds may have the same binding sites. Several review 
articles have appeared dealing with competition and di,: >i; icic.; ement, penned 
by the following authors: Brodie, 1966: Meyer and Guttman, 1968: Hartshorn, 
1970; Sellers and Koch-Weser, 19 7 0a , b: Swid ler, 1971: Wardell, 1974: 
Koch-Weser and Sellers, 1976b. Solomon (1971) has considered competition 
between drugs and endogenous compounds for tissue and plasma binding sites. 
Specific drug interactions with warfarin will be considered in chapter 3 whilst 
competition between fatty acids and other compounds wi(. 1. he covered in 
chapter 4. 
The clinical significance of drug competitions is not well understood, 
due to the many readjustments of drug kinetics which may follow displacement. 
A small displacement may cause a very large increase In free drug levels. 
If a drug which is 99% bound has a 1% displacement then the free drug levels 
will be almost doubled. This does not mean that the plasma free drug level 
is doubled however. The displaced drug is free to distribute throughout the 
body water and the final increase in plasma free level, and any 
potentiation of pharmacological effect, will depend upon what effect 
an elevated free drug concentration has upon metabolism and excretion. 
It has been suggested recently that the significance of 
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displacement depends largely upon the mode of elimination of the drug 
(Shand et at., 1975). If the rate of elimination of a drug is proportional 
to the free drug concentration, then displacement may result in a temporary 
Increase in free drug, perhaps to toxic levels, but the increased rate of 
metabolism or excretion will soon reduce the drug concentration back to 
normal levels. On the other hand if drug elimination Is 'first order' i. e. 
rapid and unrelated to free drug concentration, then displacement may result 
in permanently elevated plasma Levels, since they is no compensating 
Increase in metabolism or excretion. But as elimination is rapld, this type 
of displacement is not likely to have clinical significance. 
Despite all the compensating changes, drug competi. tton can have clinically 
significant or even disastrous effects. The well known displacement of 
warfarin by various agents can result in periods of excessive hypoprothrom- 
binaemia which has resulted in serious and fatal hemorrhages (Koch-Weser 
and Sellers, 1971; see chapter 3). The displacement of bilirubin by sulphon- 
amides was tragically demonstrated in a famous study where premature infants 
were given either oxytetracyclin or a penicillin/sulphisoxazoI combination 
to protect against infection. A large percentage of those children treated 
with the penicillin-sulphonamide mixture succumbed to death which was 
associated with kern icturu s (Silverman et al., 1956). A good example of 
displacement from tissue binding sites is provided by two drugs which 
have been used in the treatment of malaria: pamaquine, which suppresses 
the tissue form of the parasite and mepacr-ine, whi. ch is active against the 
blood form. When patients on mepacrine therapy are given pamaquine the 
plasma levels of the tatter drug are 5 to 10 fold the expected level and in the 
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toxic range, due to the avid binding of mepacrine to tissue sites (Brodie, 
1966; Zubrod et al ., 1948). 
An unusual exampLe of drug Interaction at the binding Level is provided 
by the work of Dollery et al. (1961). Patients receiving chlorothiazide 
were given the antlhypertensive pennpidine at normal doses, the resulting 
plasma level of pem pid ine was three fold normal, but there was no increase 
in hypertensive action. Later studies by Breckenridge and Rosen (1971) 
showed that at normal dose levels pempidine was about ,ý fý bound in untreated 
plasma, but about 40% bound to plasma from subjects pretreated with chtoro- 
thiazide. The mechanism of this potentiation of binding is still unknown 
since no similar increase could be reproduced in vitro. 
The proposed mechanism of action of two groups of <ir ugs demonstrates 
a possible, beneficial facet of displacement. It has bier suggested that 
the anti rheumatic activity of drugs such as salicylate, phenylbutazon. e and 
indomethacin may be due to a displacement of tryptophan or small peptides 
from plasma proteins (McArthur et al., 1971; Smith et al. , 1971). Similarly, 
Brodie (1965) proposed that some anti-inflammatory drugs act by displacing 
steroids from plasma binding sites. 
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1: 7 DRUG-PROTEIN BINDING METHODOLOGY 
1: 7: 1 INTRODUCTION 
For some applications, it may be sufficient to know only the percentage 
of drug which is bound in plasma at one particular concentration., This type 
of Information is, however, of no value if an understanding of the Interactions 
Involved is desired. To typify any binding reaction tho minimum requirements 
are an estimation of the affinity of the protein for the tlgand and an idea 
of the number of available binding sites. These parar oters are calculated, 
in a variety of ways (see chapter 2, section 2: 2: 14), from a knowledge of 
the total drug and normally total protein, concentratiori., phis an experimental 
estimate of one or more of the components of the following equilibrium: 
k1 
D1 +P -c---k DP Equation (1) 
2 
where Df is free drug, P is uncomplexed protein, DP is the drug-protein 
complex and k1 and k2 are the rates of the forward and reverse reactions 
respectively. Protein-binding techniques can be broadly divided into non- 
spectroscopic methods, which are generally designed t: ) estimate the 
concentration of free drug and spectroscopic methods which are more often 
Involved in measurements of the drug-protein complex. 
Several comprehensive discussions of the methodology of protein- 
binding have appeared, including those of Goldstein, 1949; Meyer and 
Gutman, 1968; Steinhardt and Reynolds, 1969; ChigneLL, 1971,1972,1973; 
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Bush and Alwin, 1973; Sykes and Hull, 1973; Bridges and Wilson, 1976. 
1: 7: 2 EQUILIBRIUM DIALYSIS 
Equilibrium dialysis can truly be called a 'classical' technique, as it 
was probably the first technique used in binding studies (Osborne, 1906) 
and has remained popular since that time. In binding studies, Ligand may 
start on either the protein or the buffer side of the membrane and dialysis 
Is continued until free drug has equilibrated between the two solutions. 
The technique, in its classical form, suffers from several drawbacks, which 
have been considered in detail by Steinhardt and Reynolds (1969). Their 
conclusions, many of which apply to all techniques involving a membrane, 
can he summarised thus: Errors may be introduced by arty of the following 
factors - a) Donnan Inequalities (Donnan 1924) duo to the presence of 
a membrane, unless they are suppressed by high salt 
concentrations. 
b) Salt and buffer components (e. g. NaCL, acetate, veronal) 
or membrane impurities can compete for binding sites, 
although phosphate seems to have little effect (Klotz, 1953; 
Keen, 1966; Nilsen and Jacobsen, 1975). 
c) The membrane may bind free drug (Agren, 1968) or the protein- 
drug complex (Steinhardt and Reynolds, 1969). 
d) The time taken for equilibration may be slow (up to 48 hrs) 
with the concommitant possibility of protein denaturation 
and bacterial growth. 
e) The method is unsuitable for plasma samples, since low 
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molecular weight components will equilibrate across the 
membrane. 
f) Dilution of the, protein phase by osmosis may occur. 
The development of purpose built apparatus and membranes has minimised 
several of these problems. The miniature dialysis cells designed by Weder 
and Bickel (1970) are achieving widespread popularity, due largely to dialysis 
times of one or two hours only. An extension of equilibrium dialysis, dynamic 
dialysis is also proving popular and is based upon the fact: that the rate of 
diffusion of a drug out of the protein/drug compartment is proportional to 
the concentration of the dialysable species (Bush and Alvin, 1973; Chlgnell, 1971). 
This approach has been used to study the binding of warfarin, phenol red 
and methyl orange (Meyer and Gutman, 1970) and also trypcophan (Fuller and 
Roush, 1974) to albumin. Since the rate of dialysis Is slow, a very sensitive 
assay for free ligand is required, radioactively labelled tigand of high 
specific activity has been used (for instance Fuller and Roush employed 
14C 
tryptophan, sp. act. 0.5 Cl. rnM-1). A technique with similarities 
to dynamic dialysis is that of dynamic permiation, where she rate of permiation 
of ligand into a suitable medium (nylon has been used -- ßottari et at., 1975) 
is taken to be proportional to free ligand concentration. 
1: 7: 3 ULTRAFILTRATION AND DIAFILTRATION 
Ultrafiltration describes the process of forcing a small proportion of a 
protein-ligand solution through a membrane to form a Protein free ultra- 
filtrate. The concentration of ligand in the ultrafiltrate is assumed to 
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correspond closely to the free drug concentration of the original solution. 
This technique is fast, but care must be taken not to remove a large 
percentage of the initial solution, otherwise the equilibrium may be disturbed 
because of the effective reduction in total ligand concentration and increase 
in protein concentration. The membrane employed In many ultrafiltration 
methods is the simple regenerated cellulose tubing and pressure is most 
often provided in the form of centrifugal force. Those sources of error of 
dialysis associated with the membrane will also be aptparont in ultrafiltration 
methods, with the exception of Donnan inequalities . An additional problem 
with ultrafiltration is the possible formation of a concentration gradient of 
macromolecule above the membrane due to the forces used for filtration. 
This is not likely to affect purified albumin binding studios, since albumin 
will not migrate significantly under the relatively weak forces used (normally 
1,000 g-2,000 g) but problems may occur with particulate samples such as 
subcellular fractions. In this respect the standard, T(-)ri. cbara type ultra- 
fI Itration apparatus (Toribara eta l., 1957; see f ig . 2: 1) is termed 'dead-ended', 
that is to say, there is no agitation of sample above the membrane. 
The continuous ultrafiltration, or diafiltratton, technique does riot suffer 
from being dead-ended, nor can there be an upset In PrTu Librium with removal 
of filtrate . The technique is described in detail elsewhere 
(chaper 2) but 
briefly the method is to place the protein solution into an ultrafiltration cell 
which is bounded by a membrane. The cell is part of a closed system and 
pressure is applied by pumping drug solution Into the cell, ultrafiltrate is 
continuously formed at the same rate as drug solution is introduced. Analysis 
of ultrafiltrate for drug, plus a knowledge of the stock concentration and the 
flow rate, make possible the estimation of bound drug over a wide range of 
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total drug concentrations. A complete binding isotherm can be produced 
from a single experiment using just one protein sample. Diafiltration was 
introduced by Blatt and his colleagues (Blatt et al ., 196f; ` and has been 
used in drug binding studies by a few workers (Ryan and T_tanna, 1971; 
Damon and Sapira, 1972; Crawford et al ., 1972; Thompson, 1973). 
A commercial modification of ultrafiltration named 'Centriflo' (Amicon 
Corp., High Wycombe, Bucks .l has recently been introduced and was 
evaluated as part of this project (see chapter 3). The technique is typified 
by ease and speed of operation and has been used by other workers to study 
drug-protein interactions (Wallace and Whiting, 1974; Booker and Darcy, 
1973). 
1: 7: 4 ULTRACENTRIFUGATION 
The separation of free ligand from bound by sedimentation of the drug- 
protein complex in a strong gravitational field offers the attractive proposition 
of no membrane being necessary. In the most commonly used approach to 
ultracentrifugal studies of drug-protein interactions (for example Schachman 
and Edelstein, 1966), a protein gradient is produced in a protein ligand 
solution by high speed centrifugation. Determination of protein and 
ligand concentrations at various points along the centrifuge tube allows 
an extrapolation to zero protein concentration and thus an estimate of free 
drug concentration. The calculations involved may be complex and lengthy, 
but the availability of optical scanning of samples during centrifugation for 
Instant assessment of concentrations may make the technique more convenient. 
This approach has been used to study the binding of various dyes to albumin 
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with good agreement of the results with those obtained with equilibrium 
dialysis (Steinberg and Schachman, 1966). 
The ultracentrifuge has also been used in a simpler series of binding 
experiments by Bickel and Steele(1974). They studied the binding of various 
drugs to subcellular fractions by incubating the fraction and drug together 
followed by complete sedimentation in the centrifuge . The drug concentration 
In the particle-free supernatant was taken to represent the free drug concen- 
tration. This approach was explored during the present project and is 
considered further in chapter 3. 
1: 7: 5 GEL FILTRATION 
There have been several approaches to the use of cross-linked dextran 
gels (most commonly 'Sephadex' gels) in protein-ligand studies, but all are 
based upon the assumption that free ligand can penetrate into the matrix 
of the gel whilst the protein fraction is excluded. The simplest method Is 
that introduced by Scholtan (1964) in which dry gel is added to a drug-protein 
mixture. After equilibration, the get matrix is assumed to have a drug 
concentration equal to that of free drug. The gel is isolated and free drug 
is estimated after elution. This batch method, using Sephadex, has been 
utilised in several studies (Ahtee et al. , 1967; Pearlman and Crepy, 1967) 
and recently, using polyacrylamide gel, by Himberg et AL. (1976). Wilson 
(1974) found the batch technique unsuitable for the measurement of sulphon- 
amide binding to albumin. 
Hydrated get, packed into columns, can be used in several modes to 
estimate protein binding. In the 'zonal' method, a small volume of drug- 
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protein mixture is applied to the column then eluted with buffer. This 
results in a separation of the mixture into two zones, one of free drug the 
other being protein-drug complex. It has been suggested, however, that 
the rate of dissociation of the drug-protein complex is normally more rapid 
than the rate of elution and that the zonal method may yield misleading 
results because of this (DeMoor et!., 1962; Chigne. lt, 1971). A method 
which attempts to overcome this drawback was introduced by Hummel and 
Dryer (1962) and involves the pre-equilibration of a coluüin with drug solution 
before the application of a small volume of drug-protein mixture. The elution 
is then carried out using drug solution. This method has been used by some 
groups (Fairclough and Frutton, 1966; Crawford et al ., 1971; Nambu and 
Nagai, 1972) but is extravagant in the use of drug solution. The method 
should yield very accurate results, since the free drug concentration is set 
by the experimental conditions rather than being detenr Led by analysis 
(Steinhardt and Reynolds, 1969). 
In a comparison of several get chromatographic methods, Wilson (1974) 
found that 'frontal analysis' gave the most reliable results . For this 
technique a large volume of drug-protein mixture Is applied continuously 
to a column with subsequent elution using buffer solution. From the drug 
concentrations in the leading and trailing boundaries of the elution profile 
the free drug may be estimated. Several drug-albumin interactions have 
been studied in this way (Cooper and Wood, 1968, Kriegelstein and 
Kuschinski, 1968; Müller and Wollert, 1976). 
1: 7: 6 OTHER NON-SPECTROSCOPIC TECHNIQUES 
Thermodynamic parameters associated with a drug-protein interaction 
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can give information on the types of bond which are involved in the binding 
and are thus useful quantities to determine. Experiments performed over 
a range of temperatures allow calculation of the enthalpy jnd entropy 
changes of an interaction but these parameters can be determined directly 
using heat burst microcalorimetry (Chignell, 1971; Chignell and Benzinger, 
1972). The technique gives a measure of the temperature change when 
drug and protein solutions are mixed and has, for instance, been used to 
determine the thermodynamic parameters for the warfari_ir hSA interaction 
(O'Reilly et al ., 1969). 
Fast reaction techniques must be used if an estimate of the kinetics 
(i. e. the rates of association and dissociation) of a drticr-protein Interaction 
is desired. This is an area where there Is a surprisinc> paucity of data, 
considering the importance of the dissociation rate in determining the clinical 
significance of protein binding (Meyer and Guttman, 1968). The kinetics 
of binding may be measured by observing the interaction either following 
rapid mixing of the components (continuous flow and stopped flow methods), 
or after a perturbation of the complex (Relaxation methods, e. g. temperature 
jump (T-jump) ). Taylor (1972) has reviewed fast reaction techniques 
with. relevance to pharmacological reactions. T-jump has been used In a 
study of dye binding to BSA (Froese et at., 1962), stopped flow in an 
examination of the bilirubin-BSA complex (Chen, 1974) and continuous flow 
in a later study of the same interaction (Faerch and Jacobsen, 1975). 
Affinity chromatography has been largely restricted to the purification 
of various biological materials (see Cuatrecasas and Anfinsen, 1971), but 
protein-ligand interactions may be studied if either protein or drug can be 
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immobilised on an affinity column. Dunn and Chaiken (1975) have examined 
the binding of Staphlococal nuclease to a nucleotide Iigancl which was 
covalently linked to Sepharose, whilst the opposite apprmich of complexing 
the protein with agarose was used in studies of the albumin binding of 
various compounds including bilirubin, fatty acids, tryptophan and cortisol 
(Reed et al ., 1975). 
Electrophoresis has been the standard technique used in the separation 
of plasma proteins for several years. The method can also be carried out 
in the presence of ligand and the results give valuable qualitative information 
on which proteins are involved In binding and can also yLold some quantitative 
estimation of the relative binding to different proteins (Goldstein, 1949; 
Desgres and De Traverse, 1966; Meyer and Gutman, 1 11619). 
Many drugs are typified by high tipopl, hilicity and tow water solubility. 
The partition of a drug between organic phase and aqueouu ;, protein containing 
phase has been used to estimate binding of such compounds, where ligand is 
initially dissolved in the organic solvent. Binding may be estimated from 
partition co-efficients in the presence and absence of protein. The inter- 
action of BSA with variousorganic ions (Karush, 1951), antibiotics (Scholtan, 
1963), steroids (Scheliman et a1.1954; ALfsen, 1.963), itid fatty acids 
(Goodman, 1958a, b; Ashbrook et al., 1975; Spector et al., 1969,1971) 
has been examined in this way. Some caution ought to be exercised before 
placing great confidence on results from partition experiments since the 
organic phase may interact with the protein, causing a change in conformation 
(Alfsen, 1963) and protein is very susceptible to unfolding or denaturation at 
organic/aqueous interfaces (Steinhardt and Reynolds, 1969). A dynamic 
partition technique has been introduced recently (Robertson and Madsen, 
-67- 
1974) which is related to normal partition methods in the same way that 
dynamic and equilibrium dialysis techniques are related. The partition 
of l igand between a liquid, protein phase and an agar med ium, conta irx ing 
growing bacteria, has been used to study binding (javidan and Mrtek, 1973a, b, 
1975) with apparently better precision than an equivalent chemical method. 
For the analysis of drug binding in vivo several methods have been 
suggested to give good estimations of plasma free drug concentration. 
For drugs which are not actively transported, a good Index of free drug is 
the concentration found in protein-poor body fluids such as cerebrospinal 
fluid (CSF) or saliva (Koch-Weser and Sellers, 1976a). ?A good agreement 
has been found between unbound diphenylhydantoin in plasma and the 
concentration in CSF (Lund et al. , 1972) or saliva 
(Bochner et al. , 1974) 
iri man. An in vivo dialysis method, where a small cellulose dialysis 
sac was Implanted in the peritoneal cavity of rats, has been described by 
McQueen (1968). It was found, for the long acting drug sulphormethoxine, that 
the equilibrium sac concentration was close to the plasma free concentration. 
The method has been used to study the displacement of sulphomethoxf. rie by 
phenylbutazone (McQueen, 1969) and the binding of salicylate, with its 
effect upon plasma tryptophan (Wilson, 1974). 
1: 7: 7 SPECTROSCOPY - GENERAL 
The preceding methods can supply accurate estimations of the concen- 
tration of bound or free ligand, but generally these techniques do not give 
any information on the nature of the ligand-protein complexes. The 
characteristic interactions of light with ligand or protein may well be altered 
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by binding, and thus spectroscopic techniques can provide detailed Information 
concerning the character of the complex. Quantitative measurements of 
binding can also be made using optical methods, but calcLd ti. ons generally 
Involve several assumptions which may lead to greater errors than are 
present in data from non-spectroscopic methods. The following authors 
have contributed review type articles of the role of optical methods in drug- 
protein interactions: Steinhardt and Reynolds (1969), Chignell (1969,1971, 
1972 a, b, 1973,1974) and Bridges and Wilson (1976). 
1: 7: 8 ABSORPTION SPECTROSCOPY 
The absorption of light due to the electronic transi-Liuns of proteins and 
drugs is typically in the ultraviolet (Ti'! ) region of the ý poctra (200 nm - 
380 nm), although some drugs do absorb visible light. alle characteristic 
absorption of free drug or protein may be changed profouttclly when bound, 
but the absorption of the protein is from such a complex mixture of transitions 
that interpretation of changes may be difficult. Gross changes In protein 
UV spectra are generally thought to reflect major confonnational changes, 
unfolding or denaturation (Polet and Steinhardt, 1968; Steinhardt and 
Reynolds, 1969) . Changes in ligand absorption may be more easily under- 
stood and have been most informative in many protein binding studies. 
I 
Several types of electronic transition give rise to aka! -sorption in the 
UV region; saturated hydrocarbons contain only strongly hound a electrons 
which require a large input of energy for excitation to a* antlbonding 
orbitals, equivalent to absorption in the far UV. Unsaturated compounds 
containing double or triple bonds or an aromatic system contain 7r electrons 
-69- 
which may be excited to a 71 * anti-bonding orbital. N-n* transitions 
are of an electron from a non-bonding atomic orbital (lone pair) into a Tr 
antibondirg orbital, which occurs in molecules containing a double bond 
between heteroatoms. The final type of transition is less important, since 
it only occurs in saturated systems with bromine, sulphur or nitrogen atoms, 
that is the n-Q* transition from non-bonding to 6 antibonding. If portions 
of the absorption spectra of a ligand can be ascribed to one of these transitions 
then changes with binding may indicate which pails of thy: molecule are most 
involved in the interaction. By measuring the extinction coefficients of 
bound and free tigand quantitative data can be generated, providing the 
extinctions can be proven to obey Beer's law (Steinhardt and Reynolds, 1969). 
Klotz (1960 and Klotz et al. 1946) has used this approach to estimate the 
binding of various azo dyes to BSA, which is typified by a marked reduction 
in dy : absorption around 500 nm. 
Studies of changes in Iigand absorption with binding are often accompanied 
by measurement of the ligand's spectra in solvents of various polarity in 
order to mimic the movement of ligand into the hydrophobic binding site 
(Laurence, 1952). In this way, it has been shown that HABA (2- [4'hydroxy- 
phenyazo] benzoic acid) binds to a hydrophobic area of BSA (Baxter, 1964) 
and the dye has subsequently been used as a 'spectrophotometric probe' 
in binding studies with sulphonamides (Morigushi et at., 1968), sulphonyl- 
ureas and phenothiazines (Zia and Price, 1975), tetracyclines (Zia and Price, 
1976) and L-thyroxine (Morigushi et a1, , 1974). 
Most of the ligands mentioned thus far have absorption maxima in the 
visible region, far from the absorption of the protein. Many drugs, however, 
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absorb light in the same region as proteins. In these cases spectral 
modifications may be very small in comparison to the total. absorption. 
Under such circumstances difference spectroscopy, using tandem cells, 
has been employed. Herskovits (1967) pioneered the use of tandem cells 
in which protein and ligand are separated in the reference cell, but combined 
in the sample cell. The difference spectra produced are often multiphasic 
reflecting modification of both protein and 1lgand spectra with binding. 
Tandem measurements have been used in investigations ot the albumin 
binding of phenylbutazone (ChigneLi, 1969a), flufenamic acid (Chignell, 
1969b), phenothiazines (Huang andGabay, 1974), bitirubin (Krasner, 1973) 
and steroids (Ryan, 1968). 
1: 7: 9 FLUORESCENCE SPECTROSCOPY 
The loss of energy from an electron, excited due to the absorption of 
light, may occur by any one of several possible mechanisms (see fig. 1: 5). 
Fluorescence Is the phenomenon which is observed when light Is re- 
emitted by a molecule when an electron returns to the ground state from 
the first excited singlet state. Absorption of UV light normally results 
in the excitation of an electron to one of the vibrational sub levels of 
the first excited state, the vibrational energy being rapidly lost by radiation- 
less processes before light is re-emitted. Since energy is lost previous 
to emission the fluorescence is always at a longer wavelength than 
absorption. The fluorescence of any molecule is typified by the wave- 
lengths of maximum excitation and emission, the quantum yield, the 
fluorescence lifetime and the fluorescence polarisation. These parameters 
are exquisitely sensitive to the environment of the fluophor which makes 
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fluorescence an ideal tool to probe ligand-protein interactions. (For a 
more detailed account of the theory of fluorescence and biological 
applications of the technique see Chen, 1972). 
There are several possible approaches to the use of fluorescent 
spectroscopy In drug-albumin studies; since albumins are mostly class 
B proteins (i. e. they contain tryptophan; Weber, 1960) they are themselves 
fluorescent, and ligand binding may modify the phenomei; on. The ligand 
under study may be fluorescent, the parameters of which may change with 
binding. Finally if the ligand is non-fluorescent and does not modify 
the protein's fluorescence the technique may still be used if ligand binding 
influences the fluorescence of a 'probe' molecule which is complexed with 
the protein. Chignell (1970b, 1972,1973,1974) has authored several 
review articles concerning fluorescence spectroscopy and. protein binding. 
a) Protein Fluorescence 
Human Serum Albumin has one tryptophan residue, whilst the Bovine 
variety has two. The fluorescence of both proteins is due almost completely 
to the tryptophan residues with a small contribution from tyrosine and even 
less from phenylatanine. Enhancement of albumin fluorescence with ligand 
binding is rare, but quenching is relatively common and occurs because of 
one or two processes. If the environment of the fluophor, protein tryp- 
tophan, is altered, then the fluorescence characteristics may also be changed. 
Thus, conformat Iona I change, unfolding or partial denaturation could account 
for ligand induced fluorescence alterations. This process is thought less 
common than that of energy transfer between excited protein tryptophan and 
bound ligand (Chignell, 1972). 
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The process of energy transfer may be likened to the induction of 
vibrations in a tuning fork by the vibrations of a nearby tuning fork of 
the same frequency. Forster (1951) has shown that for energy transfer 
to occur the emission band of the donor molecule and the absorption band 
of the acceptor must overlap. Energy which is transferred In this way may 
either be lost by radiationless processes, or re-emitted at the emission 
wavelength of the acceptor molecule. The efficiency of energy transfer 
varies as a function of the distance between the two molecules, a fact 
which has been used to calculate the proximity of binding sites to albumin 
tryptophan (Chignell, 1970a, b, 1972). Energy transfer between warfarin 
and albumin tryptophan will be discussed further in chapter 3. 
The quenching of albumin fluorescence by energy transfer has been 
used to quantify the binding of bilirubin (Chen, 1971), dicoumerol (Chigne[L, 
1970a) and thyroxine (Steiner et at., 1966) whilst the quenching of albumin 
with steroid binding is thought to be due to conformational changes 
(Attalah and Lata, 1968). The influence of fatty acids on albumin f luore s- 
cence is considered in chapter 4. 
b) Ligand Fluorescence 
The binding of a fluorescent molecule to protein may result in the 
modification of one or more of the parameters of fluorescence. The change 
in fluorescence indicates a change in environment and in this way molecules 
can be used as fluorescent probes of their own binding sites . Drugs which 
are fluorescent and which change their characteristics upon binding Include 
chlorpromazine (Teller et al., 1968), camptothecin (Guarino et at., 1973) 
p 
and warfarin (Chignell, 1970a; Wilson, 1974). The fluorescence properties 
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of warfarin and other coumarin derivatives will be covered more fully in 
subsequent chapters . Changes in ligand fluorescence can be used to 
obtain estimates of the various binding parameters of t}: (! interaction 
(Chignell, 1972) but such values will not, of course, reflect any binding 
which does not affect the ligand fluorescence. 
c) Fluorescent Probes 
Any small molecule which undergoes a large change in fluorescent 
properties with binding to a macromolecule can be termed a fluorescent 
probe, including those drugs mentioned in the previous section. Fluorescent 
probes can be used to monitor changes In macromolecule structure or 
conformation, or to reflect competition of other ligands for the probe's 
binding sites (see Edelman and McClure, 1968 for a general review of the 
field) . The earliest and probably still the most populý. r probes are the 
aminonaphthalenesulphonate derivatives such as 1-ar, i. i. ntonaphthelene-8- 
sulphonic acid (ANS), 2-p-toluidinylnaphthalene--6-su _i) roriic acid (TNS), 
and 5-dimethylaminonaphthalene-1-suIphony[ (dansyl) amino acid derivatives. 
These compounds have an increased quantum yield and a blue-shifted 
emission maximum when bound to protein or In other hydrophobic environments, 
compared to aqueous solution . ANS, especlalLy, has been used In a great 
many studies of drug-albumin interactions, being displaced by drug in order 
to obtain an estimate of the drug's binding parameters (for example HSU 
et al., 1974). The fluorescence polarisation of the ANS-BSA complex 
has been used to determine the orientation of the probe when bound, and to 
gain insight to the topography of albumin binding sites (Anderson and Weber, 
1969). 
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Several alternative probes, which, because of their differing structures 
may bind to sites other than those of ANS, have been introduced recently: 
kynurenin (Churchich, 1972); tetracyclines (Popov et at. , 1971); bilirubin 
( Krasner, 1973); iprindole (Wilson, 1974); acridines (Ma et al ., 
1974) and sulphophthaleins (Nishikimi and Yoshino, 1972). 
The suitability of the fluorescent probe approach for drug-albumin 
studies, with particular reference to coumarins and drug displacements is 
discussed at length in chapter 3. 
1: 7: 10 CIRCULAR DICHROISM AND OPTICAL ROTATORY DISPERSION 
Circular dichroism and optical rotation are two phenomena which 
occur when plane polarised light interacts with a solution of an optically 
active molecule. Even a brief explanation of the phenomena must be 
preceded by an account of the nature of polarised light. Electromagnetic 
radiation is composed of electric and magnetic fields oscillating at right 
angles to each other and in a plane perpendicular to the direction of 
propagation of the beam. Light may be collimated to produce radiation 
of one wavelength only and polarised so that the electric and magnetic 
vectors oscillate in single planes only, such light Is Illustrated In figure 1: 7a . 
For further explanation only the electric vector will be considered, since 
it is this wave with which electrons exchange energy. Plane polarised 
light may be considered as the sum of two waves of circularly polarised 
Light of opposite sign, the vectors of which are of fixed magnitude, rotate 
in opposite direction from the same centre of rotation and are exactly in 
phase (figure 1: 7b ). When such a beam enters an optically active solution 
-76- 
Figure 1: 7 The olarizatton of radiation 
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a. Plane-Polarized Radiation . The direction of prop>ogation is along the 
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b. Circularly-Polarized Radiation. Only the electric vector Is shown. 
By convention, this Is right circular polarization, slnce an observer at 
point P would see the field rotating In a clockwise direction. 
c. The same circularly-polarized wave as shown above, represented as 
the sum of two plane-polarized waves. 
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the left and right components may be retarded differentially, which results 
in an emergent ray of the same circularly polarised components but now out 
of phase. The resultant of these two is a plane polarised beam emerging 
at an angle to the entering beam (see figure 1 : 8b ). This type of activity 
is known as optical rotation (OR) and a scan over different wavelengths is 
termed the optical rotatory dispersion (ORD) of a sample. Note that ORD 
is due to different refractive indices for left and right circularly polarised 
light and may thus be observed at wavelengths where t: ho molecule does 
not absorb light. If the two circularly polarised beam.:; are absorbed 
differentially then the emergent ray will be eliptically polarised as shown 
in 1: 8c . This second phenomenon is known as a circular dichroism 
(CD) and since it is an absorptive process, it can only be observed at 
wavelengths where the molecule absorbs light. The combination of unequal 
absorption (CD) and unequal velocity of transmission :: lt) of left and right 
circularly polarised beams (as in fig. 1: 8d ) at the wavelength region 
where an optically active molecule absorbs light is called a "cotton effect" . 
(For a detailed treatise on the theories of optical activity see Lowry, 1964). 
The applications of CD and ORD to problems in pharmacology have been 
reviewed by Chignell (1968,1970; Chignell and Chignetl, 1972). 
The optical activities of proteins are the result of a great number of 
chromophores including helical portions of the structure, and thus CD and 
ORD spectra are complex and difficult to interpret. Any small changes 
which may result from ligand binding are equally difficult to interpret but 
such measurements have been used to examine the interaction of proteins 
with azodyes (Markus and Karush, 1958), detergents (see review by Perrin 
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Figure 1: 8 The effects of optlcaiiy active media on pol-arized licht 
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wavelength where light Is absorbed but rotation Is zero. EL and ER are 
In phase . 
D. Optical rotation and dLchroism of light. 
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and Hart, 1970), and some small organic molecules (Helmer et at., 1968). 
Some drugs, especially those of natural origin, are optically active and 
ORD/CD may be used to study their Interactions with proteins, but the 
vast majority of drugs are not optically active. Nevertheless the latter 
group of compounds form the bulk of molecules whose binding to proteins 
have been studied using CD/ORD. 
This paradoxical situation arises because a symmetrical (non-optically 
active) molecule may be perturbed upon binding by an asymmetric centre of 
the protein to give rise to induced or extrinsic optical activity. Many 
small molecules, particularly those with a high affinity, produce such 
extrinsic effects with binding to albumin. CD measurements of these 
complexes can be used to quantify the binding (Ikeda and Hamaguchi, 1969;, 
Rosen, 1970) and may provide detailed information on the nature of the 
complex. The binding of the following drugs to albumin has been studied 
using CD or ORD: phenylbutazone (Chignett, 1969a), ftufenamic acid 
(ChLgnell, 1969b), dicoumerol (Chignell, 1970; Perrin and Idsvoog, 1971), 
warfarin (Chignelt, 1970; Perrin and Nelson, 1972), sutphoethidole 
(Kostenbauder, et at., 1971) and benzodiazepines (Muller and Wollert, 1974,, 
1975a, b, 1976). The use of CD to study coumarin-albumin interactions is 
expanded in chapters 5 and 6. 
1: 7: 11 MAGNETIC RESONANCE -TECHNIQUES 
Nuclear magnetic resonance (NMR) and electron spin resonance (ESR; 
syn. electron paramagnetic resonance, EPR) are two closely related techniques 
which are playing an increasingly important role in studies of ligand-rnacro- 
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molecule interactions. Both techniques are based upon the fact that some 
charged sub-atomic particles have a spin and an associated magnetic field. 
In the presence of an external magnetic field such particles align in the 
same direction as the external field, but they can, with the absorption of 
characteristic quantities of energy 'flip'to be aligned in the opposite 
direction. It is the absorption of energy and the subsequent relaxation to 
the normal state which are studied in magnetic resonance techniques. 
ESR is concerned with the resonance of unpaired electrons such as 
those in transition metals and free radicals. Since there are few natural 
examples of unpaired electrons the stable spin probe has been used in many 
studies of biological systems. Few free radicals are stable under 
R 
biological conditions, but the nitroxide radical (1 _N - 0) Is stable in 
R 
aqueous solution at neutral or alkaline pH. In studies of ligand-protein 
interactions the spin probe can be complexed with the protein, or may be 
part of the ligand. Changes in the ESR spectrum with binding are Interpreted 
as either an increase or a decrease in the degree of Immobilisation of the 
probe . Triazine labelled BSA 
(Blanchard et al., 1973,1975) has been used 
in binding studies with various anionic compounds and a series of tricyclic 
antidepressants. The acidic drugs were thought to cause a partiat 
unfolding of albumin, reflected by a conversion of 'strongly Immobilised' 
probe to a 'partially immobilised' state. The basic drugs were found to 
produce the opposite shift with binding. A similar approach has been used 
to study surfactant binding to BSA (Oakes, 1973b) . The alternative variation, 
having a labelled ligand, has been used by Lagercrantz and Setaka (1975) 
in a study of HSA binding of a nitroxide derivative of stearic acid. 
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In NMR, the particles of interest are atomic nuclei with non-zero spin. 
Since the nuclei 
1H, 2H, 13 
C, 
14 
N, 
170 
and 
31P 
are a11. members of this 
group NMR has a far wider application to biological probloms than ESR. 
Proton magnetic resonance (PMR) Is the most common form of NMR, at 
Least In regard to biological studies, since the other nuclei are less 
abundant in nature and enrichment Is necessary to yield detectable signals. 
The application of NMR to pharmacological problems has been well reviewed; 
Burgen and Metcalf, 1970; Fisher, 1971; Hollis, 197`' ind Sykes and Hull, 
1973. PMR is a most useful tool in ligand protein interactions since the 
various protons of a ligand give characteristic signals in the spectrum and 
the changes upon binding can give a direct indication of which portions of 
the ligand are involved in the interaction. The application of PMR to drug- 
albumin studies was pioneered by jardetsky and co-workers, with their 
studies of the interaction of BSA with Penicillin G and jardetsky, 
1965) and sulphonamides (Jardetsky and Wade -jardetsky, 1965). Sub- 
sequently, the interaction of albumin with diphenylhydramine (van der Vlies, 
1970); acetylsalicylic acid (Sykes, 1970); parasympath tcoiytics (Wiegand, 
1975); surfactants (Oakes, 1973) and the renal contrast medium atrizoate 
(Rodrigues De Miranda and Hilberes, 1976) have been examined using the 
PMR technique. 
Some of the disadvantages of NMR for drug-protein studies will be 
discussed in chapter 6. 
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1: 8 THE RATIONALE OF THE PRESENT INVESTIGATIONS 
From the preceding introduction it can be said that there are two easily 
discernable facets of the drug protein binding field, clinical aspects and 
molecular aspects, neither of which are near to being completely understood. 
The clinical aspects are tremendously important for the determination of 
correct drug dosage and regimen, and in predicting drug interactions at the 
binding level. Many more in vivo type experiments ought to be performed 
to increase our understanding of the pharmacokinetic consequences of 
plasma and tissue binding. It may be argued that the clinical situation 
will never be fully understood until the 'microscopic' n, -tt. ure of drug-protein 
Interactions is well documented. Studies of the moler; uular character of 
ligand-albumin complexes may be justified on that bas T. s alone, but these 
Interactions are worthy of investigation in their own right, without any 
extenuating arguments. 
Albumin is a truly remarkable protein. How is it possible for a single 
macromolecule to interact with a myriad of synthetic and natural compounds 
and yet have apparently specific binding sites for virtually each one? 
Clues to the answer of this question must be sought from detailed analyses 
of l igand-albumin complexes. It is ho ped, that in this way, the present work 
will contribute to a final solution of the paradox. 
Many of the compounds for wh, i, ch albumin has the highest affinity are 
amphiphiles, that is to say they have both hydrophilic and hydrophobic 
portions, and furthermore, the majority are acidic in nature. Several previous 
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reports of competition between various organic acids for albumin binding 
sites have suggested that these compounds may bind to only a few areas 
of the protein. With these two observations in mind the binding of a 
series of medium chain fatty acids and a series of coumarin drugs to albumin, 
and their mutual interaction have been thoroughly studied . 
The fatty acids form a homologous series with constant, Ionic, carboxyl 
groups and a range of hydrophobic, hydrocarbon chains. A good knowledge 
of their binding, obtained from ultrafiltration experiments at differing 
temperatures, should provide some insight into the relative contribution of 
ionic and hydrophobic interactions in the formation of the. complexes. The 
Influence of fatty acid binding upon protein structure was studied by 
measurement of protein fluorescence. 
The coumarin anticoagulants are a clinically important group of drugs 
which are typical of the organic acid type compounds avidly bound by 
albumin. The binding of a series of coumarins was examined using the 
circular dichroism technique which is highly sensitive to molecular geometry 
and ideally suited to studies of the relationship between ligand and binding 
site. The enantiomers of two coumarins, warfarin and phenprocoumon, and 
their binding to albumin were studied in order to assess the influence of 
steric factors upon binding. 
Previous studies in our laboratories (Wilson, 1974) have shown that 
warfarin is a suitable fluorescent probe for albumin binding sites. This 
approach was extended and phenprocoumon was also examined as a possible 
probe. The competition of fatty acids and coumarins for binding sites was 
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examined using both the fluorescence and ultrafiltration techniques. 
In addition to the continued examination of fluorescence measurements 
for their suitability in drug-albumin studies, several other binding methods 
have been evaluated . The commercially available versions of ultrafiltration 
(Centriflo), diafiltration and equilibrium dialysis (Dianorm) are 
compared with other well-tested techniques.. 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2: 1 MATERIALS 
2: 1: 1 CHEMICALS 
Album ins 
UnLess otherwise specified, Bovine Serum Albumin refers to Cohn 
fraction V BSA, powdered, from Sigma Chem. Co., St. Louis, Mo., U. S. A., 
lot 24C - 1740,96 - 99% albumin, remainder mostly Globulins, 15.6% 
nitrogen content. SimiLarly, Human Serum Albumin refers to Albumin Kabi, 
lyophilized powder from ABKabI, Stockholm, Sweden, lots 30299 and 
49641,98% of total protein as albumin. In certain spectroscopic 
studies BSA and HSA were purchased from Behringwerke AG, Marburg, 
Germany, 100% pure by electrophoresis, batch No's A821 and 4729 
respectively. 
Drugs 
The drugs used were obtained from the following sources: Warfarin 
(anhydrous), Sigma Chemical Co.; Phenylbutazone, Biorex Laboratories Ltd., 
London; Phenprocoumon, Roche Products, Welwyn Garden City, Herts; 
Acenocoumarin and Coumachlor were gifts from Professor E. Jähnchen, 
Dept. Pharmacology, University of Mainz, Germany; Sulphamethoxazole 
was donated by Burroughs-Wellcome, Beckenham; the enantiomers of 
warfarin were gifts of Dr. A. Breckenridge, University of Liverpool, England, 
Salicylic acid, (> 99.5%) from BDH Ltd. 
All fatty acids were purchased from B. D. H. Ltd., Poole, Dorset either 
standard grade, 98 - 101% by acidimetric assay, or specially pure, 99.5% 
-88- 
where available. All fatty acids were re-distilled before use. Ethyl 
carbamate was obtained from BDH, octyl carbamate was synthesised by 
the Chemistry Division of the Chemical Defence Establishment, Porton 
Down, Wiltshire. Radiolabelled fatty acids were purchased from The 
Radiochemical Centre, Amersham as the 1- 
14C 
labelled sodium salts. 
Rad io labe l Led carbamates were kind gifts of Mr. S. Wood and were 
produced by custom synthesis at the Chemical Defence Establishment. 
Scintillant materials were purchased from Packard Instrument 
International, Zurich, Switzerland. All other reagents were of general 
or analytical grade, normally from BDH Ltd. Regeneratod cellulose 
Visking Tubing, 18/32" was obtained from The Scientific Instrument Centre 
Ltd., London. Spectrapore membrane tubing was donkiLod by M. S. E. Ltd, 
Crawley, Sussex. Diaflo membranes were purchased from Amicon Ltd ., 
High Wycombe, Bucks. 
2: 1: 2 ANIMALS 
Hepatic microsomes were prepared for binding experiments from male 
Wistar-albino rats (Porton strain) and male Syrian hamsters. The source 
of the animals, their diet and housing conditions were all as described by 
Wilson (1974). 
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2: 2 METHODS 
2: 2: 1 GENERAL 
Unless otherwise stated, experiments were carried out using phosphate 
buffer 1/15 M (67 mM) at pH 7.4, which was prepared from solutions of 
NaH2PO4: 2H20 and Na2HPO4: 12H20 in glass distilled water. Albumin 
solutions were prepared by allowing the protein to dissolve overnight at 
a temperature of 4°C. Both BSA and HSA were assumed to have a molecular 
weight of 69,000, an overestimation by some 3% (M. W. calculated from 
amino acid composition BSA - 66,210 HSA - 66,248, Peters, 1975)) which 
compensated for the approximate 3% impurities in the various albumin 
preparations . 
2: 2: 2 ULTRAFILTRATION 
In all studies, ultrafiltration was achieved by centrifugation, using one 
of two techniques. Routinely, ultrafiltration was performed through 
dialysis tubing membranes supported in a Toribara type apparatus (Toribara 
et at., 1957). Forcomparative purposes the commercial ultrafiftration system 
Centrif10 (Amicon Corp., High Wycombe, Bucks. ) was also used. 
a) Toribara Apparatus 
As illustrated in figure 2: 1 the Toribara-type ultrafiltration apparatus 
consisted of a 50 ml polypropylene centrifuge tube (M. S. E. Ltd., London, 
England) into which a glass tube with scintered disc was placed. The 
glass tubes contained a scinter of porosity grade one and were manufactured 
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Figure 2: 1 The two types of ultrafiltration apparatus used in this work. 
Toribara apparatus 
Rubber cap 
ellulose bag 
7 La ss Toribara tube 
Incorporating 
c inter disc (Grade 1) 
Polypropylene 
centrifuge tube 
(50 ml) 
Centriflo apparatus 
D iaf to membrane, 
laminated to pa per 
support 
Polyethylene support 
Centrifuge tube (50 ml 
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by the University glassblowers. Scinters which became discoloured or 
were suspected of being contaminated in any way were cleaned using the 
violent oxidative reaction between fuming nitric acid and methonal. 
Visking (regenerated cellulose) dialysis tubing (18/32" Scientific Supplies 
Co. Ltd ., London, England) was used throughout all experiments and was 
prepared in the following fashion: - surface contamination was removed by 
several washes of the visking strips (_ 22 cm) in tap water. Strips were 
then boiled In distilled water for one hour followed by several rinses with 
distilled water. This process was found to be sufficient to remove the 
sulphorous compounds which contaminate visking tubing. During some 
portions of the work an organic wash was incorporated at this stage, but 
since the process was wasteful of methanol and gave no observable 
benefit it was discontinued in later studies. Following rinsing, visking 
strips were stored overnight in distilled water then trcimsi'erred to phosphate 
buffer (1/15 M, pH 7.4) prior to use. The ultrafiltratlon procedure took 
the following routine: drug/albumin solutions (6.1 ml) were transferred 
using either a syringe or a disposable pasteur pipette, to a visking bag, 
formed by careful knotting of one end of a 22 cm visking strip. As much 
air as possible was excluded from the bag then the bag was sealed with a 
second knot . The bag was folded Into a 'U' shape and placed on the 
scintered disc of the glass tube inside a centrifuge tube. The centrifuge 
tube was capped to prevent drying of the visking bag, and was ready for 
centrifugation. Gentle treatment of the cellulose tubing was necessary 
at all times to prevent the formation of minute holes in the bag. The 
assembled centrifuge tube was centrifuged in an MSE Mistral 6L centrifuge 
(using the 6x 1L swing out rotor with 4x 50 mL rubber adaptors) at 2,000 g 
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(av) (2 
,2 00 r. p .m .) 
for one hour at thermostatically controlled temperatures 
from 4°C to 37°C . After centrifugation, glass tubes were removed from the 
apparatus, bags were checked for signs of leakage and duplicate samples 
(0.1 m l) of u ltrafi ltrate were taken for drug analysis . 
In all experiments, tubes were included which contained only drug 
solution, in order to check for loss in the system. An overall recovery 
of 95% was deemed the minimum acceptable level. 
b) Centrif lo 
The components of the CentrifloR system are shown in figure 2: 1. 
AD iaf to 
R 
membrane (Am icon Ltd ., High Wycombe, Eng land .. 
See chapter 
3 for details of this type of membrane) Is formulated into a cone which 1s 
supported by a plastic support, this in turn fits into a graduated centrifuge 
tube. Diaflo membranes were soaked overnight in distilled water, then 
after removal of excess liquid using paper tissues, the membranes were 
centrifuged for ten minutes In an MSE Mistral 6L centri. 117uge (using 6x IL 
swing out rotor with 4x 50 ml rubber adaptors) at 1,000 r. p. m . in order 
to remove further liquid. Drug-albumin mixtures (3 ml to 5 ml) were 
pipetted into the dried cones and centrifugation as before at 1,000 r. p. m. 
at 200C or 370C, for 5 minutes was found to be enough to remove .- 10% 
total volume as filtrate. Samples of filtrate were then taken for drug 
analysis . Cones were cleaned for re-use using the following procedure: 
after emptying, the cones were rinsed several times with 5% saline solution 
followed by washing for 3-4 hours in circulating tap water. The cones 
were then rinsed thoroughly in distilled water before storage in 10% ethanol. 
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Figure 2: 2 The arrangement of apparatus for the continuous 
ultrafiltration procedure. 
Magnetic stirring 
bar 
U ltraf i Ltrate , 
Membrane 
to fraction collector 
Magnetic 
stirring table 
Filling port and 
safety valve 
Inlet port 
Reservoir of stock 
drug solution 
Constant 
flow pump 
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2: 2: 3 DIAFILTRATION 
The diafittration (syn. continuous ultrafiLtration) apparatus used 
in this study is Illustrated In figure 2: 2. The binding of Sodium Salicylate 
and Sulphamethoxazole to BSA was examined using this technique. A 
brief consideration of the theory of continuous ultrafiltration will aid the 
understanding of the practical routines. 
A diafiltration cell Is, simply, a cell bounded by a membrane which 
is permeable to solvent and ligand but impermeable to macromolecules. 
A solution of ligand is passed Into the constant volume cell at such a 
speed that it equilibrates with the macromolecule. Since the cell has 
a constant volume, continuous addition of ligand solution results in the 
production of an ultrafiltrate through the membrane, which is macromolecule 
free and may be collected in fractions and analysed for free ligand. 
concentration. 
The Ultrafiltration of a well stirred, constant volume sample is readily 
amenable to mathematical analysis,. Blatt (1968) has provided a compre- 
hensive series of mathematical models to describe such situations. The 
treatment below best suits the conditions used in this work. 
Consider the following system: - 
Concn =C 
0 
STOCK 
C 
0 
CELL 
Concn =C 
Volume V 
ULTRAFILTRATE 
FRACTION 
Cl 
dV 
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The amount of ligand inside the cell, A=C. V. If the cell contains no 
binding macromolecule then Cl =C and for a small addition from the stock: - 
dA =C dv - C. dv 0 
but A=C. V ". , VdC = dv (Co - C) 
rearranging and integrating :- 
c dC" v dv 
Of c0-c -jv 
[-Ln (Co-C)] [V ]o 
putting in the limits: - 
LnCo C=v Co V EQU 1 
Cv 
o-C V 
or: - C-e 
0 
V 
C=c0 (1-e 
v) 
EQU2 
O's 
From equation 1 it is apparent that a graph of LnC0 -C against v (volume 
of ultrafiltrate) will have a slope of -- an intercept of Co and will, of 
course, be a straight line. The linearity of such a graph and the value 
of the experimental cell volume (V) are useful checks that there are no 
anomalies in the system. Binding of ligand to the apparatus, for example 
would yield an experimental cell volume larger than the actual cell volume. 
(Note that this graph is constructed from an experiment with no macro- 
molecule present). 
It is reasonable, that if the Ligand concentration is zero at the start of the 
experiment, then: - 
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Amount Added = Amount Inside + Amount Eliminated 
v 
or: Co v= CV -º- fC dv EQU 3 
0 
This is fully compatible with previous calculations and may be checked 
as follows: - 
V 
From equ. 2 
V 
J C. dv 
V 
(1 -ev) . dv =fC o 
v V 
or: f C. dv 
v 
= [C .v+C .Ve 
V] 
o o 
v 
v v i. e. j C. dv .v+C =C .V (e 1) o o 
_v 
but from equ. 2 again: (e C 
v- 1) c 
o 
V 
f C. dv = C. v - C. V 00 
v 
or: Co v=C. V +rC. dv i. e. EQU 3 
If some drug is bound, equ. 3 is modified 
v 
Co .v= V(Cf +Cb)+f Cf. dv 
0 
which rearranges to: = 
Co 'v 1v 
Cb -V- Cf -Vf Cf -dv EQU 5 
Cb is the value one wishes to calculate, 
C VV 
, Cf at id v are all 
known, the final term may therefore be calculated from a graph of 
Cf against v :- 
Cf The lag volume only applies to the 
volume collected, not added. 
i. e. Vi= volume collected minus 
the lag volume. 
Lag V. Vi+l v 
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by the trapezoidal rule, if x= no. of fractions collected 
i=x 
_v Area =i=zill. (V +1 
Vi. ). (Cfi + Cfi 
+ 1) =j 
CF. d 
Thus, from a knowledge of the stock ligand contration Co, the cell 
volume V, the ligand flow rate and the free ligand conch Of in each 
fraction of ultrafiltrate the concentration of bound ligand Cb may be 
calculated. 
From this theory it should be obvious that two types of experiment 
are performed for each ligand under study, one with protein in the cell 
and one without. Both experiments follow the same procedure. 
A stirred ultrafiltration cell (Model 12 - Arnicon Ltd., High Wycombe, 
England) was used with a 'Diaflo' polyolefine membrane (PM. 10, Amlcon). 
Ligand was pumped with a constant flow pump (Labatron, Munich, Germany) 
and fractions were collected using an L. K. B. Ultrorack 7000 fraction 
collector (L. K. B. Instruments Ltd ., South Croydon, Surrey). The apparatus 
was arranged as in figure 2: 2 with all connecting tubing in Teflon. 
preliminary experiments were performed to determine the exact Internal 
cell volume, the protein retentivity of the. membrddne and to check the 
accuracy of the pump and fraction collector. ALL solutions were degassed 
before use in order to prevent air bubbles forming in the pump or cell. 
The pump was equilibrated with stock ligand solution for 30 mans before 
each experiment. Membranes were soaked overnight in distilled water 
to remove the glycerol protective coating, then equilibrated with buffer 
by gentle stirring for one hour prior to use. 
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The cell was assembled ensuring that the supporting disc below the 
membrane and the outlet tubing were full with buffer to eliminate any 
dead space. The cell was then completely filled with buffer or protein 
solution and connected to the pump. The cell was stirred whilst Ligand 
was pumped into the cell at a rate of,.. 3ml. hr-1 and fractions of ultrafiltrate 
were collected each 10 mans. Experiments were continued for 8- 10 hrs, 
allowing about two cell volumes of ligand solution to be added. Aliquots of 
each fraction, the cell contents and the stock ligand solution were taken 
for drug ana[ysis. 
2: 2: 4 EQUILIBRIUM DIALYSIS 
The binding of Sodium Salicylate to BSA was studied using the Dianorm 
equilibrium dialysis system (MSE, Crawley, England) in order to evaluate 
the apparatus. The system Is based upon the design of Weder (Weder and 
Bickel, 1970; Weder et a[., 1971), and consists of up to 20 dialysis cells 
which can be rotated at a constant speed in a temperature controlled water 
bath . 
The cells are made in two halves which fit together, the membrane 
being sandwiched between them, slightly tensioned and clamped In the 
process. The shallow sample cavity is at the centre of each half cell 
and is separated from the neighbouring cavity by the membrane. Holes 
around the edges of the cells facilitate filling the cavities after assembly. 
The cells and stoppers are made of PTFE (Teflon) to minimise binding of 
ligands, and have an internal volume of 1 . 36 mL per half cell. 
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The apparatus was used in the following manner: - Spectrapor 2 
(M. W. cut off 12,000-14,000 - MSE Pub. No. 520) regenerated cellulose 
membrane was prepared as described in section 2: 2: 2 for Disking tubing. 
The membrane was dried with paper tissue before assembly of the cells. 
To one half cell 1 ml phosphate buffer (PH 7.4,67 mM) was added using 
an automatic pipette (Oxford Labs. ), whilst to the other half of the cell 
1 ml of drug-protein or drug-buffer solution was added. Cells were 
stoppered and dialysis was carried out at 20°C with the cells rotating at 
10 rpm. At the end of the dialysis period aliquots were, removed from each 
half cell for drug determinations. 
2: 2: 5 ULTRACENTRIFUGATION 
U ltracentrifugation was used in an attempt to quantify the reversible 
binding of Ligands to the mlcrosomal fraction of liver homogenates. The 
method of centrifuge sedimemtation used was basically that of Bickel and 
Steel (1974) which was in turn a modification of that of Ernster and Orrenius 
(1965). Ligand was added to a microsomal preparation (about 1.5 mg 
protein. ml-1, prepared as described in section2: 2: 13) at various concen- 
trations and allowed to equilibrate for ten minutes at 4°C . Suspensions 
were then transferred to centrifuge tubes (10 ml -- MSE) and centrifuged 
at 100,000 g. av. for 1 hr at 4°C (in the MSE Super Speed 50, at 40,000 
rpm using a 10 x 10 ml fixed angle rotor). After centrifugation aliquots 
of the particle free supernatant were taken for drug analysis. 
-100- 
2: 2: 6 ABSORPTION SPECTROPHOTOMETRY 
The visible and ultraviolet absorption spectra of various coumarins 
and their complexes with albumin were recorded using a Perkin-Elmer 
356 double beam/double wavelength spectrophotometer (Perkin Elmer Ltd., 
Beaconsfield, England) coupled with an A3, flat-bed, X-Y recorder. The 
wavelengths of the apparatus were calibrated using an Holmium Oxide 
filter, and were found to be accurate to + 0.2 nm over the totat wavelength 
range. Spectra were recorded using conventional stoppered quartz cells 
(Helma Ltd ., Westcliff-on-sea, Essex) at 25 
0C and 0-1A units full 
scale. With final concentrations of albumins (BSA or USA, Behringwerke, 
-5 -5 Marburg, Germany) at 3x 10 M and coumarins 2x1UM In phosphate 
buffer (pH 7.4,67 mM), the following spectra were recorded; - 1, Buffer 
in sample and reference - if baseline not flat ± 0.01 A units material 
discarded; 2, Coumarin - Sample, Buffer-Reference-coumarin absorption 
spectra; 3, Albumin - Sample, Buffer-Reference-albumin absorption spectra; 
4, Coumarin/Albumin - Sample, Buffer-Reference-Spectra of coumarin/Albumin 
complex; 5, Coumarin/albumin - Sample, albumin-Reference-spectra of 
bound coumarin; 6, Coumarin/albumin - Sample coumarhi--Reference, - 
difference between bound and free coumarin, plus spectra of Liganded 
albumin. (See figure 5: 4- for an example of these spectra). 
2: 2: 7 FLUORESCENCE SPECTROPHOTOMETRY 
All fluorescence measurements were made using 1 cm quartz cells 
(Helma Ltd) in a Perkin-Elmer MPF 3 spectrofluorometer coupled to a 
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Perkin-Elmer QPD-33 Recorder (Perkin-Elmer Ltd., Beaconsfield, 
England) at a controlled temperature of 30°C + 1°C unless otherwise 
specified. Activation and emission slit widths of 5mm were used in all 
measurements. It should be emphasised that the fluorescence 
intensities and maxima reported in this work are uncorrected, except for 
dilution where applicable. Thus, because of lamp and photomuLtiplier 
variations and the phenomenon of self-absorption (inner-filter effect) 
results In this work are comparable with those obtained under similar 
conditions using the same equipment but not necessarily comparable with 
other data. Corrections which could have been employed, and the reasons 
for not doing so will be discussed in Chapter 3. 
ALL results were obtained by measuring luminescence at an angle of 
90 0 to the activation beam, spectra were recorded using a wavelength 
scan speed of 120 nm. min and a chart recorder speed of 12 cm. min-1. 
Fluorescence titrations took the following general procedure: - 
2 ml of solvent (either buffer or protein solution) were pipetted Into a 
1 cm cuvette which was stopped using a subs seal stopper, mixed, and 
allowed to equilibrate to the cuvette holder temperature (300 C+ 1°C) . 
An initial spectra was recorded at the desired excitation wavelength. 
Fluorescence or quenching agent was then added through the Suba Seal 
using a 10 p1 microsyringe (Terumo-Shandon, Camberley, Surrey or S. G. E. , 
N. Melbourne, Australia) and a second spectra was recorded, superimposed 
upon the first. Subsequent additions were made in the same way, mixing 
being achieved by several inversions of the cuvette. Total additions 
were never more than 40 p 1, which constitutes a 2% dilution. Addition 
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of up to 40 uL of buffer to 2 ml of fluorescent protein or probe solution 
produced changes in fluorescence insignificant In relation to the overall 
experimental error. 
Fluorescence titrations of three types were performcd: -- 
a) quenching of albumin fluorescence, in this case the fluorescence of 
2 ml HSA or BSA (5 x 10-6M to 5x 10-5M) was measured using an 
excitation wavelength of 290 nm and the effects of ul additions of quencher 
(1 x 10-3M -1x 10-1M) were recorded. b) Fluorescuance of probe molecules, 
for these experiments 2 ml of buffer (phosphate pH 7.4,67 mM) or albumin 
(HSA or BSA 5x 10 -6 to 5x 10- 
5 M) were titrated with. Probe solution 
(1 x 10-3M -5x 10-3M) . The fluorescence of the probe was recorded 
with an activation wavelength of 320 nm. If applicable, the quenching of 
protein fluorescence could be monitored using the same sample. 
c) Displacement of a fluorescent probe, in this instance a probe-protein 
mixture (generally a ratio of 1: 1 and about 1x 10M5M) was titrated with 
increasing amounts of displacing agent. The fluorescence of the probe 
(excitation 320 nm) and, in some cases the protein (excitation 290 nm) 
were monitored. 
2: 2: 8 CIRCULAR DICHROISM 
Circular Dichroism measurements were made at 27°C with a Cary 61 CD 
spectropolarimeter (Cary, Monrovia, Calif., U. S. A. ) which was calibrated using 
d-camphorsulphonic acid. Spectra were recorded using cylindrical quartz 
cells of 10 mm pathlength (Helma Ltd., Westcliff-on-Sea, Essex) with a 
full scale deflection of 0.050 and a spectral band width of 2 nm. 
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The CD spectra of albumin alone (3 x 10- 
5 
M, HSA or BSA) or albumin 
plus ligand (6 x 10 M) were recorded in phosphate buffer (pH 6.6 to 8.2, 
67 mM) .A baseline of phosphate 
buffer atone was recorded regularly to 
check for changes in machine response. At least 3 different spectra were 
recorded and a mean spectra was produced manually by superimposition and 
drawing a mean by eye. Only very small deviations were seen between 
different spectra of the same sample. Difference spectra were obtained by 
subtracting the elipticity for albumin from the drug-albumin spectra. This 
was performed from measurements every Snm. In the case of enantiomers 
bound to albumin, the intrinsic optical activity of the Isomer was also 
subtracted to give a 'double difference spectra'. The results are expressed 
-2 -1 
as molar elipticities 6 (deg. cm . dmole ) which urc: calculated with 
respect to albumin concentration (3 x 10- 
5 
M), tota L drug concentration 
(6 x 10- 
5 M) or bound drug concentration. In some cds^s anisotropy 
factors (g-values) were calculated, following the method of Chignell (1969), 
using the equation: - [8] 
g 3300 xc 
where [e] Is the molar elipticity of the drug bound (or in buffer for enantiomers) 
and e is the molar extinction coefficient of the drug bound (or in buffer for 
enantiomers). 
2: 2: 9 NUCLEAR MAGNETIC RESONANCE 
In a limited study of the binding of warfarin and phenprocoumon to BSA, 
_2 the following conditions were used: drug (1 x 10 M) was dissolved 
initially in NaOD (30% in D20) then made up to volume in D20. Solutions 
of the same drug concentration were also prepared with BSA concentrations 
-104- 
of 1,2,3 and 4% (6.77 x 10-5 M-2.89 x 10-4 M) . NMR spectra were 
obtained at 40°C using a Varian XL-100 instrument equipped with Fourier 
Transform (F. T. ) facilities. Spectra were recorded from 50 transients using 
the F. T. system. 
2: 2: 10 LIQUID SCINTILLATION COUNTING 
Carbon-14 Labelled ligands were used extensively throughout the 
work reported here, particularly in ultrafiltration experiments. In the 
early sections of the project the following counting conditions were used: - 
0.1 ml of sample (aqueous) was added to 10 mt Bray's scintillant (Napthalene 
60 g. L 
1; PPO, 4 g. L-I; dimethyt POPOP, 0.2 g. L 
1; 
Analar Methanol, 
100 mt. L-1; ethane dial, 20 ml. L-1 in 1". 4 Dioxa. n) In glass scintillation 
vials. Radioactivity was measured using a Packard TriCarb 3320 instrument 
(Packard Ltd ., Reading, Berks. ). The bulk of the scintillation counting 
was, however, carried out as follows: 0.1 ml samples were transferred to 
polypropylene 'mini vials' and diluted with 0.4 ml distilled water. 4.0 ml 
of Toluene/Synperonic (BDH) scintillant was added (2: 1 Toluene: Synperonic, 
4 g. L- 
1 PPO) and shaken to form a clear gel. Vials were 'counted' using 
an LKB Wallac 1210 Ultrobeta liquid scintillation counter. A total of 20,000 
counts were recorded (S. D. of counting 1.4%) or in the case of low activity 
samples 30 minutes counting time was used. The scintillation counter 
was programmed to automatically correct for quenching by the external 
standard channels ratio method. Efficiency of counting was normaLLy 
87-90%. 
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2: 2: 11 DRUG ASSAYS 
a) Salicylate. 
Sodium Salicylate was determined by a fluorometric method based on 
that of Ole (1971). 0.1 ml of Sodium Salicylate standard solution (10-100 x 
10-5 M) or sample was mixed with 4.9 ml 5N NaOH. Solutions were 
allowed to stand for 10 min before fluorescence was determined at an 
emmission wavelength 395 nm with excitation at 320 nm . 
b) Phenprocoumon and Warfarin. 
Phenprocoumon and Warfarin concentrations in samples from dialysis 
binding experiments were measured using a modification of the method 
of Seiler and Duckert (1968) as described by J haschen _L at. (1976). The 
method is based upon the fluorescence of the drugs in 0.5 M NaOH. 
c) Sulphamethoxazole. 
Sulphamethoxazole concentrations were measured using a modification 
of the Sulphonamide assay of Bratton and Marshall (1939). The procedure 
followed was as described by Rieder (1970). 
2: 2: 12 RESOLUTION OF PHENPROCOU MON 
Racaemic Phenprocoumon was resolved into its enatltiomers by 
fractional crystallisation using a modification of the method of West and 
Link (1965). 
Quinidine (5.2 g, 16 mMoles) and rac. Phenprocoumon (8.9 g, 33 mMoies) 
were dissolved In a warmed mixture of chloroform (25m1) and acetone (50 ml). 
A first crop of phenprocoumon quinidine salt (5.2 g) was collected after 
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crystallisation had proceeded for 16 hours at 22°C C. ([a] 
20 
+ 92.2 0 C1 
0 Butan-2-one) . After holding the filtrate at -15 C for 16 hours a further 
2.8 g of salt were collected. Both crops were re-crystallised twice 
from 1: 4 (v/v) absolute ethanol-chloroform, yielding 3.71 g of phenpro- 
coumon quinidine satt ([a] 
20 
+ 760 Cl Butan-2-one) . 
S(-) phenprocoumon was recovered by shaking the quinidine salt with 
25 ml each of chloroform and 5% NaOH, then acidifying the aqueous layer 
with HCI. The solid thus formed was re-crystallised twice from 70% 
ethanol-water to yield 1 . 21 g S(-) phenprocoumon. ([a] 
25 
- 123.7 C1 
Ethanol). Overall yield 27%, m. p. 176-1800C. 
The filtrates from the fractional crystallisation, plus those from the 
first recrystalLisations of the two crops of S(-) phenprocoumon quinidine 
salt were combined then reduced to a glassy residue by votary evaporation. 
Crude R(+) phenprocoumon was formed by alkali-chloroform partitioning 
and acidification as described previously. The crude R(+) phenprocoumon 
(5 g) and quinine were dissolved ethanol (90 ml), then warm water (35 ml) 
was added. This solution was held at -12°C for 48 hours yielding crude 
R(+) phenprocoumone quinine salt. This was recrystallised three times 
from 70% ethanol to give 3 .4g R(+) phenprocoumone quitildine salt. The 
R (+) phenprucoumon was recovered exactly as described for the other 
enantiomer. The final yield was 1.19 g (26%) R(+) phenprocoumon 
ýaý 
25+ 124 Cl Ethanot, m. p. 176-1800 C). 
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2: 2: 13 MICROSOMES AND BINDING SPECTRA 
Hepatic microsomaL fraction was prepared for studies using centrifuge 
sedimentation and for use in the examination of the binding spectra of 
coumarins. Microsomes were prepared as follows: - male rats (- 150 g) 
or hamsters (/--, 50 g) were killed by cervical dislocation, livers were 
Immediately excised, weighed and transferred to ice cold KCl (1.15% w/v). 
The gall bladder was removed in the case of the hamster. Livers were 
quickly and thoroughly scissor chopped, then well washed with several 
changes of ice cold KCI. All subsequent operations were carried out 
between 0oC and 4oC. Chopped livers were homogenised in Tris 
buffered KCl (66 mM Tris-HCL pH 7.4,1.15% KCL -3 ml per g liver) using 
a potter-Elvejhem type, teflon-glass homogeniser at a speed of 2400 r. p. m. 
with four return strokes. The homogenate was centrifuged at 15 , 000 g av. 
(MSE High Speed 18,8 x5 ml rotor, 13,500 r. p. m. ) in polypropylene 
centrifuge tubes for 20 min. The resulting supernatant was transferred to 
25 ml polycarbonate centrifuge tubes and centrifuged at 105,000 g av 
(MSE Super Speed 50,8 x 25 ml rotor, 40,000 r. p. m. ) for 1 hour. The 
supernatant was decanted off, the surface of the pellet was washed with 
Tris buffered KCL and the microsomes were homogenised in 25 ml Tris 
buffered KCL for centrifugation as described above. The final pellet was 
either re-suspended In Tris buffer (66 mM, pH 7.4) for Immediate use or 
suspended at about 10-20 mg protein . m11 In SVT (0.25 M Sucrose, 0.4 mM 
EDTA, 20 mM Tris/HCL pH 7.4) and frozen at -40°C for storage. 
Micro soma l protein was determined by the method of Lowry et al. (19 51) 
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and cytochrome p 450 concentrations by the method of Omura and Sato (1964). 
Cytochrome p 450 - substrate induced spectra (binding spectra) 
were determined by a modification of the method of Scherikman et at. (1967). 
4 ml or 5 ml of a microsomal suspension (1 -2 mg protein . m11) in 
Tris buffer (66 mM Tris-HCL pH 7.4) was equally divided between two 
quartz 10 mm cuvettes which were then stopped with Suba Seats. Using 
the primary cell compartment of the Perkin Elmer 356 spe(; t: rophotometer 
at 25 
0C and In the split beam mode a difference spectra between the two 
cuvettes over the range 350 - 500 nm was recorded. Any adjustments 
necessary to give a flat baseline were made. Substrate (normally 250 mM 
in DMF-dimethyiformamide) was introduced into the s ýmple cuvette using 
a 10 pt microsyringe (Terumo - Shandon) and equa i amount of solvent 
was added to the reference cuvette. The resulting difference spectra was 
recorded superimposed upon the baseline. Further additions of substrate 
and solvent as described above were made in order to determine the 
kinetics of the cytochrome p 450 spectral interaction . 
The spectral dissociation constant, Ks, and the maximal change Amax, 
were foundusing Lineweaver-Burk plots, as described by Al-Gallany (1975). 
2: 2: 14 DATA ANALYSIS, STATISTICS, THERMODYNAMICS AND 
COMPUTER ANALYSIS 
A study of the Interaction of a ligand with a macromolecule will normally 
lead to a knowledge of the following terms: the concentration of the macro- 
molecule (some conclusions can be made without this value), the total 
concentration of ligand, the concentration of bound and/or free ligand. 
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The problem still remains as to the way In which the data is analysed and 
presented. 
The simplest, and still popular, method is to simply report the 
percentage of total drug or ligand bound. Without any further information 
such a figure is useless and often misleading, even if reported together 
with the total drug and protein concentrations, 'percentage bound' tells 
little of the nature of the interaction. A graph of percentage bound 
against total ligand (see fig. 2.3), still presented in some reports, shows 
merely that more drug is bound at lower concentrations. More useful 
parameters may be derived by considering the drug-protein interaction to 
obey the law of mass action. (Drug protein interactions are generally 
considered to be dynamic equilibria which can be treated in this way; 
Goldstein, 1949; Edsall and Wyman, 1958; Klotz and Hunston, 1971). 
Consider the interaction of a drug molecule with a single site on the protein: - 
k1 
P+ Df -k PD 
2 
where P= unliganded protein Df = free drug PD = drug protein complex, 
kl and k2 are the rate constants for the forward and reverse reactions 
K_j 
PD] 
k=1 
EQU 1 
A ýP]"LDfý k2 
KA is the association constant, or more correctly apparent association 
constant since concentrations are always used rather than activities. 
_ 
[P] I f] 
_ 
k2 
^1 EQU 2 D [PD ]k KA 
KD Is the dissociation constant. Both the association and dissociation 
constants are referred to as equilibrium constants . It is convenient to 
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Figure 2: 3 Graphical presentation of binding data. Two less useful plots. 
60 
% Bound 
40 
20 
Total drug concentration 
r 
10 
5 
Free drug Df 
These plots and those in figure 2: 4 are generated from the following 
hypothetical binding data: (modified from Davison 1971). 
Free drug 
Df M 
Total drug 
M 
Bound r 
1 
r 
1 
Df rr 
r 
Df 
1x 10-5 1.99 x 10-5 50 0.099 10 1x 105 1.01 x 10-4 1x 104 
1x10-4 1.90 x10-4 47 0.9 1.1 1x104 1.11x10-4 9 x103 
1x10-3 1.50 x10-3 33 5.0 0.2 1x103 2.00xl0-4 5 x103 
1x 10-2 1.09 x 10-3 8 9.0 0.11 1x 102 
-3 
1.11 x 10 9x 102 
1x 10-1 1.0099 x 10-1 1 9.9 0.1 1x 101 1.01 x 10-3 9.9 x 101 
Abbreviations explained in the text. 
0.01 0.1 0.01 0.1 
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rearrange equation 1 in terms of r, the ratio of drug bound to total protein, 
moles drug bound 
r total moles protein 
from Equ 1 KA [P][Df] = [PD] 
KA [P] [Df] 
r= KA [P ][Df]+[P] 
[PD J+(P] 
KA [Df ] 
KA([ Df]+ 1) EQU 
3 
Consideration of the equilibria between protein and ligand can take two 
forms from this point, either a site-oriented approach or a stoichiometric 
approach. 
Site Binding Constants 
The most common approach to binding equilibria assumes that the 
protein has a certain number of pre-existing binding sites to which a ligand 
can bind, this is the type of analysis used in this work. Equation 3 
describes the interaction of drug with a single site, lt there are n of 
these sites on the protein, then the following equation v, iiI. L apply: - 
n KA [Df] 
r KA([Df] + 1) EQU 
4 
A simple graphical plot of r against Df (fig. 2 . 3) is a hyperbola and 
is difficult to fit, however there are several transformations of equation 4 
which will give a linear plot provided that: all the 'n' sites are equal In 
binding affinity and that the binding of one molecule doe not affect the 
binding of subsequent molecules i. e. there is no co-operation or interactions 
between binding sites. 
The reciprocal or Klotz (1946) plot Is based upon the following translation 
of equation 4_n+K EQU 5 
r A[Dfý 
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Figure 2: 4 Graphical presentation of binding data 
Klotz or reciprocal plot 
1 
r 
10 
5 
1x10-3 
Df 
r 
1x10-4 
Scatchard plot 
10 
3 
S 
Modified reciprocal plot 
r 
Three popular, linear translations of the hypothetical binding data shown 
in figure 2 :3. 
5 10 104 1 105 
Df 
0.01 0.3 
Free drug Df 
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A graphical plot of 
r 
vs Dý 
has an intercept on the y axis of 
n f 
a slope of nK 
and an x intercept of -KA. This plot suffers from the 
A 
disadvantage of spreading low values of 
r 
very poorly, a similar plot, 
D 
with the same limitations has been used in which rt 
J 
is plotted 
against Df (Klotz, 1953 - see fig. 2.4). 
The Scatchard (1949) plot is based upon the following form of 
equation 4: - r nK - rK EQU 6 [D f] R 11 
where ýD 
is plotted as a function of r, giving 1y intercept of nKA, 
f 
slope KA and x intercept n. (see fig .2 . 4) . 
More often than not, however, experimental data plotted as in fig .2 .4 
will not give a straight line. This could be the result of one or more of 
the following causes a) The binding sites are nut independent e. g. there 
may be co-operativity in binding b) binding of tigand may Induce a 
conformational change In the protein c) the Ligand may bind in several 
different ways to the protein or finally d) binding sites are not equivalent. 
Whilst the first three possibilities are very piausiblo reasons for 
curvature of a Scatchard or Klotz plot it is the fourth (d) which is generally 
thought to be responsible i. e. there exist two or more classes of site 
which each have their own n and KA values. Thus considering the 
Scatchard plot only, equation 4 must be modified: 
r= 
nl KA1 [Df ]+ n2 KA2 [Df ] 
.... 
nI KA, [Df ] 
EQU 7 1+ KA1 [Df]1+ KA2 [ Df ]1+ KAI [Df ] 
up to the 'ith' class of site. 
-114- 
r 
Df 
x 104 
Figure 2: 5 The non-linear Scatchard plot 
10 
6 
4 
2 
7 
r 
A theoretical Scatchard plot for a ligand with two classes of binding site. 
The curve is a hyperbola with the following binding parameters: ni = 2, 
n2 = 7, K1 =4x 104 , K2 =3x 103 
1234S678 
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It is obvious then that the intercepts of a curved Scatchard Plot will not 
have the same simple values as the linear variety. If it is assumed that 
a curved Scatchard plot such as that in fig. 2.5 is due to the presence of 
two sets of binding sites then the curve may be resolved into two partial 
plots (straight lines) each representing one single set of binding sites 
which are the asymptotes of the curved line. The ways in which a curve 
may be fitted to experimental points and the subsequent derivation of 
binding parameters will be dealt with in a later section. Curved reciprocal 
and modified reciprocal plots will not be considered SIE-ice the Scatchard 
plot was the method of choice for this work, however, Klotz and Hunston 
(1971) have dealt with those situations. 
Stoichiometric Binding Constants 
In contrast to the site binding concept, a stoichioaletric approach 
considers the addition of each molecule of ligand to protein in a 
sequential manner. Thus the protein P Is considered to interact with 
ligand D to form a species PD1 which can then bind a second ligand 
molecule to form PD2 etc. i. e. 
p+D -= PD 1 
PD 1+D PD Z 
PD2 +D PD3 
PD 1-1 +D`, PDl 
For these series of equilibria a series of stoichiometric equilibrium 
constants may be defined: - 
[PD11 
K1 [P1 [D I [PD11 = K1 [ PI [D] 
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K2 = PDPD2 
D 
[PD2 ]= K1K2 [P] [D] 
2 
etc. . 
The analysis of ligand-macromolecule equilibria in this way was 
first proposed by Klotz (1946 and Klotz et at. , 1946) and has been used 
recently by several groups especially that of Spector, Ashbrook and 
Fletcher (see Spector.!., 1971; Fletcher et al ., 1970) for the analysis 
of long chain fatty acid anion binding to albumicz. Klotz: (1974; Klotz and 
Hunston, 1975) has discussed at length the relationship between the site 
and stoichiometric approaches. 
The stoichiometric analysis of binding data undoubtedly has certain 
advantages over the site orientated models. In particular, it does not 
assume a certain number of pre-existing sites and is therefore compatible 
with the formation or destruction of sites upon binding of tigand. The 
stepwise model Is also sufficiently general to account for other types of 
co-operativity, electrostatic interactions and other phenomena which may 
be associated with drug-protein binding . As has been stated already the 
Scatchard model assumes that these phenomena are negligible. The 
Scatchard plot, however, produces parameters which are accurate enough 
for most purposes and generally these parameters may be compared with 
those from the Literature since the Scatchard model is the most popular. 
Moreover the concept of, say, one primary class of sites and one secondary 
class, is easy to visualise and it is simple to equate displacement 
phenomena with such a situation. 
In addition a stepwise analysis of data may require the calculation of 
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ten or more separate equilibrium constants which must assume that the 
experimental data is highly accurate. In binding studies, where 
experimental error can be quite high, it seems more reasonable to restrict 
computations to the estimation of one, two or three association constants 
and numbers of sites. It is interesting to note that the calculation of 
stepwise equilibrium constants by the method of Fletcher et al. (1973) 
requires firstly a fit of the data to the Scatchard model to obtain initial 
estimates of the binding parameters. 
From the various arguments presented above, coupled with the need 
for sophisticated computer facilities for convenient estimation of 
Stoichiometric equilibrium constants, it was decided to analyse the data 
of this work by the method of Scatchard. The limitations of this approach 
are, however, acknowledged. 
CURVE FITTING AND PARAMETER ESTIMATION 
Having chosen the Scatchard model to fit experimental binding data, 
it is necessary to consider how best to estimate the parameters from the 
data. This process can be carried out in two ways, either by plotting 
the data and physically determining the parameters from the curve, or by 
a statistical method, many of which are now computerised. The derivation 
of data from Scatchard plots by graphical means has been considered by 
several authors: Pennock (1973); Rosenthal (1967); Weder et al. (1974). 
Whilst statistical methods have been covered by Feldman (1972); Weder 
et al. (1973); Priore and Rosenthal (1976). 
It is perhaps pertinent to point out a common misconception; consider 
the Scatchard plot as follows: - 
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Intercept 1 
r 
[Dfl 
Intercept 4 
r 
it is common practice to draw in asymptotes at the extrccniities of the 
curve, as has been done here, to give the Intercepts the following values 
1= n1KA1 + n2KA2; 2= n1 + n2; 3= n1; 4=n2K2, and to calculate 
the binding parameters from these quantities. This is, ? however, Incorrect. 
Klotz and Hunston (1971) have derived the actual values, it is sufficient 
to say that whilst intercept 1 is n1K1 + n2K2 and 2 Is nI + n2, 
intercepts 3 and 4 do not represent simple values. It is necessary to 
shift these assymptotes, keeping the slope the same, until they are in a 
position such as illustrated in fig. 2 .5 before a full estimation of the 
binding parameters can be made. It is the mechanism of this shift which 
is the crux of the graphic parameter estimation. Where computer analysis 
was not used in this work a graphic method based upon that of Berson and 
Yalow (1959) was employed. 
The routine analysis of data was performed using z; computer program 
devised by Dr. John Francis of Roche Products, to whom I am most indebted. 
The computer program is a general fitting program which uses a non-linear, 
weighted, least-squares regression procedure. This process minimises: - 
w. e2 where e= (y observed -y calculated and 1 
2)w= var 
(Yobs. y81) 
i. e. Evar e) 
Is minimised. 
Intercept 3 Intercept 2 
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For the protein binding analyses, data Is fitted to the Scatchard (1949) 
equation: r_n. 
K. [Df] 
K ([Df] + 1) 
concentration of bound ligand Since r= 
concentration of protein ([p]) 
and bound = Total ([ T ]) -free ((Df ý) 
the equation may be re-written: - ET I=[D]+P. 
K( 
Df] 
fK pf ]+1) 
Thus, form classes of binding site, the program fits to the equation: 
m ni. Ki. [D } 
+e [T] = [Df ]+Pi Ki ý[D f+ 1) 
where [T] is the dependent variable and [ Df] is the independent variable. 
is calculated each iteration from the current estimates var Yobs 
. 
Ycalc. 
of n. and K. and the entered values of S. D. (y) and S. D. (xi) by means of: - 
n 
var -y)= var (y )+rA 
yca lc ._1. var (xj ) (Yobs. caLc. obs. l`A xi l 
where xj is the independent variable [Df I and y is the dependent variable I TI 
This procedure has the most important advantage of weighting that region of 
n dimensional space according to the accuracy with which it is defined by 
the experimental observations (y and xi). There is some doubt, however, 
concerning the derived S. D. 's of the coefficients. These may not have 
their normal statistical meaning since the errors in a least-squares procedure 
should only be associated with the dependent variable (y). This in no way 
affects the accuracy of the fit, however. 
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STATISTICS 
Where applicable results are expressed in the form: x. + S. E. M. (n) 
i. e. mean + standard error of the mean, with the number of observations. 
Differences between groups of observations were determined using the 
students 't' test with (n1 + n2) -1 degrees of freedom. Statistical 
manouvres were performed using either an Olivetti programma 101 or a 
Wang programmable calculator. 
THERMODYNAMICS 
Thermodynamic parameters of the interaction of fatty acid anions with 
BSA were determined using the following well known relationships: 
The free energy of binding (A G) was calculated from AG =- - RT In K 
where R is the gas constant, T is in 
0K 
and for K, the Equilibrium constant, 
the apparent association constant was used. The enthalpy of binding (A H) 
was assumed to be constant over the temperature range 283°K to 310°K and 
was thus calculated from: 
K2 
ZH in K1 R TZ T1 
The entropy of binding (A S) was calculated using the values found 
for AG and A H, and the relationship: Qs CMG T 
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CHAPTER THREE 
THE EVALUATION OF SEVERAL TECHNIQUES FOR USE 
IN DRUG-PROTEIN BINDING STUDIES 
-122- 
3: 1 INTRODUCTION 
There is a multitude of techniques available to quantify and 
characterise the equilibrium between a ligand and its binding sites. 
Many of these techniques are well established and thoroughly tested. 
These 'classical' methods have been discussed in chapter one and have 
been reviewed by several authors: Goldstein, 1949; Edsall and Wyman, 
1958; Rosenburg and Klotz, 1960; Steinhardt and Reynolds, 1969; 
Chignell, 1971; Bridges and Wilson, 1976. In recent years, several new 
or modified techniques have been introduced which are designed for the 
observation of a particular facet of the binding equilibrium or are supposed 
to be quicker, easier or cheaper alternatives to existing methods. Three 
such techniques, in the form of commercially available equipment, have 
been evaluated as part of this project. The conditions of the evaluations 
were such that comparisons may be made with previous work from these 
laboratories, concerning the merits of several, well known protein binding 
techniques (Wilson, 1974). A wide range of ligands was used in this 
study, with differing physico-chemical properties. 
Warfarin has been shown to undergo a marked change iri fluorescence 
properties upon binding to albumin (ChignelL, 1971). This phenomenon 
has been used in our laboratories to probe the albumin binding sites for 
warfarin and to monitor the displacement of warfarin by competing ligands 
(Wilson, 1974). This approach has been studied further, and the related 
coumarin, phenprocoumon (PPC), which is a widely prescribed anticoagulant 
in Northern Europe, has been evaluated as a possible fluorescent probe. 
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Monitoring the displacement of warfarin using the fluorescent probe 
approach was used to study the competition of sulphamethoxazole for 
the coumarin binding sites. Sulphamethoxazole (SMX) is the sulphonamide 
portion of the antibacterial combination co-trimoxazole, which has been 
implicated in the potentiation of hypoprothrombinaemia when co-administered 
with warfarin (Hassall et al ., 1975; Tilstone et al ., 1976). 
The surprising paucity of data concerning drug binding to extravascular 
tissue has already been mentioned in this thesis. It is possible that the 
scarcity of information is due to the lack of suitable methods for the study 
of binding to tissue preparations. With this in mind, tl1o- technique of 
centrifuge sedimentation was included in our schedule of methods for 
evaluation. The interaction of fatty acids with hepatic microsomal 
suspensions was chosen as a model system for this investigation. 
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3: 2 EXPERIMENTAL APPROACH 
3: 2: 1 FLUORESCENCE MEASUREMENTS 
All fluorescence measurements were made with a Perkin-Elmer MPF 3 
spectrophotof luorimeter, using solutions prepared in 67 mM sodium phosphate 
buffer, pH 7.4. Fluorescence titrations of buffer or albumin solutions 
(BSA was Conn fraction V from Sigma, HSA was crystal li. ný, from Kabi or 
Behringwerke) with coumarin drugs were performed by a modification of 
the method of Daniel and Weber (1966) as described In section 2: 2: 7. 
The cuvette normally contained 2 ml of buffer or albumin solution (5 - 20 x 
6 
10- M) to which was added microlitre volumes of warf Irin or phenprocoumon 
(1 -5x 10-3 M). Displacement experiments involved I: he addition of 
microlitre quantities of competitor (stock concentration up to 2x 10-2 M) 
to 2 ml of drug-albumin solution. The type of compet+l: ion Involved was 
determined from Dixon (19S3) plots. 
3: 2: 2 EVALUATION OF NOVEL BINDING TECHNIQUE S 
Sodium phosphate buffer (67 mM, pH 7.4) and Boviau Serum Albumin 
(Conn fraction V, Sigma) were used throughout the evaluations. All 
experiments were performed at 20°, except the centrifuge sedimentation, 
which was carried out at 40 to preserve the viability of the microsomes. 
Continuous ultrafiltration was performed using an Amicon ultrafiltration 
cell (Standard model, size 12) fitted with a 'Diaflo' membrane (type PM 10, 
Amicon). The binding of sodium saticytate (stock concentration 1.0 x 
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10-3 M) and sulphamethoxazole (stock concentration 1 . 18 x 10-3 M) to 
BSA (2.9 x 10-4 M) was determined. Binding parameters were computed 
from this data using the Modfit 27 fitting programme as described in 
section 2: 2: 14. Continuous ultrafittration does not permit the estimation 
of free or bound drug at pre-determined total drug concentrations. For 
this reason, the percentage bound values in tables 3: 1 and 3: 2 do not 
correspond exactly to the total drug concentrations presented. Table 3: 3 
shows the actual total drug concentrations at which the percentage bound 
was determined. 
'Centrifto' ultrafiLtration cones (Amicon) were used in the estimation 
of BSA (2 .9x 10-4 M) 
binding of sodium salicylate (3 75 90 x 10-5 M), 
ethyl carbamate (1 - 7.5 x 10-3 M) , hexyl carbamate 
(8.5 - 50 x 10-4 M) , 
hexanoic acid (1 . 67 - 5000 x 10-5 M) and valeric acid (1 . 67 - 5000 x 10-5 M) . 
Trace amounts of 
14C labelled compounds were used for the estimation of 
carbamates and fatty acids. 
'Dianorm' equilibrium dialysis cells (MSE) were employed to examine 
the interaction of BSA (2.9 x 10-4 M) with sodium salicylate (3.75 - 90 x 
5 
10- M). Spectrapor 2 purified cellulose membrane (Spectrum Medical 
Industries), which has a molecular weight cut-off of J. 2; x]00 to 14,000, was 
used in the dialysis cells. 
Binding estimates from the above techniques are compared with those 
obtained using the standard, Toribara ultrafiltration apparatus (see section 
2: 2: 2) and with values reported by Wilson (1974). 
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3: 2: 3 TISSUE BINDING MEASUREMENTS 
Centrifuge sedimentation was employed in attempts to measure the 
binding of Lauric acid (0.01 - 3.75 x 10-6 M) and octanoic acid 
(0.06 - 5000 x 10-6 M) to rat hepatic microsomal suspensions (1.5 mg 
-1 14 protein. ml ). Trace amounts of C [abetted fatty acids were used to 
estimate the ligand concentrations. 
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3: 3 FIGURES AND TABLES 
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Figure 3: 1 Ultrafiltration cell elution curves for sodium salicylate 
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The stock salicylate concentration was 160 u g. ml-1 . The cell was initially filled with sodium phosphate buffer, 67 mM, pH 7.4 (+) or 0.29 mM BSA in phosphate buffer (o) . 
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Figure 3: 2 Scatchard plot of the interaction of sodium salicylate with BSA 
at 21° C, as measured by the continuous ultrafiltration technique 
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The solid symbols and the line refer to two normal experiments. 
The open symbols refer to data obtained after eight hours pre-stirring of the 
protein sample. 
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Figure 3: 3 Scatchard plot of the interaction of sutphamethoxazole with 
BSA, as measured by the continuous ultrafiltration technique 
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The circles and crosses refer to two different experiments. 
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Figure 3: 4 Semi logarithmic plot of Co -C against volume of eluate for 
the continuous ultrafiltration of suiphamethoxazole 
30( 
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The original sulphamethoxazole concentration (Co) was 300p g. ml -1 . 
The concentration of sulphamethoxazole in the eluate (C) was estimated for 
each 0.966 ml fraction. 
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Figure 3: 5 Modified Scatchard plot of the interaction of octanoate with 
rat hepatic microsomes, as determined by centrifuge sedimentation. 
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The experiment was carried out at a protein concentration of 1.5 mg/ml in 
phosphate buffer pH 7.4,67 mM at 4oC. 
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Figure 3: 6 The titration of phosphate buffer and HSA with phenprocoumon 
or warfarin 
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Fluorescence 
intensity 
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The HSA concentration was 1x 10-5 M. Fluorescence was measured at the 
wavelength of maximum emission, using an excitation wavelength of 320 nm. "= phenprocoumon "= warfarin 
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Figure 3: 7 The titration of HSA with phenprocoumon or warfarin. 
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The HSA concentration was 1x 10-5 M. Emission was measured at the 
wavelength of maximum fluorescence. 
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Figure 3: 8 Uncorrected fluorescence emission spectra of 
phenprocoumon-albumin complexes 
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Figure 3: 9 Uncorrected fluorescence emission spectra of warfarin - albumin 
complexes 
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Figure 3: 10 The effects of suiphamethoxazole on warfarin/HSA fluorescence 
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Figure 3: 11 Dixon plot of the displacement of warfarin from Human Serum 
Albumin (5 x 10-6 M) by sulp', iametZOxazole as measured by 
the f luore scent probe tec inique . 
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TABLE 3: 5 A comparison of the percentage binding of ethyl and hexyl 
carbamates to bovine serum albumin using two ultrafiltration 
techniques 
PERCENTAGE BOUNDa 
ETHYL CARBAMATE HEXYL CARBAMATE 
Total carbamate 
concentration Toribara Centrif to Toribara Centrif to 
x 10-3 M method method method method 
n. s. 
0.42 84.3+0.4 85.8+0.6 
n. s. 
0.625 78.2+0.8 79.7+0.9 
n. s. n. s. 
0.83 73.4±0.9 71.6+1.1 11.6+0.6 13.4+0.7 
1.25 60.9±0.6 57.2±0.8 10.9+0.5 12.6+0.4 
n. s. n. s. 
2.00 48.1±0.5 49.3+0.6 9.1+0.2 9.9±0.7 
n. s. n. s. 
2.50 34.9±0.3 35.3+0.7 8.6+0.7 9.9+0.6 
n. s. n. s. 
3.00 32.7±0.6 34.1+0.9 8.0+0,3 9.0+0.7. 
n. s. n. s. 
4.00 32.5+0.4 33.2+0.6 7.6+10.7 8.8+0.9 
*** n. s. 
5.00 30.4±0.5 33.8±0.4 5.4±0.6 6.7+0.5 
All experiments performed at 250 C with BSA at a concentration of 29.0 x 10-5M 
in phosphate buffer (67 mM, pH 7.4) 
a- Mean + S. E. M. (n = 5) 
Statistical tests of significance by the students 't' method 
n. s. =p>0.05, *=p<0.05, ** =p<0.01 , *** =p<0.001 
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TABLE 3: 6 The binding of Lauric and Octanoic acids to hepatic microsomal 
suspensions as measured by the centrifuge sedimentation technique 
Total fatty acid 'Free' fatty acid in supernatant after sedimentation 
concentration 
x 10-6 M OCTANOATE TAURATE 
concn .x 10 
-6 M Mean % concn, x 10-6M Percentage 
5000 4945,4905 98.5 - - 
500 477.5,482.5 96.0 - - 
50 47.25,47.75 95.0 - 
5.0 4.27,4.25 85.2 - 
3.75 - - 2.84 + 0.29 78.4 + 6.0 
2.50 - - 1.85 + 0.025 74.2 + 1.0 
1.25 - - 0.904+0.019 72.4+1.55 
0.5 0.429,0.422 85.1 
0.375 0.317,0.329 86.1 0.267 -+ 11.009 71.1. i- 2.36 
0.25 0.206,0.212 83.6 0.178 , 0.002 71.1 + 0.94 
0.125 0.102,0.106 83.4 . 0914 + . 0018 73.1 + 1.45 
0.0625 0.0529,0.055 86.3 . 0447 + . 0004 71.5 + 0.56 
0.0125 - - . 0087 + . 00009 69.6 + 0.74 
Experiments were performed at 40C with rat hepatic microsomes at a final 
concentration of 1 .5 mg . ml 
-1 
. Results are presented as Mean + S. E. M. 
(n = 4) or as duplicate determinations. 
-145- 
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3: 4 RESULTS AND DISCUSSION 
3: 4: 1 CONTINUOUS ULTRAFILTRATION 
Preliminary studies of the continuous ultrafiltration (diafiltration) 
apparatus suggested that it was well suited to the type of binding experiments 
which we wished to perform. The PM 10 Diaflo membranes, which are 
hydrous gels of the complex interaction of polyanions and polycations 
supported by an inert, porous backing (Blatt . et a[. , 1965,1967), seem to 
be ideal for this technique. They have a very high solvent permeability 
(unlike conventional regenerated cellulose) and a published retentiv: l:, - 
for albumin of>98% (Amicon Publication No. 426). When buffer was 
uLtrafiltered through the cell containing 2% w/v BSA for several houzc, no 
protein could be detected in the uttrafiltrate. In addition, the membranes 
probably do not bind ligands extensively. Membrane binding was checked 
by comparing the experimental cell volumes, derived from plots of log Co -C 
against (see figure 3: 4 for an example and section 2: 2: 3 for the theory), 
with the known cell volume, determined by careful weighing of the cell 
empty and full of a liquid of known density. The actual. cell volume was 
found to be 14.05 ml, whilst experimental cell volumes of 14.13 and 14.05 ml 
for sulphamethoxazole and 14.46 and 14.86 mL for sodium salicylate were 
recorded. The values for su lphamethoxazo le are within experimental error 
of the actual value and suggest no binding of this compound to the membrane 
or other portions of the apparatus. The slightly higher values for sodium 
salicylate suggest that there may be some loss of drug, but only a small 
amount . 
-147- 
Typical eluate drug concentration curves are shown in figure 3: 1, for 
the ultrafiLtration of sodium salicylate (1 x 10- 
3 
M) through buffer and BSA 
(2% w/v, 2.9 x 10 -4 M) solutions. The shapes of the curves are as 
expected, that in the presence of protein showing lower eluate drug 
concentrations, especially at the beginning of the experiment where total 
drug concentration is low and the percentage bound is high. The total 
and bound concentrations of drug for each fraction were calculated as 
described in section 2: 2: 3 and are displayed in the form oI Scatchard 
(1949) plots in figure 3: 2 for salicylate and figure 3: 3 for sulphamethhoxazole. 
It is obvious from figures 3: 1 - 3: 4 that diafittration is capable of yielding 
a great many data points with good consistency between experiments and very 
little experimental scatter. It is very tempting to assume that the binding 
parameters calculated from such data must be highly accurate . Au 
examination of tables 3: 1 and 3: 2 will show that such m -lssuniptiou would 
be invalid, at least for these experiments. The percf fange of drug bound, 
at all concentrations and for both drugs, is substantially higher when derived 
from diafiltration experiments than the equivalent values from any of the 
other techniques. The detection of apparently greater binding with 
diafiLtration is also exhibited in table 3: 4 where the binding parameters 
calculated from this technique are compared with published values, derived 
using other techniques. The diafiltration parameters are greater than ali 
the previous published values with the exception of the early values from 
Meyer and Gutman (1970), which have been superseded by later and lower 
values of K1 and K2 In a recent publication (Cruze and Meyer, 1976). 
Before seeking an explanation for this anomalously high binding, it must be 
stated that other workers using the diafiltration technique have encountered 
-148- 
similar discrepancies. Ryan and Hanna (1971) studied the binding of 
testosterone to BSA by diafiltration and equilibrium dialysis methods. 
They found that diafiltration gave consistently higher nK vr'lues than 
equilibrium dialysis- In a comprehensive study, Blatt and co-workers (1968) 
found disparate results for the binding of both methyl orange and Ca 
++ to 
HSA from continuous ultrafiltration and direct ultrafiltration experiments. 
The differing results from diafiltration and other techniques have no 
obvious explanation, but are probably due to a combinat;. on of the following 
possibilities: a) The binding of ligand to the cell or membrane would give 
apparently high binding. Whilst there was little difference between 
experimental and actual cell volumes, this is not a definitive test for loss 
of ligand. In addition, this test is carried out in the absence of protein and 
the ceLi constituents may have different properties in the presence of protein. 
b) It is possible, but unlikely, that there Is some weakness in the theory 
of ultrafiltration and thus in the mathematical manipulations used to calculate 
the binding data. c) Again, it is conceivable, but even more unlikely, that 
the parameters from the other methods are falsely low. The facts that 
there is good agreement between the other methods, which are based upon 
differing physico-chemical principles, makes this explanation difficult to 
believe. d) Another explanation is that the protein's binding characteristics 
are changed by the continuous stirring which is inherent in the technique. 
It would be ironic if stirring were the source of error, since it Is one of the 
supposed advantages of diafiltration that stirring prevents concentration 
polarisation (see section 1: 7: 3). 
To investigate the possibility that stirring may denature or alter the 
conformation of the protein, a sample of albumin was stirred for eight hours 
-149- 
prior to the start of a normal experiment. The binding of sodium salicylate 
to this preparation was measured in the usual way and the results are shown 
in tables 3: 3 and 3: 4 and figure 3: 2. The pe? -<. eritage s;:! i. r: ylatc bound at 
low concentrations was not significantly different from the values obtained 
from freshly prepared albumin solutions, but at higher total ligand concen- 
trations there was a consistent reduction in salicylate bound . This trend 
Is reflected in the binding parameters, where the n1K1 values from normal 
414 
and pre-stirred samples are very similar (13.3 x 10 M_ . and 12 .6x 10 
M-1 respectively) but the pre-stirred sample showed fewer secondary sites 
and a lower total binding constant, n2K2 (27 x 102 M-1 compared to 
2 -1 for untreated albumin). The conclusion from this study 36 x 10 M-1 
is that prolonged stirring does seem to have an effect oti aLbumin but the 
result is a reduced, not enhanced, binding. Ryan and Hanna (1971) also 
reported a reduced binding affinity for the testosterone ""KKSA complex when 
the BSA was subjected to diafiLtration conditions for 12 hours. 
Theoretically, diafiltration has some outstanding attributes. During 
the course of a standard ultrafiltration experiment, the volume of drug- 
protein solution is reduced by the removal of the ultrafiltrate. This 
results in an effective concentration of the protein which may alter the 
equilibrium position of the ligand-protein interaction (probably higher 
binding wouldbe observed because of the increased protzAn concentration). 
Continuous ultrafi[tration cannot suffer from such Innacuracies since the 
sample volume is kept constant throughout the experinteilt and protein 
cannot escape the cell. Diafiltration allows for the determination of a 
complete binding curve in a single experiment. This may save both time 
and labour, but probably more important is that only one protein sample is 
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used. This could be most valuable if the protein source is limited, when 
atypical plasma or tissue is under study, for example. The technique 
offers considerable possibilities for automation, especially if the eluate 
ligand concentration can be continuously monitored by spectroscopy. 
Drug displacement studies can also be performed using diafiltration. 
In this case, the primary ligand is ultrafiltrated through the cell until 
equilibrium is reached. Further uLtrafiltration, with a stock solution of 
both primary and displacing llgand, provides a constant primary ligand 
concentration, with increasing displacer concentration. This approach 
has been used to study the sallcyLate displacement of sodium urate and 
methyl orange from HSA binding sites (Campion and OL: en, 1974). 
This impressive series of advantages is of no value, however, if the 
source of the anomalously high binding cannot be located and eradicated. 
Until this is achieved, it must be concluded that continuous ultrafiltration 
yields innacurate binding parameters and is therefore not to be recommended. 
3: 4: 2 CENTRIFLO ULTRAFILTRATION 
In a study of protein binding techniques, Wilson (1974) concluded 
that ultrafiltration, using a modified Toribara apparatus, was the method 
of choice fora wide variety of ligands . Toribara type ultrafiltration has 
been used extensively in this project, but whilst the actual experimental 
time is short, preparation of the membranes and the manipulations to form 
filled bags are time consuming and require delicate handling. The 
method of Centriflo ultrafiltration (Amicon), In which the membrane 
is laminated to a preformed cone requiring the minimum of preparation, was 
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seen as a welcome addition to the arsenal of protein binding techniques and 
has been thoroughly investigated in our laboratories. 
The binding of salicylate to BSA, measured using Centriflo and Toribara 
ultrafiltration techniques and several other methods, is displayed in Table 3: 1. 
The BSA binding of ethyl and hexyl carbamates, estimated by the two ultra- 
filtration methods, is shown in Table 3: 5. In addition, the suitability of 
Centriflo to measure albumin binding of fatty acids and the plasma free 
Levels of cortisol and calcium was examined. 
The percentage of salicylate bound to BSA, determined by Centriflo, 
over the range of drug concentrations used (3.75 - 90.0 x 10-5 M), agreed 
well with those from Toribara type ultrafiltration. A similar comparison for 
the binding of ethyl and hexyl carbamates also showed good agreement. 
The slightly higher values obtained from Centrifto for carbamate binding 
are probably due to loss of tigand by membrane binding . The uttrafiltration 
14 
of protein free C carbamate solutions through Centrifto membranes 
gave ^j' 95% recovery of radioactivity in the ultrafiltrate. In contrast to 
this good level of recovery, the same experiments with fatty acids showed 
very large losses of ligand. Using hexanoate and valerate at concentrations 
of 50 mM to 16.7 µM the loss of fatty acid was as great as 80% and 
consistent losses were found over the entire range. The method was, then, 
considered unsuitable for the determination of fatty acid binding. 
In a study of the suitability of the Centriflo method for the determination 
of plasma free concentrations of endogenous substances, the levels of 
cortisol and calcium in the ultrafiltrates of human plasma samples were 
determined. The estimated percentage of calcium free in plasma, 54.8% 
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(Total Ca ++ 10.4 ± 0.5 mg/100 ml, free Ca 
++ 5.7 ± 0.6 mg/100 ml) agrees 
well with values obtained by other methods and previous values for ultra- 
filterable calcium obtained from Centriflo experiments (Farese et al ., 1970; 
Halver, 1972). Free cortisol levels were, however, much lower than the 
expected 5- 15%. The binding of cartisot to Centrifto membranes was 
examined in the absence of protein. A maximum recovery of only 64% (at 
a total cortisol concentration of 1x 10 
5 
g. L- ) was obtained. Farnsworth 
(1974) has used Centriflo to measure free plasma cortlsol levels and reported 
a value of 1 . 1% free, which is 
lower than would be expected, probably due 
to binding of the steroid to the membrane. 
Centrifto cones have been used in studies of the human plasma binding 
of digoxin (Wallace and Whiting, 1974), diphenylhydantQ)ill 
(Booker and 
Darcey, 1973) and a series of disopyramide derivatives (Chien et al., 1975). 
In these literature studies, digoxin was not found to bind to Centriflo cones, 
but only 88% of diphenylhydantoin and as little as 40% of disopyramide was 
recovered upon filtration of aqueous solutions through the cones. These 
losses were supposedly compensated for by using correction factors, but 
this ignores the fact that the membrane may not bind the same quantity of 
ligand in the absence and presence of protein. 
It seems that Centriflo cones are particularly efficient at binding lipophilic 
small molecules. The membrane of the cone Is of the same family (DlafLo) 
as that used in the continuous ultrafiltration experiments but is a different 
formulation. (The Centriflo membrane is named CFSOA and has a molecular 
weight cut off at 50,000, the membrane indlafiltration was PM 10 which 
has a cut off value of 10,000) . It must be concluded that Centriflo is not 
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suitable for the study of lipophilic ligand binding to protein unless a good 
recovery of the ligand can be proven . Provided that the I. igand under study 
does not bind significantly to the membrane cones, Centriflo ultrafittration 
is a good, quick method for the determination of free ligand In a protein 
solution. The technique is very simple to perform, especially if research 
resources allow disposal of the membrane cones after a single experiment. 
The cones can be cleaned for re-use up to seven or eight times, but this 
procedure is lengthy and involved if complete removal of residual protein 
and ligand is to be ensured. It must be remembered that the cones have 
a molecular weight cut-off value of 50,000. This allows the filtration 
of small proteins or polypeptides, which may be undesirable In experiments 
involving plasma or tissue suspensions. 
3: 4: 3 DIALYSIS CELLS 
Since the Initial description of the phenomenon of dialysis (Graham, 
1851) and the first use of equilibrium dialysis in ligand-macromolecule 
studies (Osborne, 1906) this technique 
has remained popular in drug-protein 
binding Investigations, largely because of its physical simplicity. The 
theoretical disadvantages of equilibrium dialysis have already been discussed 
(see section 1: 7: 2) and in addition to these, experimental problems such as 
leaking knots, different bag dimensions and long dialysis time all contribute 
to variable results. Several investigators 
have proposed modified dialysis 
apparatus to overcome these inadequacies. 
Probably the most successful design to date is the half-cell system of 
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Weder and Bickel (1970; Weder et al ., 1971). Wilson (1974) considered 
a commercial version of this apparatus 
(Kontron Diapack) to be most 
satisfactory for the majority of albumin binding experim^nts. As part of 
this study of protein-binding methodology, a further development of the 
apparatus of Weder and Bickel (1970), Dianorm (MSE Scientific Instruments), 
has been evaluated. 
The binding of sodium salicylate to BSA studied using Dianorm is 
reported in figure 3: 1 with equivalent values from other techniques. The 
percentage bound estimates are In good agreement with those from the 
similar Kontron system and also those from ultrafiltrati<rn experiments ' 
which have already been discussed. The membranes which were used in 
the present study were of regenerated cellulose, but of a higher purity and 
better characterised than standard dialysis tubing. Spectrapor 2 (Spectrum 
Med. tnd . Inc. ) was emptoyed, which has a molecular weight cut-off of 
12 , 000 - 
14,000 and is of such a thickness to allow dialysis to proceed 
about twice as quickly as ordinary regenerated cellulose membrane. 
The combination of the well designed Dianorm apparatus with the advanced 
cellulose membranes produces a technique with the admirable qualities of ease 
of operation, fast experimental times, good temperature control and small 
sample volumes which make it Ideal for most ligand-macromolecule studies. 
In addition, no problems have been encountered with loss of ligand due to 
binding to the apparatus. The half cells are carved from blocks of poly- 
tetrafluro3thylene (PTFE) which is renowned for its Ineitness. Regenerated 
cellulose membranes seem to bind lipophilic compounds with less avidity 
than the synthetic polymeric membranes. Work in our laboratories has 
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demonstrated less than 5% loss of Cortisol In studies using cellulose 
dialysis membranes, and fatty acids are recovered with similar efficiency 
In ultrafiltration experiments employing Viski. ng tubing (see chapter 4). 
Half-cell equilibrium dialysis may be particularly suitable for the 
examination of ligand binding to suspended tissue fractions since samples 
are continuously, but gently, agitated ensuring no settling of particulate 
matter and there are no forces to promote the deposition of material on the 
membrane. This possibility is being investigated cur-cently in the Department... 
3: 4: 4 CENTRIFUGE SEDIMENTATION 
The interactions of fatty acids with hepatic, microsomaL suspensions 
was studied both as a model system for the tissue binding of small molecules 
and also to further our understanding of fatty acid-prot':. üi and fatty acid- 
P 450 complexes. The binding of octanoate and laurdto to rat hepatic 
microsomes was measured using an approach similar to that of Bickel and 
Steel (1974). Table 3: 5 shows the results obtained. The initial determinations 
were performed over the fatty acid concentration range 5-0.0125 x 10-6 M 
with a protein concentration of 1 .5 mg/ml. These concentrations were 
chosen to obtain a good range of fatty acid: cytochromc: 1' 450 ratios. 
(Cytochrome P 450 concentration wasr 1 nmole/mI or ti tx 10-6 M) . It 
was surprising to discover that there was little binding; 10% to 20%, with 
no apparent variation with concentration. Since these compounds are known 
to interact with hepatic microsomes, eliciting type 1 spectral changes with 
Ks values of 3 . 45 x 10-4 M for octanoate and 0.79 x 10-4 M for Taurate 
(Al-Gailany, 1975), it was assumed that the method of centrifugal sedimentation 
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is unsuitable for studies of this type. However, further studies, using 
octanoic acid at higher concentrations (5 x 10- 
4M 
to 5x 10- 
2 
M), suggest 
that the technique can yield some usable binding data. The results obtained 
at these higher concentrations are included In table 3: 5 and figure 3: 5, but 
it must be stressed that these values are from preliminary measurements only 
and that conclusions drawn from them must be considered in this light. 
The percentage of octanoate In the supernatant varied from 95% to 85% over 
the concentration range 5x 10-2 M to 5x 10, - 
4 M. The data is presented 
in figure 3: 5 in the form of a modified Scatchard plot. From the values at 
high fatty acid concentration an affinity constant of 5.06 x 102 M-1 and a 
total binding capacity of 69.6 nmole. mg-1 were calculated. These values 
are of the same order of magnitude as those reported by Rickel and Steel 
(1974) for the interaction of several acidic drugs with hepatic microsomes. 
If these parameters are correct, remembering that they are calculated from 
preliminary experiments only, then they must represent 'non-specific' 
binding to the proteins, lipids and membranes of the mlcrosomal preparation. 
This is reflected in both the very low affinity constant and the large binding 
capacity. 
Included in figure 3: 5 are some of the data points calculated from low 
fatty acid concentrations. It is possible that these values form a portion 
of a second set of binding sites. This proposed second set of sites would 
be characterised by studies with fatty acid over the concentration range 
5- 50 x 106 M where, unfortunately, we have no results to date. From the 
available information, it seems that this second set of sites would have a 
very low capacity, less than 1 nmole. mg-1, but a higher affinity, Ka = 104 M-1 
-157- 
to 105 M-1. These parameters are comparable with the cytochrome P 450 
concentration (0.6 nmotes. mg-1) and the spectral dissociation constant 
for the octanoate -P 450 interaction (KS =3 . 45 x 10_ 
4 
[\-I, Al-Gailany, 1975). 
Much more work is needed before the technique of centrifuge sedimemtation 
is fully characterised. On theoretical grounds, it seems unlikely that the 
method would yield good estimates of free drug In the microsomal suspension. 
The sedimentation of the particulate matter would be expected to disturb the 
initial equilibrium. The equilibrium would only be ur<4. fected if all the 
macromolecules of the pellet were freely available to drug In solution or If 
the bound drug does not dissociate during the 60 min centrifugation. Never- 
theless, Bickel and Steel (1974) did show a good correlation between binding 
parameters obtained from equilibrium dialysis and cne:: xifuge sedimentation 
techniques. 
In conclusion, whilst centrifuge sedimentation is ideal for the analysis of 
irreversible binding to tissue preparations (Ernster and Orrenius, 1965), the 
application of the technique to the study of freely reversible Interactions 
should be considered with caution. 
3: 4: 5 FLUORESCENT PROBES 
The changes in warfarin fluorescence properties with binding to albumin 
were first reported by Chignell (1970) and have been well characterised in 
our laboratories (Wilson, 1974). In the present work, the fluorescence of 
warfarin and phen procoumon complexes with human and bovine albumins 
have been further characterised with special reference to the nature of the 
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binding sites. In addition, the fluorescent probe technique has been 
considered as a tool. to monitor drug competitions for albumin binding sites. 
a) Coumarins as fluorescent probes of their own 
binding sites 
The titration of albumin with either PPC or warfarin results In a 
quenching of the protein fluorescence and a marked enhancement of coumarin 
fluorescence, as illustrated in figures 3: 6 to 3: 9. Thes emission spectra 
are presented in the uncorrected form, as are all fluore. sconce data in this 
report. This fact must be remembered when comparisons are made with 
published spectra which are corrected or which were obtained using 
equipment or conditions other than those used here. it was felt unnecessary 
to correct the fluorescence spectra for the variations in illumination and 
photomultip1ier response since our interest is mainly 3r1 modifications in 
spectra rather than the absolute spectra. The data is also uncorrected for 
any 'inner filter' effects. This is the phenomenon of absorption of exciting 
or emmitted light by components of the solution under study. For the 
compounds under study, inner filter effects may occur, since the coumarins 
absorb light at the wavelengths of both excitation and emission for albumin 
and also at their own excitation wavelength (self absorption) . For these 
(and other) reasons, coumarin concentrations were kept as low as possible 
during titratlons to minimise changes in optical density (typical O. D. change 
at 320 nm for a complete titration was about 0.2). In addition, the 
Illumination for albumin fluorescence measurements was at 290 nm where 
the protein absorbs substantially less light than at 270 - 280 nm. 
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Phenprocoumon in buffer has about a two fold higher fluorescence 
Intensity than warfarin (see figure 3: 6). This disparity, a well as the 
magnitude of fluorescence, is enhanced upon binding to n ! )um in . At 
equimolar drug: HSA concentrations the fluorescence of warfarin is 
enhanced by about 7 fold and that of PPC by over 10 fold. Under the same 
conditions, but in the presence of BSA, warfarin fluorescence intensity 
is enhanced by 4 to 5 fold, PPC fluorescence enhancement is about 10 fold, 
the same as for HSA binding. The wavelength of maxtnn i emission for 
both coumarins undergoes a blue shift of 5 to 6 nm with Likiding to either 
albumin. 
The enhancement and spectral shift of ligand fluorescence with binding to 
protein is thought to be due to the hydrophobic nature of the binding sites. 
The wavelength of fluorescence emission is dependent upon the loss of 
energy from the excited electron before it returns to the ground state. Since 
the excited state has a higher dipole moment than the ground state, solvent 
re-orientation around the excited electron will be greater in a polar environ- 
meet, producing more energy loss and emission at a longer wavelength, 
relative to transitions in a non-polar environment (Chen, 1972). Fluorescence 
yield is dependent upon the number of excited electrons which return to the 
ground state via radiationiess processes such as internal conversion from 
the triplet state (see figure 1: 5 for an energy level diagram) . The dipole 
moment of the triplet state T1 is less than that of the singlet state S1. 
As before, solvent re-orientation around S1 w1LL be greater In polar environ- 
ments, leading to loss in energy and a reduction in the singlet-triplet energy 
gap. Inter-system crossing is thus greater in polar systems and fluorescence 
Is decreased (Brand and Gohlke, 1972). The binding sites of the coumarins 
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must then, be either non-polar or must maintain the solvent in a rigid structure 
which prevents re-orientation (Edelman and McClure, 1968) . 
The binding of the coumarins to albumin is also as:; cciated with a 
quenching of albumin fluorescence (see figures 3: 7,3: 8 and 3: 9). Two 
processes can cause a reduction of albumin fluorescence. Either the 
binding of coumarin results in some change In the environment of the 
albumin tryptophan residues (which account for almost all of the protein 
fluorescence) or there is a transfer of energy from the tryptophan 
molecules. From the fluorescence spectra of the warfarin-HSA or warfarin- 
BSA complexes excited with light of 290 nm it is difficult to decide which 
process is taking place. The fluorescence intensity is reduced to about 
50% and there is a pronounced red shift in the emission maximum. It is 
possible that these effects are due to a conformational change leading to 
the tryptophan residues being more exposed to the polar solvent. The spectra 
of PPC-HSA and PPC-BSA complexes, however, show clearly that energy 
transfer is occurring. When the complexes are Illuminated with light of 
290 nm it Is re-emitted at the wavelength of phenproc: oumon fluorescence; 
380 nm. Energy transfer probably does not contribute significantly to the 
enhancement of coumarin fluorescence when excited at 320 nm, since few 
albumin tryptophan residues will be affected by radiation of this wavelength. 
Although the presence of energy transfer reactions in the warfarin-albumin 
complexes is not definitively shown in figures 3: 8 and 3: 9, the phenomenon 
does occur, since the excitation spectra of the complex, measured using the 
emission wavelength of 380 nm, shows peaks at both 290 nm and 320 nm. 
Chignell (1970) has used the efficiency of energy transfer between HSA 
tryptophan and warfarin to estimate the distance between the two fluophores 
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as 3.45 nm. 
The greater fluorescence enhancement and the apparently more efficient 
energy transfer between PPC and albumin compared to warfarin and albumin 
might suggest that the two coumarins bind to different sites. There Is, 
however, considerable evidence to support the view that these two very 
similar molecules bind to the same site. In chapter 6 It is shown that 
phenyibutazone competes for the binding sites of both coumarins, a fact 
which is supported by the reports that PPC and phenylbutazone (SeL[er and 
Duckert, 1968) and warfarin and phenylbutazone (Aggeler et at. , 1967; 
Solomon et al., 1968) share the same binding sites. Furthermore, recent 
data has shown that warfarin, phenprocoumon and, acenocoumarol all bind 
to the same class of high affinity site on HSA (Sudtow et al ., 1976). Thus, the 
disparate fluorescence characteristics of PPC and warfarin complexes with 
albumin must be due to the differing optical characteristics of the two 
molecules and/or differing modes of binding. 
The greater fluorescence enhancement of PPC may be explained by the 
fact that PPC is bound more avidly by HSA and BSA than is warfarin (see 
chapters 5 and 6, and O'Reilly, 1971). The tighter binding probably reflects 
greater hydrophobic interaction between protein and ligand. A more hydro- 
phobic environment is consistent with the greater fluorescence enhancement 
of PPC. The greater efficiency of energy transfer between albumin and PPC 
can also be partially explained by a more efficient re-emission of transferred 
photons due to the more hydrophobic environment of PPC. In addition, energy 
transfer is dependent upon the orientation of the two participating species. 
In chapters 5 and 6 it is proposed that the orientation of the main, coumarin 
ring differs in the PPC-albumin and warfarin-a Lbum in complexes. The 
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orientation of the PPC coumarin ring bound to albumin may be more 
favourable for energy transfer than is the warfarin ring when bound. 
In summary, phenprocoumon and warfarin are bound to common sites 
on albumin which are characterised by a hydrophobic nature and a reasonable 
proximity to tryptophans of bovine and human albumin. Phen procoumon 
seems to be the most suitable probe for these sites since it undergoes a 
more pronounced fluorescence enhancement with binding. The greater 
fluorescence is probably due to tighter binding of the molecule and a 
difference in the orientation when bound, compared to warfarin. 
The Fluorescent probe approach to monitoring drug Interactions 
Ail of the techniques so far described in this chapter can be used in 
studies of ligand competition for binding sites, provided that an assay is 
available which is specific for one of the Iigands. Competition studies 
either require a change in experimental routine, as is tho case with 
continuous ultrafiltration, or are simply carried out in the absence and 
presence of competitor. Standard ultrafiltration of fatty acid-albumin 
complexes in the presence of various concentrations of competitor has 
been performed as part of this project (see chapter four) and is typical of 
the approach normally used in displacement studies. This type of 
experiment is relatively time consuming and could not practicably be 
considered for a screening of the great number of clinically possible drug 
competitions for albumin binding sites. Drug interactions by displacement 
from albumin binding sites have been postulated to exist for several groups 
of drugs, including the coumarin oral anticoagulants (Wardell, 1974). 
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The fluorescence of a warfarin-albumin mixture, excited with light at 
320 nm, is due predominantly to the fluorescence of bound drug. If a 
second ligand is added which competes for albumin binding sites the 
resulting reduction in bound warfarin will be reflected by a less intense 
fluorescence. In this section the use of the fluorescent probe properties 
of warfarin for monitoring clinically relevant drug competitions will be 
considered. The same approach has been used in studies of the communal 
binding sites of fatty acids, carbamates and warfarin, (chapter 4) and 
phenylbutazone and PPC (chapter 6). 
In their reviews of drug interactions with coumarin oral anti-coagulants, 
Koch-Weser and Sellers (1971,1976) presented data which suggested that 
sulphonamides may be Involved in such interactions but stressed that the 
evidence was somewhat hypothetical. Two recent reports (Barnett and 
Hancock, 1975 and Hansen et al ., 1975) have suggested chat the antibacterial 
combination co-trimoxazoLe, which contains the sulphonamide suiphamethoxazole 
has been responsible for spontaneous haemorrhage in patients on continuous 
warfarin therapy. In a later report (Hassall e ta [ ., 1975) su l phamethoxa zo le 
was implicated as the interacting compound when it was shown to cause 
a small rise in free warfarin when added to a warfarin-HSA solution. 
The influence of various concentrations of sulphaniethoxazole on human 
serum albumin enhanced warfarin fluorescence is shown in figure 3: 10. 
While sulphamethoxazole does reduce the fluorescence of warfarin the effects 
are quite small, even at large excesses of sulphonamide. From a Dixon- 
type plot of the data (figure 3: 11) it can be seen that the displacement Is 
of a 'non-competitive' type. Taken at face value this would suggest that 
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warfarin and sul pham ethoxa zo le do not share the same binding sites 
(N. B. competitive-type displacement is expected from a single binding 
site), but that the displacement must be due to some steric or conformational 
effect. However, we must be careful not to take too literally the comparison 
between enzyme kinetic data and the fluorescent enhancement measurements 
of these experiments . 
Brand and his colleagues (1967) have suggested that the percentage of 
bound drug (x) can be calculated from fluorescence titration data using the 
formula: 
(IL/IF) -1 
X (IH/IF) -1 
EQUATION 1 
where IF Is the fluorescence intensity of the free drug (i. e. in buffer) and 
IL and IH refer to the intensities in protein-solutions of low and high 
concentration. Using the fluorescence of warfarin In phosphate buffer and 
HSA at 20 x 10-6 M the percentage of bound drug in 5x 10-6 M HSA., with 
various concentrations of sulphamethoxazole present, was calculated following 
this equation. Table 3: 7 shows the results with some literature values for 
comparison. 
The use of the above equation, and indeed the whole fluorescent probe 
approach to monitoring drug displacements, requires several fundamental, 
assumptions. Considering equation 1, IH is taken to represent the 
fluorescence of the ligand when totally bound. In these experiments IH 
was measured with an albumin concentration of 2x 10-5 M, since higher 
concentrations cannot be used because of concentration quenching effects 
(Wilson, 1974). It is possible that warfarin is not 100% bound under these 
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conditions, which would explain why the fluorescent probe derived value of 
-6 -6 90% bound (HSA 5x 10 M, warfarin 2 .5x 10 M) is higher than 
comparable literature values (table 3: 7). Additionally, when calculating 
the warfarin bound in the presence of competitor, it is assumed that the 
reduction in fluorescence is linearly related to reduced binding. There are 
several possible situations where this assumption would be false. Warfarin 
may be displaced, but could bind to other sites which do not enhance 
fluorescence. Fluorescence could be reduced by inner filter effects, charge 
transfer to a second Ligand bound at another site or a conformational change 
of the protein with the binding of a second ligand all of which could occur 
with no modification in warfarin binding. Finally, some warfarin may be 
bound at sites which are not involved in fluorescence enhancement. 
Obviously displacement from these sites would not be observed in fluorescence 
measurements. 
The concentrations of warfarin and SMX used in this study cover the 
clinically observed plasma concentrations. Continuous warfarin therapy 
in man leads to steady state plasma levels of 0.6 to 3 .1 mg. L-1 (2 x 10-6 M 
to 1 .0x 10 
-S M, Breckenridge and Orme, 1972). Following chronic oral 
administration of SMX a steady state plasma level of 60 mg. L-1 (2.3 x 10-4 M 
Nolte and Buttner, 1974) has been reported. (Note that the albumin concentratioi 
5 
used, 0.5 x 10- M, is much lower than the plasma albumin levels of about 
5x 10- 
4 
M) . It is possible, then, that the plasma SMX: warfarin ratio of a 
patient under co-therapy could reach over 100: 1 . The Increase In free 
warfarin under these conditions is very dramatic (see table 3: 7). However, 
in common with all in vitro demonstrations of albumin displacement, it is 
Impossible to predict if a clinically Important change In anticoagulant control 
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would result from the SMX: warfarin competition. Factors such as 
redistribution and tissue binding, increased elimination and metabolism 
will all affect the final outcome of the displacement (Wardell, 1974). 
Recently, two groups have published data concerning the use of 
warfarin fluorescence in displacement studies. Henry and Wosilait (1975) 
tested a series of compounds, at one concentration (25 x 10-6 M), for their 
ability to alter the fluorescence of warfarin (5 x 10-6 M) In HSA solution(7.24 
x 10- 
6 
M) but made no attempt to estimate changes In bl. cl. ding. SudLow and 
colleagues (1975) studied the effects of various drugs (about 15 x 10-6 M) 
on HSA (16.4 x 10-6) enhanced warfarin (2 x 10-6 M) fluorescence. They 
found a good correlation between the percentage reduction in warfarin 
fluorescence and the reduction in binding measured by equilibrium dialysis. 
They did not calculate the binding of warfarin in the presence of competitors, 
from fluorescence measurements, nor did they consider the type of competition 
invo Lved . 
Fluorescent probe monitoring of drug competition for binding sites has 
several advantages over traditional methods. The technique can be very 
quick and easy to perform and it uses the minimum of drug and protein. Low 
concentrations of drug are used which permit clinical levels to be studied and 
can be useful for compounds which are poorly soluble in water. It is the 
concentration of bound drug which is monitored unlike equilibrium dialysis or 
ultrafiltration where the much lower free concentration has to be assayed. 
The technique is, then, ideal for the routine screening of drugs for possible 
interactions with the coumarin oral anticoagulants at the binding site level. 
However, because of the assumptions and possible sources of error which 
have been outlined, strongly positive results should be confirmed with a 
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second technique before action is taken. 
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CHAPTER FOUR 
INVESTIGATIONS INTO THE BINDING OF MEDIUM-CHAIN 
FATTY ACIDS TO SERUM ALBU MIN 
-169- 
4: 1 INTRODUCTION 
Free fatty acid is the form in which fat is released, from adipose 
cells, into the blood. Some fatty acid (FA) is associated with lipoproteins 
in the blood, but the vast majority Is transported bound to serum albumin. 
The binding of fatty acids, thus rendering them more soluble, is one of 
the most Important, physiological roles of albumin. The interaction of 
human albumin with those fatty acids of physiological Importance to man 
has been studied by several workers: Goodman, 1958; Reynolds et at. , 
1968; Spector et at. , 1969; Ashbrook et at. , 1975, and has been the 
subject of a recent review: Spector, 1975 . 
A study of the interaction of a homologous series of medium chain 
length fatty acids is of interest for several reasons. Such a series of 
molecules, with a constant charged head group and increasingly lipophilic 
hydrocarbon chain, provides a useful series of model compounds for 
investigations into the relative importance of ionic and hydrophobic 
Interactions in ligand-protein binding. Also, medium chain length 
triglycerides are being increasingly used in the dietary treatment of several 
metabolic diseases of man, and it is important to have a thorough under- 
standing of their interaction with albumin. Finally, several metabolic, 
transport and absorptive reactions are known to be chain length dependent 
and it was thought that this trend may be reflected in albumin binding 
parameters . 
The fatty acids used in this study have between five and nine carbon 
atoms, and the IUPAC names, used throughout this report, are as follows: 
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pentanoic acid (C5), hexanoic acid (C6), heptanoic acid (C7 ), octanoic 
acid (C8) and nonanoic acid (C9). The trivial names of these compounds 
are often used in the literature and are rather more descriptive than their 
systematic counterparts. Pentanoic acid has the most pungent and 
disagreeable smell of all fatty acids and is appropriately named valeric 
acid from the Latin valerum, meaning: to be strong . Hexanoic, octanoic 
and decanoic acids have the characteristic odour of goats and are named 
caproic, caprylic and capric acids, respectively, after the Latin c, ºper: 
the goat. Nonanoic acid is also known as pelargonic acid, since it is 
present in the essential oil of Pelargonium roseum . 
Ultrafiltration measurements of the binding of these fatty acids to 
Bovine Serum Albumin (BSA) were made under conditions which permit 
comparison of the results with the data of Wilson (1974) concerning the 
interactions of a series of aliphatic carbamates with MA. Ultrafiltration 
competition measurements were made for the fatty acids with carbamates, 
warfarin and fatty acids of different chain length. The effects of the various 
fatty acids upon the fluorescence of BSA, and warfarin, when bound to 
albumin, were also studied. 
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4: 2 EXPERIMENTAL APPROACH 
Ultrafiltration was performed at 37° C and 10° C using the modified 
Toribara apparatus, as described in chapter 2. The final BSA (Conn 
fraction V, Sigma) concentration was always 2% w/v (2.899 x 10-4 M 
assuming a molecular weight of 69,000), whilst the final fatty acid 
concentration was varied between 5x 10-2 M and 1.7 x 10-5 M. The 
assay of fatty acid concentration was achieved by the addition of a small 
volume (100 Pt) of radiolabelled fatty acid (ti 2 pCi. ml-1) to each sample, 
before ultrafiltration, and subsequent liquid scintillation counting of the 
ultrafiltrate. The mass of the labelled fatty acid and t`x- dilution of the 
sample were taken into account in all data calculations. The binding of 
fatty acid in the presence of warfarin, carbamate or other fatty acid was 
measured in the same manner. 
The quenching of the tryptophan fluorescence of BSA (Conn fraction V) 
by fatty acid was investigated by titration, as described in chapter 2. The 
influence of fatty acids upon the fluorescence characteristics of warfarin 
when bound to BSA or HSA was also studied. For fluorescence measurements, 
the albumin concentration was normally 1x 10-5 M. Microlitre additions 
were made from stock solutions of 1x 10-3 M, 1x 10-2 M or 1x 10-1 M 
for fatty acid and 2x 10-3 M for warfarin. 
The FA/BSA interactions are Illustrated in the form of Scatchard (1949) 
plots. Binding parameters were computed from the data using the Modf it 
27 computer programme, as described in section 2: 2: 14. Two models were 
chosen to describe the interactions, both of which were based upon two 
classes of binding sites. In model 1, the coefficients nl, n2, K1 and K2 
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were allowed to take any value. In model 2, n1 was fixed as 1, I. e. a 
single high affinity binding site was assumed. An estimate of the 'goodness' 
of the fit can be obtained from the 'S' value which describes the nearness of 
the computed curve to a perfect parabola (where S=1 . 0000) . 
The partition coefficients of the fatty acids were calculated using the 
method of Leo et al. (1971). AA log.? value of 0.50 was assumed for 
each incremented change of one CH2 unit and values were calculated from 
log. P (octanol/water) = 1.94 for hexanoic acid. The value for hexanoic 
acid is a mean of several measured and calculated estimates from Leo 
et a[. (1971). 
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4: 3 FIGURES AND TABLES 
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Figure 4: 1 Scatchard plots for the interaction of Pentanoate (Valerate)with 
BSA at 100 C and 370 C-. 
Val . 10 
L. 
R 
VRL . 37 
4 
cc 
R 
The data points represent the means of at least four experimental values 
at differing total pentanoate concentrations. 
The lines join the computed points for the same total concentrations. 
-1 
. The units of the y axes are Mx 10- 
3 
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Figure 4: 2 Scatchard plots of the interaction of Octanoate with BSA 
at 100 C and 370 C. 
nrr_1Q 
LL 
R 
OCT_37 
LL 
O`[ 
R 
The data points represent the means of at least four experimental values at 
differing total octanoate concentrations. 
The lines join the computed points for the same total concentrations. 
The units of the y axes are M-1 x 10-3. 
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Figure 4: 3 Scatchard plots for the interaction of Hexanoate, Heptanoate 
and Nonanoate with BSA. 
HEPT. 37 
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The data points represent the means of at least four experimental values at 
differing total fatty acid concentrations. 
The tines join the computed points for the same total concentrations. 
-1 The units of the y axes are Mx 10- 
3 
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Figure 4: 4 The relationship between the binding parameters of the 
fatty acid/BSA complex and the partition coefficients of the 
fatty acids 
6 
log. Kl 
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Pentanoate Hexanoate Heptanoate Octanoate Nonanoate 
The binding parameters were measured at 100 C(A) and 370 C (0). 
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Figure 4: 5 Uncorrected spectra of BSA in the presence of warfarin and 
octanoate 
1 
M) 
(8 x 10-6 M) 
rin + Octanoate 
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30 
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The excitation wavelength was 290 nm. 
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Table 4: 5 Thermodynamic parameters of the interaction of BSA with 
fatty acid anions 
LIGAND AG (free energy) AH AS 
and class of site 0 0 (enthalpy) (entropy) 10 C 37 C 
First class 
Pentanoate - 5645 - 5827 -- 3732 + 6.76 
Hexanoate - 5901 -- 6207 - 2697 + 11.32 
Heptanoate - 6134 - 6545 - 1821 + 15.24 
Octanoate - 7589 - 8021 - 3059 + 16.01 
Nonanoate - 7702 - 8070 - 3848 + 13.62 
Second class 
Pentanoate - 3616 - 3670 ( - - 
Hexanoate - 3806 - 4542 + 3909 + 27.26 
Heptanoate - 4409 - 4945 + 1219 + 19.88 
Octanoate - 4507 - 5088 + 1268 + 20.41 
Nonanoate - 4707 - 5187 + 319 + 17.76 
The thermodynamic parameters were calculated from the association 
constants shown in tables 4: 2 and 4: 3. 
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Table 4: 6 The effect of fatty acids on the fluorescence of Bovine 
Serum Albumin 
Concentration 
of fatty acid 
-4 
percentage fluorescence of Albumin 
(with the wavelength of maximum emission) 
M x 10 
Pentanoate Hexanoate Heptanoate Octanoate Nonanoate 
0 100 (341) 100 (341) 100 (341) 100 (341) 100 (341) 
0.4 99.5 97.9 97.1 93. ) (340) 88.3 (339) 
0.8 - 95.1 93.7 86.5 (340) 81.0 (337) 
1.2 97.4 93.9 90.3 - "- 
1.6 - - 89.8 81.8 (339) 74.5 (334) 
2.0 97.2 92.9 - - - 
2.4 - - 89.7 78.2 (338) 73.3 (332) 
4.0 96.1 91.7 88.3 72.4 (337) 71.6 (330) 
6.0 94.4 89.0 87.5 69.4 (336) 70.1 (329) 
8.0 - 88.8 (338) 85.3 67.6 (335) - 
10.0 - - 85.1 (340) 66.5 (333) 67.0 (327) 
The BSA concentration was 1x 10-5 M. An excitation wavelength of 290 nm 
was used. The wavelength of maximum fluorescence is only Indicated if 
different from the initial value of 341 nm. 
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Table 4: 9 The competition of carbamates and fatty acids for albumin 
binding sites 
Concentrations x 10-4 M Approximate ratios Percentage of 
Ligand Competitor Ligand/albumin Ligand/competitor 
ligand bound 
Pentanoate nButyl- 
Carbamate 
0.1 - 1: 2 5 - 87.04 + 0.03 
0.1 0.083 1: 2 5 1: 1 86.83 + 0.09n .s. 
0.1 0.33 1: 25 1: 3 87.05 + 0.03n. s. 
0.1 1.67 1: 25 1: 17 86.84+0. Ion. s. 
0.1 33.0 1: 25 1: 300 ** 82.. 37 + 0.01 
1.0 - 1: 2 .5 - 82.58+ 0.29 
1.0 1.67 1: 2.5 1: 2 82.611 0.13n. s. 
1.0 8.33 1: 2 .5 1: 8 81 . 64 ± 
0.04** 
1.0 16.7 1: 25 1: 17 
*** 80.52+0.07 
1.0 33.0 1: 25 1: 33 *** 77.59 + 0.01 
nOctYl- Nonanoate 
Carbamate 
0.5 - 1: 5 - 94.46+0.13 
0.5 0.5 1: 5 1: 1 95.02 + 0.19n. s. 
0.5 2.5 1: 5 1: 5 93 . 50 + 0.36* 
0.5 5.0 1: 5 1: 10 93.89033n. s. 
0.5 10.0 1: 5 1: 20 92.70 +0.06*** 
The albumin (BSA) concentration was 2.5 x 10-4 M in phosphate buffer, 66 mM 
0 
pH 7.4 (20 C). Results are expressed as mean ± SEM (r. = 4). Comparisons 
to binding without competitor by students 't' test. n. s. =p>0.0 5, 
*=p<0. OS, ** =p <0.01, *** =p<0.001 . 
-188- 
Table 4: 10 Competition between various fatty acids for albumin 
binding sites 
Concentrations x 10-4 M Approximate ratios Percentage of 
Ligand Competitor Ligand/albumin Ligand/competitor 
ligand bound 
Octanoate Pentanoate 
0.1 - 1: 25 - 98.75 ± 0.01 
0.1 0.5 1: 25 1: 5 98.70 ± 0.02n. 
s. 
0.1 10.0 1: 25 1: 100 98.63 + 0.06** 
0.1 100.0 1: 2 5 1: 1000 97.51 + 0.04 
0.1 1000.0 1: 2 5 1: 10,000 91.39 + 0.02 
10.0 - 4: 1 - 82.05+0.19 
10.0 10.0 4: 1 1: 1 80.36 + 0.04 
10.0 25.0 4: 1 1: 2.5 68.07+0.01 
10.0 500.0 4: 1 1: 50 66.44 + 4.62 
10.0 1000.0 4: 1 1: 100 
*** 59.98 + 0.23 
Pentanoate Octanoate 
0.2 5 - 1: 10 - 60.24 + 0.87 
0.25 0.125 1: 10 2: 1 59.60 + 0.16n. s. 
0.25 0.25 1: 10 1: 1 61 . 32 -t- 0.51n. 
s. 
0.25 1.25 1: 10 1: 5 60.68 + 0.72n. 
s. 
0.25 2.50 1: 10 1: 10 57.99 + 0.42ns. 
0.25 250.0 1: 10 1: 1000 5.59 + 0.75 
25.0 - 10: 1 - 15.78 + 0.38 
25.0 2.50 10: 1 10: 1 14.02 + 0.86n. s 
25.0 25.0 10: 1 1: 1 5.59+0.86 
25.0 125.0 10: 1 1: 5 2.81 ± 0.08 
The albumin (BSA) concentration was 2.5 x 10-4 M In phosphate buffer, 66 mM 
0 
pH 7.4 (20 C). Results are expressed as mean ± SEM (n = 4). Comparisons 
to binding without competitor by students 't' test. n. S. =p>0.05, 
*=p <0.05, ** =p<0.01, *** =p <0.001. 
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4: 4 RESULTS AND DISCUSSION 
Much of this chapter Is devoted to a study of the binding of medium 
chain fatty acid anions to Bovine Serum Albumin using the ultrafiltration 
technique. The reasons for examining the binding of a series of fatty 
acids have already been explained in the introduction to this chapter and 
in section 1: 8, but no mention has yet been made of the reasons for the 
choice of technique or protein. Ultrafiltration and Bovine Albumin were 
used initially to retain continuity with previous work in the department 
(Wilson, 1974) but both can be justified In other ways. Ultrafiltration 
has the admirable qualities of being quick, relatively simple and cheap, 
and for these reasons is the method of choice from a practical viewpoint. 
Ultrafiltration has been shown to be sound theoretically and suitable for 
the study of a wide range of ligands (Wilson, 1974). The technique has 
the advantage over dialysis that there can be no Donnan inequalities, but 
the volume of ultrafiltrate must be kept small so as to avoid disturbing 
the ligand-protein equilibrium. 
If the conclusions from binding studies are to be applied to clinical 
situations then human albumin, or better still, human plasma, should be 
used as the protein component. Whilst there is some interest in medium 
chain fatty acid binding with relevance to medium chain triglyceride diets 
for certain human disorders, the main aim of this investigation is to 
characterise the molecular nature of the interaction. The final choice of 
BSA is largely for convenience, and financial reasons. The protein is 
plentiful and inexpensive and as such has been used in the majority of 
in vitro binding experiments. In addition, Bovine and Human Serum Albumins 
are structurally very similar (see section 1: 2: 5) and their binding properties 
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are normally qualitatively, if not always quantitatively, similar. Therefore, 
any general conclusions which are drawn from these studies with BSA can 
probably be applied to HSA binding. 
The BSA in this work was used as supplied (Conn fraction V, Sigma 
Chemical Co. ) and not defatted in any way. The fatty acid content of this 
particular preparation is not known, but previous studies of Conn fraction 
V BSA have estimated the FA content as 0.2 to 0.5 motes FA/mole albumin 
(Chen, 1967). It may seem anomalous to study the binding of fatty acids 
to albumin which already has some fatty acid associated with it, but many 
methods of defatting are rather 'harsh'. Even the mos i gentle, charcoal 
treatment, which is claimed to have no deleterious effects upon the protein 
(Chen, 1967), has come in for some criticism. Steinhardt and co -workers 
(1972) used this method to defat BSA and concluded "the defatted protein, 
even after restoration of fatty acid, is irreversibly changed from the protein 
which has not undergone the defatting procedure". It is possible then that 
the advantages of removing fatty acid to produce a naked albumin are out- 
weighed by the disadvantage of having a protein molecule which is no 
longer in its native form. In addition, lt can be argued that albumin always 
has associated with it a small amount of structurally Important fatty acid and 
that any method of removal will produce a 'non-physiological' protein molecule. 
The group of Soler-Argilaga have demonstrated that albumin bound fatty acid 
has two forms, one pool has a high turnover rate, the other a very slow 
turnover rate. (S oler-Arg ilaga et al., 1975; Soler-Arg ilaga and Hi. mberg, 
1976). They showed that perfused rat liver would remove 45% of fatty acid 
at a ratio of 1 .3: 1 with albumin, but only 0.3% when the ratio was 0.35 : 1. 
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4: 4: 1 ULTRAFILTRATION DATA 
From ultrafiltration experiments, the concentration of free fatty acid 
at various total fatty acid levels, in the presence of 2%, (w/v) BSA, was 
estimated. The data was plotted in the form of Scatchard graphs, which 
were non-linear in all cases. The non-Linearity was taken to represent 
the presence of two classes of binding sites, the simplest explanation of 
a curved Scatchard. Initial estimates of the number oI ; iLes and the average 
association constant for each class were made by the it : hod of Berson and 
Mallow (1959) from the Scatchard plots. The binding data was then fitted 
to the two-site Scatchard equation using the Modfit 27 computer program. 
The computer derived binding parameters are given in tables 4: 2 and 4: 3 
for the interactions at 100 C and 370 C. These values ire those derived 
using model 2 (see section 4: 2), where n1 is set at 1. Fable 4: 4 shows 
a comparison of some of the parameters from model 2 with the equivalent 
values using model 1, where all the coefficients can take any value. 
The product n1K1 is very constant, regardless of the model chosen. The 
parameters for nonanoate at 370 C illustrate well one of the advantages of 
predetermining n1 as 1 The computer fit, in this case, gave n1 = 0.17 + 0.2, 
which is obviously the product of a false minimum in the least squares regression 
Such false estimates are removed by stipulating nl =1. In addition, by 
setting nl as 1, the primary association constant k1 can be compared with 
the first association constant of the stepwise approach to data analysis. 
The binding data is illustrated, in the form of Scatchard diagrams, In 
figures 4: 1 to 4: 3. In these diagrams, the points represent the experimental 
data, each point being a mean of at least four separate determinations of 
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free drug at a particular total drug concentration. The line of the graph 
joins the best fit, computed values of r and 
D at the same total drug 
f 
concentrations as the experimental points. It can be seen from these 
graphs, that the computerised best fit often 'Ignores' those data points 
at very high r values. This is particularly noticeable with the shorter 
chain length fatty acids (see figures 4: 1a, b and 4: 3 a, b) . The 
phenomenon is probably caused by two factors. Firstly, the data at high 
r values tends to have a greater error associated with It, since the 
concentration of ligand bound is very small, relative to the estimated free 
concentration, For instance, at a total ligand concentration of 50 mM, free 
drug concentrations estimated as 49.50 mM and 49.75 mM give bound drug 
values of 500 uM and 250 11 M, which is very poor reproducability. Thus, 
because of the weighting system of the computer programiiie and these 
relatively large errors, data at high r values Is given little weight in the 
final fit. This, possibly, shows an Inadequacy of the computer programme, 
since however variable high r values may be, they are nevertheless essential 
components of the complete binding curve. Secondly, it is possible that 
two classes of sites does not adequately describe the interaction between 
fatty acids and BSA. Preliminary investigations have shown that a model 
with three sets of binding sites may more accurately fit the experimental 
data. However, the errors of the binding parameters of the third class of 
sites are so large as to make them almost useless. For example, the 
interaction of nonanoate with BSA fits very well (S =1 . 0000) to a model 
with three sets of sites where n1 =1 .3+0.12, n2 = 8.7 +1 . 4, n3 = 10.5 
+ 10.2 and k3 = 55.2 + 111.9 M-1, but little significance can be attached 
to the coefficients n3 and k3 . 
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The binding parameters of the BSA - fatty acid complex were profoundly 
affected by the chain length of the Ligand and by the temperature at which 
the equilibrium was studied. The affinity constants and number of binding 
sites increased with increasing chain length but the transitions were very 
different for the primary and secondary classes of binding . The secondary 
affinity constants and number of sites increased smoothly with chain length. 
There is a good correlation between log. n2K 2 and 
log. P, as shown in 
figure 4: 4b. In contrast, nI remained relatively constant with chain 
length, and the relationship between log. Kl and 1.09-P is not linear (figure 4: 4a). 
There Is a smooth Increase of K1 from pentanoate to heptanoate, but there 
is a sharp Increase in affinity for the octanoate - BSA complex. This sharp 
increase is seen regardless of the manner of representiuj Lhe interactions. 
Thus, graphs of K1 vs. P, K1 vs. chain length, AG vs. log. P etc. all show 
a sharp break at octanoate, for measurements at both I ()0 C and 37 
0 C. 
The increased avidity of octanoate binding is probably not due to any 
intrinsic property of the fatty acid, since the physico-chemical characteristics 
of the series of fatty acids change smoothly with chain length (see table 4: 1). 
The Interaction of fatty acids with serum albumin has been investigated 
by several groups. Major contributions have come frone the following 
publications: for the binding of long chain (C > 12) fatty acids to BSA: 
Spector et al., 1969,1971; tong chain fatty acids to HSA: Goodman, 1958; 
Ashbrook et al., 1975; medium chain fatty acids to BSA: Boyer et al., 1946; 
Terisi and Luck, 1952; Reynolds et at. , 1968; medium chain fatty acids to 
HSA: Ashbrook et aj., 1972. From this data several authors have correlated 
the chain length of the ligand with the strength of binding. Flansch (1968) 
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used the data of Terisi and Luck (1952), concerning medium chain fatty 
acid binding to BSA, and found a good correlation between binding affinity 
and the tipophiticity of the ligand, as represented by the octanol/water 
partition coefficient. This conclusion and similar findings by other 
authors (e. g. Reynolds et al ., 1968) has led to the common conception 
that fatty acid binding is linearly related to chain length or lipophilicity. 
Our findings of a sudden increase in affinity for the transition from C7 to 
C8 was, therefore, a surprising one. However, thorough reading of the 
Literature reveals that other workers have found related phenomena but 
have, perhaps, not expanded upon them as fully as might be expected and 
have certainly not offered any convincing explanations. 
The substantial data of Ashbrook and his colleagues (1972,1974) con- 
cerning FA binding to HSAhas been summarised recently by Spector (1975). 
The relationship between Log . K. (association constants derived from the 
multiple equilibrium approach) and chain length was found to be sigmoidal, 
not linear. Increasing the chain length from C10 to C12 produced a 
surprisingly large increase in affinity for HSA. Spector (1975) expressed the 
opinion that the phenomenon is due to the 'configurational adaptability' of 
the binding site being greatest for Lauric acid (C12) but offered no further 
explanation. In a survey of alkyl sulphate and sulphonate binding to BSA, 
Steinhardt and Reynolds (1969) considered that multiple contacts of the 
alkyl chain were responsible for high energy binding and that chains of less 
than eight carbons may be incapable of multiple contacts and thus have a 
reduced binding affinity. The same authors, however, concluded that 
carboxylates and sulphates or suiphonates probably do not have the same 
binding sites. 
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Tanford (1972) has considered the rote of chain length in medium chain 
fatty acid binding to BSA using the data of Terisl and Luck (1952) and 
Reynolds et at. (1968). A graph of the free energy of L ; ai. ng against 
chain length showed a break point at C8, in common with our results. 
In this case, however, the break was associated with a less than expected 
increase in tG, the opposite finding to our results. Tanford (1972) suggested 
that it becomes increasingly difficult to find suitable locations for the hydro- 
carbon chain as the length is increased beyond seven c: licbons. It is probable, 
however, that this analysis is not based upon high affi: tity binding. Both 
groups, from which Tanford drew his data, did not examine FA: albumin ratios 
of less than 1: 1. It is likely, then, that the high affinity sites were not 
fully explored. This explanation is supported by the fauc that both groups 
reported four to seven primary binding sites, rather thani the one to two found 
in our work. The analysis of fatty acid binding affini. i-y, r. orrelated with 
lipophilicity, by Hansch (1968), using the data of Teri,, t aad Luck (1952), must 
also be based upon secondary binding. 
There have, then, been several previous observations of non-linear 
relationships between affinity for albumin and chain length of iigand, but 
no satisfactory explanation of the phenomenon has been presented. There 
are several theories which can explain the enhanced primary binding of 
octanoate relative to the shorter fatty acids. The proposals can be divided 
into two groups, one of which is based upon a single site binding all the 
fatty acids, the other postulates the existence of different sites for fatty 
acids of different chain lengths. 
If all the fatty acids bind to the same high affinity site on the albumin 
molecule then the enhanced binding of octanoate coulcl be explained by one 
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of the following possibilities: - a) The binding site possesses at least 
two areas of hydrophobicity. This concept is illustrated below: 
0 -- --G. / mal/ 
,, 
C/ 
C/ \C \C/ \C C \O + 
The binding site is portrayed as a cleft In the protein including a 
positively charged area with which the polar head group of the fatty acid 
is associated, and a groove of non-polar character. In the middle of the 
groove is an area of particularly high lipophilicity. Only fatty acids of 
eight carbons or more can associate with the area of high hydrophobicity. 
Such an arrangement would explain the recent findings of Ruf and Gratzl 
(1976) concerning the interaction of nitroxide spin Labelled stearate to BSA. 
They reported that the polar head group Is rigidly fixed and available to 
soivent, the middle of the molecule is also rigidly held but is shielded 
from solvent and the non-polar end of the ligand is more available to solvent 
and has a greater mobility. b) The binding of fatty acids with eight or 
more carbon atoms induces a conformational change In tho protein leading 
to a greater stability of the complex. This Is equivalent to the proposal of 
Spector (1975) to explain the non-linear relationship of log . K. to chain 
length for the binding of fatty acids to HSA. The theory is also comparable 
with the Idea of configurational adaptability of binding sites proposed by 
Karush (1950). c) High affinity binding may be dependent upon the contact 
of the ligand with several areas of the protein. Fatty acids of less than 
eight carbon atoms may not be able to make such multiple contacts. 
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This "Inch worm" type of binding has been proposed by Tanford (1972) for 
amphiphile binding to albumin. The inability of short alkyl chains to form 
multiple contacts with proteins has been suggested to explain the reduced 
binding of sulphates and su(phonates with fewer than eight carbon atoms 
(Steinhardt and Reynolds, 1969). 
Any alternative theory, involving two types of high affinity sites for 
short and medium chain length fatty acids, must include an explanation of 
why the short chain fatty acids do not interact with the site for the medium 
chain compounds and vice versa. Whilst it Is easy to Imagine the short 
chain site being too smatL to accommodate more than seven carbons, it is 
difficult to explain why short chain fatty acids could not 'fit' a larger site. 
It is possible that the distance between the point of attachment of the 
carboxyl group to the protein and the area to which the side chain binds Is 
greater than 7 carbons in length. The area of side chain binding would 
have to have a very high affinity for hydrocarbon chains, since octanoate, 
which would just bridge the proposed gap, has a much larger association 
constant than the shorter chain length compounds. Further consideration 
will be given to these theories of fatty acid binding in the final discussion 
to this chapter, after competition and fluorescence data has been presented. 
The temperature dependence of the binding equilibrium between FA and 
albumin is illustrated In the Scatchard plots of valerate/BSA and octanoate/ 
BSA (figures 4: 1 and 4: 2) and in the binding parameters at 10 0C (table 4: 2) 
and 370 C (table 4: 3). The effect of temperature is consistent over the 
range of fatty acids. The primary binding association constant (K1) is 
greater at 100 C than at 37° C whilst the converse relationship holds for 
-198- 
secondary binding. This disparity is reflected in the thermodynamic 
parameters of the interactions (table 4: 5) where the high affinity binding 
is characterised by a negative enthalpy change (AH) and the secondary 
binding by a positive A H. 
The enthalpy change for the high affinity binding is relatively constant 
and is probably due to the binding of the carboxylate group to the protein. 
The increasingly favorable free energy change (AG) with increasing chain 
length Is due to the greater, positive entropy change (A S). Positive entropy 
changes in ligand binding is normally assumed to reflect hydrophobic 
Interactions (Tanford, 1973) but Klotz (1973) has shown I: hat electrostatic 
interactions can also be entropicatty driven. However, It Is likely that 
then S values reflect hydrophobic Interactions In this case, since they 
increase with chain length. Thus, fatty acid binding to the high affinity 
site is a combination of electrostatic interactions with the carboxyl group 
and hydrophobic bonding with the side chain. 
The termodynamic parameters of secondary binding are probably less 
reliable than the primary values, for two reasons. Firstly, the errors of 
K2 are larger than K1 for the same reasons as were previously discussed for 
the estimation of K3 . Secondly, K2 is an average values for several sites, 
unlike K1 . The use of average K values to calculate thermodynamic 
parameters has led to serious errors (Spector et al. , 1969, Spector, 1975). 
The entropy and enthalpy changes for pentanoate are not included in table 
4: 5 since K2 at 370 C was atypically low, probably because of the high 
computed n2 of this interaction. The binding to secondary sites Is 
accompanied by positive enthalpy and entropy effects, which is characteristic 
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of hydrophobic bonding (Kauzmann, 1959). Positive enthalpy is unfavourable 
for binding, however, the net negative AG is due to the favourable entropy 
gain. The entropy gain occurs because the binding of the fatty acid results 
in the release of water molecules from the "icebergs" around the alkyl chain, 
and consequently, in the release of the configurational entropy of the alkyl. 
group (Nagwekar and Kostenbauder, 1970; Nagwekar and Muangnolcharoen, 
1973). Secondary fatty acid binding appears, then, to be entirely hydrophobic 
in nature. 
4: 4: 2 FLUORESCENCE DATA 
a) Intrinsic fluorescence of albumin 
The U. V. fluorescence of albumin, like other class B proteins, is due 
largely to transitions of tryptophan, with only a small contribution from 
other aromatic residues. Bovine Serum Albumin has two tryptophan residues 
whilst Human Serum Albumin has only one. From the published amino acid 
sequences of the two proteins it is known that the tryptophan which is 
common to both is situated in the cleft between loops 3 and 4 and corresponds 
to the binding site isolated by Swaney and Klotz (1970). The second tryptophan 
of BSA is located within loop 3 and is thought to be buried more deeply In the 
globular structure of albumin. (A more detailed discussion of the location of 
tryptophan in BSA and HSA may be found in section 1: 2: 5). 
The effect of medium chain fatty acids upon the intrinsic fluorescence 
of BSA (Conn fraction V, as used in the ultrafiltration experiments) was 
investigated by fluorescence titration. With an albumin concentration of 
1x 10-5 M the addition of uL quantities of any of the fatty acids from a 
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1x 10-3 M stock had no effect upon the albumin fluorescence. Such a 
titration covers albumin/fatty acid ratios up to 1: 1 . 5. This is in agreement 
with the findings of Spector and John (1968) that fatty acids did not quench 
BSA fluorescence at a 1: 1 ratio. It is worth noting that the closely related 
alkyl. sulphates all quench BSA fluorescence at this ratio (Steinhardt et at. , 
1972). Titrations performed with a stock fatty acid concentration of 
1x 10-1 M covered the BSA: FA ratios 1: 4 to 1: 100, and did result in the 
quenching of fluorescence. The percentage reduction in J. )M fluorescence 
at various concentrations of the five fatty acids is shown In table 4: 6. 
At a molar ratio of 1: 4 there was a small quenching of fluorescence, from 
0.5% to 12% increasing with chain length. The emission maximum of 
fluorescence (341 nm) was shifted slightly to shorter wavelengths for 
nonanoate (ti 2 nnr and octanoate ( ti 1 nm) but not for the shorter chain 
length fatty acids. At higher concentrations of fatty acid there was further 
quenching up to 35%, with a maximum blue shift in. em iss ton maximum of 
14 nm to 327 nm, for nonanoate. These results are again largely similar 
to those of Spector and John (1968), except that they did not examine such 
high ratios of FA: BSA and consequently did not record as large blue shifts 
or quenchings. 
Fluorescence titrations were also performed with HSA (crystalline) 
under identical conditions as for BSA. Even at high molar ratios, none of 
the fatty acids produced marked quenching, there was perhaps a slight 
enhancement, with only a small blue shift of fluorescence emission 
maximum. Santos and Spector (1974 ) have reported that palmitate produced 
no appreciable change in the magnitude of HSA fluorescence with only a very 
small blue shift in the wavelength of maximum fluorescence. 
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Quenching of protein fluorescence with ligand binding can occur via 
one of two mechanisms. Either by some kind of energy transfer from 
fluorphor to t igand , or by a modification of 
f luo phor environment. Since 
fatty acids do not absorb light in the near U. V. it is unlikely that any 
energy transfer could occur with albumin tryptophan transitions. In order 
for resonance energy transfer to be efficient the emission wavelengths of 
the donor and the absorption wavelengths of the acceptor must overlap 
(see section 1: 7: 8). Thus, fatty acid binding must ciuse <i. change in 
environment of the fluophor to produce quenching. It has been suggested 
(Spector, 1975) that quenching may be due to an alteration In the state of 
ionisation of a protein - amino group, but this is based upon alkyl sulphate 
binding to BSA (HaLfman and Nishida, 1971) and it has already been seen 
that alkyl sulphates and alkyl carboxylates produce dissimilar effects upon 
BSA ULuorescence . 
The facts. that low molar ratios of fatty acids (where binding will be 
primarily to high affinity sites) do not produce any quenching of BSA fluorescence 
and that fatty acids produce only very small alterations in HSA fluorescence 
suggests that the area around the common tryptophan of }3SA and HSA does 
not provide one of the primary sites for fatty acid binding . The reduction in 
BSA fluorescence at higher ratios is probably due to binding near the second 
tryptophan, causing a change in the environment of the fluophor. It is 
possible that fatty acid also binds near the common tryptophan at high 
concentrations, but is is impossible to tell from the BSA data. The fact 
that high concentrations of fatty acid produced only small changes in HSA 
fluorescence suggest that the common tryptophan may be uninvolved even 
in secondary binding. Alternatively, the fatty acids m: iy bind near the 
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tryptophan without affecting the optical properties. ANS (Santos and Spector, 
1972) and iodide (Spector et al ., 1973) are thought to bind to the Swaney 
and Klotz (1970) tryptophan site in HSA and fatty acids at high concentration do 
reduce the fluorescence quenching produced by these agents. The 
displacement of ANS and iodide may, however, be due to conformational 
changes produced by fatty acid binding at nearby sites. The theory that 
BSA fluorescence quenching is due to binding to secondary sites Is 
consolidated by the fact that, although octanoate and nonanoate were more 
effective than the shorter fatty acids, there was not a dramatic increase in 
effect but a fairly smooth increase with chain length. 
b) The fluorescence of warfarin bound to albumin 
The addition of warfarin to serum albumin results in a quenching of 
albumin fluorescence and an enhancement of warfarin fluorescence. This 
phenomenon Is more thoroughly considered in chapter 3, but briefly, the 
mechanism of quenching is thought to be partially resonance energy transfer 
and partially a conformational change whilst the enhancement of warfarin 
fluorescence is due to the less polar environment of the albumin binding site. 
The effect of fatty acids upon the quenched fluorescence of albumin and the 
enhanced fluorescence of warfarin was investigated. The results obtained 
with both HSA and BSA are shown In table 4: 7. 
The effects of fatty acid upon the fluorescence of warfarin were very 
similar with both HSA and BSA. In no case did the addition of one or two 
equivalents of fatty acid have any significant effect upon probe fluorescence. 
For this reason titrations were again performed at higher fatty acid concentration 
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using 1x 10-1 M fatty acid stock. Albumin concentration was 1x 10-5 M 
and warfarin concentration was either 0.8 x 10-5 M or 1.. 6 x 10-5 M. Under 
these conditions warfarin will be bound predominantly to high affinity sites, 
of which there are two, with association constants of alma. 1x 10-5 M 
(O'Reilly, 1973, see chapters 5 and 6). The addition of four equivalents 
of fatty acid produced a small reduction in fluorescence of about 8%, with 
a little variation between fatty acids. This data strongly suggests that 
warfarin and the fatty acids do not share high affinity b i.; id ing sites. Both 
octanoate and nonanoate have larger primary associatioa constants than 
does warfarin, therefore four equivalents of these fatty acids would be 
expected to produce a substantial reduction in the bound warfarin with a 
concomitant reduction In fluorescence If they shared primary binding sites. 
Higher concentrations of all the fatty acids reduced the i: luorescence of 
the a tbum in/warfarin com p'ex, with nonanoate being th., rot effective , 
but still producing less than 50% reduction with a 25 fold molar excess 
compared to warfarin. It is likely that the primary binding sites of warfarin 
may serve as secondary binding sites for the fatty acids. It Is possible 
that the displacement of warfarin at high fatty acid concentrations is due 
to a conformational change but since the emission maximum of bound warfarin 
remains at 378 nm, even with excess fatty acid, this possibility Is less 
Likely. 
It was suggested in the previous section that some secondary fatty acid 
binding was to a section near to, but not necessarily directly on, the 
tryptophan area of Swaney and Klotz (1970). Whilst the binding of the 
fluorescent probe ANS quenches albumin very efficiently (1 mole of ANS 
decreases HSA fluorescence by more than 95% (Santos and Spector, 1.974b)) 
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warfarin binding quenches less efficiently. This suggests that warfarin, 
too, is bound near, but not at, the tryptophan site. From the efficiency 
of warfarin - HSA energy transfer Chignell has calculated that the distance 
between the two fluophors must be about 3 .4 nm (Chignell, 1970). This 
corresponds to about 70% of the "width", or minor axis, of albumin, 
measured by hydrodynamic methods (Peters, 1975; Chignell, 1970). 
(Further evidence that warfarin and fatty acids share some binding sites will 
be presented in the next section) . 
The binding of warfarin to albumin quenches the protein fluorescence and 
shifts the emission maximum towards the longer wavelength of warfarin 
fluorescence. The effect appears relatively larger for HSA since BSA has 
a second tryptophan which appears unaffected by warfarin binding. The 
addition of fatty acid to a warfarin/albumin mixture produced interesting 
changes in the quenched albumin fluorescence. These changes were 
similar for both albumins. The magnitude of the effect increased with 
increasing chain length of the fatty acid used, figure 4: 5 illustrates a 
typical titration. 
The addition of FA to the warfarin/albumin complex causes only small 
changes in the intensity of quenched albumin fluorescence, There Is, 
initially, a small decrease, followed by an increase of a similar magnitude. 
The wavelength of maximum fluorescence is more markedly affected. The 
maximum shifts from the longer wavelengths, associated with warfarin 
liganded albumin, to shorter wavelengths. This is presumably a reflection 
of the same conformational changes which produce the blue shift in albumin 
fluorescence with fatty acid binding. The tryptophan fluorescence remains 
quenched due to a combination of the fatty acid induced conformational 
-205- 
changes and the energy transfer of radiation to the residual bound warfarin. 
4: 4: 3 COMPETITION DATA 
a) Competition between fatty acids and warfarin 
The binding of heptanoate, octanoate and nonanoate to HSA in the 
presence of various concentrations of warfarin was examined by ultrafiltration. 
Table 4: 8 displays the results. At a fatty acid: albumin ratio of 6: 1, where 
much of the binding will be to secondary binding sites, all the warfarin 
concentrations produced highly significant decreases in the percentage of 
fatty acid bound, even when the warfarin concentration was half that of 
fatty acid . However, when the fatty acid: albumin ratio w , -is 0.6: 1, where 
binding would be predominantly to high affinity sites only, a five fold excess 
of warfarin was required to produce any significant displacement. These 
observations agree well with those from the fluorescence measurements and 
give added weight to the argument that warfarin and the fatty acids do not 
share the same primary binding site. It is likely, however, that the primary 
sites can serve as secondary binding sites for the other ligand. Warfarin 
has a primary association constant far larger than that for secondary fatty 
acid binding ( ti 10 
6 M- 1 com pared to ti 10 
3 M- 1) so that low concentrations 
of warfarin displace that fatty acid bound to secondary sites. When fatty 
acid is bound to its high affinity sites, displacement call only occur due to 
secondary warfarin binding and thus a large molar excess is required. 
The displacement of fatty acids by warfarin, and vice versa, has so far 
been considered In terms of competition for binding sites. A previous study 
of long chain fatty acid inhibition of warfarin binding 11,16 also shown 
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competition for HSA binding sites (Solomon et at. , 1968). Other authors 
have suggested that the Influence of fatty acids on warfarin binding Is 
mediated by conformational changes, rather than direct competition 
(Spector et al., 1973; Laliberte et al., 1976; Chakrabartl et al., 1976). 
These authors cite, as evidence, the findings that fatty acids can alter 
the dielectric properties and viscosity of albumin solutions (Soetewey eta!.., 
1972) but offer little further information as proof of conformational changes. 
Even the findings of Soetewey and colleagues (1972) may he in doubt, since 
their measurements were performed with defatted albumin, which may no 
longer hold the native conformation. There is, in short, no conclusive 
evidence to demonstrate that fatty acids substantially affect the conformation 
of drug binding sites. 
It is a common failing of all In vitro displacement experiments that the 
physiological effect of competition cannot be predicted with certainty, since 
redistribution, elimination, metabolism play important roles In determining 
the final levels of displaced compounds. From our results It would seem 
that elevated plasma fatty acid concentrations could displace warfarin, 
only if the FA/albumin ratio was predisposed to binding to secondary sites. 
Increased FA levels, due to stress or fasting, do Increase the prothrombin 
times of rats administered with warfarin (Chakrabarti et al ., 1975; Laliberte 
et at. , 1976). The theory that FA binding to secondary sites is the important 
factor Is consolidated by the observation that an Increase in free warfarin Is 
only seen when the FA: albumin ratio is greater than 2: 1 (Gugler et al., 1974). 
One important lesson which may be learned from all our studies of fatty 
acid/warfarin interactions is that either ligand can be shown to displace the 
other, provided the correct concentrations are chosen. It Is important, then, 
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to choose pharmacologically relevant levels of drugs and physiologically 
significant albumin and ligand concentrations for displacement studies, 
if clinically applicable conclusions are to be arrived at. 
b) Competition between fatty acids and carbamates 
Previous work in our laboratories has characterised the binding of a 
homologous series of aliphatic carbamates to BSA (Wilson, 1974). The 
uncharged carbamates used had the equivalent alkyl chains to the Fatty 
acids of this work. A good correlation was found, for the carbamates, 
between the binding affinity (expressed as nK) and lipophilicity (measured 
as octanol/water partition coefficient). Since the fatty acids did not show 
a smooth increase in binding with chain length it was of Interest to sec if 
these two series of compounds shared the same binding sites. The effects 
of various concentrations of n butyl carbamate upon pentanoate binding and 
the influence of nonanoate on n octyl carbamate were examined. The results 
are displayed in table 4: 9. Since Wilson (1974) did not estimate the binding 
of n octyl carbamate, the interaction of this compound with BSA was studied 
using ultrafiltration and radioactive ligand. Because of the very limited 
aqueous solubility of n-octyl carbamate it was not possible to determine a 
full binding isotherm. From the data obtained the total binding constant 
(nK or n1K1 + n2K2 if there are two sets of sites) was estimated as 6x 104 M-1 . 
Wilson interpreted his carbamate data in terms of only one class of sites which 
had a decreasing 'n' value with increasing chain length. Thus octyl 
carbamate may be considered to have the binding parameters n=2 or 3, 
K=2- 3x 104M-1. 
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From table 4: 9 it can be seen that nonanoate has no influence upon 
n-octyt carbamate binding at any of the concentrations usr d. Under the 
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conditions of these measurements (BSA =2 .5x 10 M, n1-octyl carbamate 
1x 10-4 or 1x 10-5 M) the carbamate will be bound prii, i riEy to the high 
affinity sites. Since nonanoate has a high affinity association constant 
about 20 fold higher than n-octyl carbamate and yet there is no displacement 
of carbamate these two compounds cannot have the same high affinity binding 
sites. At the highest nonanoate concentration used (1 x: 10-3 M, FA: BSA 
ratio 4: 1) there was some displacement of n-octyt carbamate which could 
be indicative of the carbamate binding site being a secondary fatty acid 
binding site. The K2 for nonanoate is of the same order of magnitude as 
the association constant of n-octyl carbamate. 
From the data in table 4: 9, using similar logic as followed above it Is 
likely that n-butyl carbarnate and pentanoate do riot sh, lco high affinity sites. 
The association constants for the two compounds are 0 ./x 103 M-1 (Wilson, 
41 
1974) and 2.30 x 10 M- respectively but even a 330 fold molar excess of 
n-butyl carbamate causes only a slight reduction in high affinity pentanoate 
binding to BSA. However at higher pentanoate concentration where some 
secondary fatty acid sites may be filled a 3.3 fold excess of n-butyl 
carbamate caused a significant reduction in fatty acid binding. Again it 
is probable that some secondary fatty acid binding is to the main carbamate 
binding sites. 
In conclusion, the neutral aliphatic carbamates seem not to have any 
mutual, main, BSA binding sites with the charged aliphatic carbamates. 
Thus the anomalous increase In binding of fatty acids of eight carbons or 
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more is probably a reflection of the nature of specific anion binding sites 
rather than a special interaction of fatty acid with a common organic ligand 
binding site. 
c) Competition between different fatty acids 
The influence of pentanoate on octanoate binding, and the effects of 
octanoate on pentanoate binding were examined by ultrafil. tration. The 
effects of various concentrations of competitor at two ligaöd concentrations 
were examined. Ligand concentrations were chosen to give situations where 
binding was predominantly to the high affinity sit-I and also where a 
significant proportion of binding was to secondary sites. Table 4: 10 shows 
that pentanoate has Little effect on primary octanoate binding. A 10,000 
fold excess of pentanoate produced only a 7% reduction in octanoate bound. 
Similarly, octanoate had no effect upon primary pentanoate binding until 
1000: 1 ratio was reached, when there was a substantial reduction in the 
percentage bound. The secondary binding of both octanoate and pentanoate 
was significantly reduced in the presence of 1 equivalent, or more, of the 
other fatty acid. 
4: 4: 4 FINAL DISCUSSION 
Several alternative explanations were presented to section 4: 4: 1 to 
account for the higher association constant of octanoate, relative to the 
shorter fatty acids. The combined fluorescence and competition data 
suggests that there may be two different binding sites, one for fatty acids 
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up to seven carbons and the other accomodating longer fatty acids. The 
following findings lead to this conclusion: - The binding of the fatty acids 
to their primary sites does not cause an alteration in the fluorescence 
properties of BSA. Therefore, the environment of both of BSA tryptophans 
are unaffected by binding. This suggests that there are no major confor- 
mational changes with fatty acid binding. Pentanoate and octanoate do 
not displace each other from their high affinity sites, except at very large 
molar excesses of competitor. If a single primary site ; mere Involved for 
both FA, then competition should be observable at much Lower competitor 
concentrations. 
A recent publication by Rodrigues de Miranda and co-workers (1976) 
contains some interesting parallels with our work. This group also examined 
the binding of fatty acid anions to BSA, and used a similar, computerised, 
fitting procedure to examine the data. They, also, found a non-linear 
relationship between chain length and binding affinity. From competition 
experiments, the group conclude that two primary sites exist for medium 
and short chain fatty acids. One site can accomodate fatty acids up to 
pentanoate, the other, fatty acids from six to at least eight carbons in 
length. The concentrations of fatty acids used in the displacement experiments 
was not reported, so it is not certain if they were designed to show 
competition for high affinity sites only. These findings are qualitatively 
similar to our work, but the break point appears to be C6 to C7 rather than 
C7 to C8. Rodrigues de Miranda et at. (1976) suggested that a limit of 
hydrophobic bonding area might be a general feature of proteins. 
It is possible that the peculiar chain length dependence of fatty acid 
binding to albumin may be a general feature of the interaction of macro- 
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molecules with alkyl chains. AL-Gailany (1975), in our laboratories, 
studied the interaction of fatty acids with hepatic microsomal suspensions. 
The FA elicit a type 1 substrate induced binding spectra from which the 
spectral dissociation constants (Ks) can be calculated. Hexanoate and 
heptanoate gave relatively large Ks values of 85 x 10 
_4 
and 21 x 10-4 M 
respectively, whilst octanoate, to undecanoate gave Ks values, changing 
-4 
smoothly with chain length, from 3 . 45 x 10-4 to 0.78 x 10 M. Again, the 
fatty acids of eight carbon atoms, or more, have different binding properties 
to the shorter compounds. 
In a recent review of fatty acid hydroxylation in rat kidney cortex 
microsomes, Ellin and Orrenius (1975) showed w -hydroxylation to be 
chain length specific. Hexanoate, and shorter fatty acids, yielded no 
hydroxylated products whilst octanoate and longer FA were hydroxylated, 
with Increasing velocity with chain length. Ellin and Orrenlus (1975) 
suggest that the shorter fatty acids are not long enough to bridge the gap 
between the binding site and the hydrophobic region of the cytochrome. 
This is a very similar theory to that which was proposed earlier, to explain 
why the short chain FA did not bind to the primary site for FA of eight carbons 
or more. 
Many of the reactions involved in normal fatty acid metabolism and 
transport are highly chain length specific. The treatment of steatorrhoea, 
caused by a variety of conditions, is based upon the fact that fatty acids 
of less than ten carbon atoms have different fates in the body, relative to 
longer fatty acids (Scheig, 1968). Medium chain triglycerides are absorbed 
without hydrolysis, broken down by intramucosal lipase, and transported to 
the liver, via the portal vein. In contrast, long chain fatty acids are 
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hydrolysed in the lumen, absorbed, recombined in the mucosa, to form 
triglycerides, then exported as chylomicra, via the Lymphatics (Bloom et at., 
1951). Many of the enzyme systems involved in fatty ac;, -'. synthesis and 
degradation are chain length specific. For example, fatty acid thiokina se , 
which catalyses the formation of acyl-CoA from saturated fatty acids, exists 
in two forms. One of these varieties will react with fatty acids containing 
4 to 12 carbon atoms, the other is capable of activating fatty acids up to 22 
carbons in length (Mahler and Cordes, 1971). 
To summarize; the albumin binding sites for fatty acids are chain length 
specific. It is likely that two primary sites exist. One is Involved with 
the binding of fatty acids up to seven carbon atoms in length, the other with 
the binding of longer molecules . These primary sites can probably act as 
secondary sites for the fatty acids for which they are not specific. This 
chain length specificity appears to be a general phenomenon of the Interaction 
of fatty acid alkyl groups with biological macromolecules. 
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CHAPTER FIVE 
OPTICAL STUDIES OF THE INTERACTION OF SEVERAL 
COUMARINS WITH SERUM ALBUMIN 
-214- 
5: 1 INTRODUCTION 
In a brilliant piece of scientific detective workoLink and his colleagues 
(Campbell and Link, 1941; Link, 1943) discovered that the agent responsible 
for the hemorrhagic disorder produced in cattle by the ingestion of spoiled 
sweet clover is dicoumerol. Dicoumerol (bishydroxycoumarin) is a dimer 
of 4-hydroxy coumarin, which does not normally occur naturally but is 
formed when sweet clover hay spoiUs in silage. It is formed from the parent 
molecule, coumarin, the substance which Imparts to new mown hay its 
typical sweet smell. The isolation of dicoumeral led to the synthesis of 
a variety of structurally related compounds possessing anticoagulant activity. 
Warfarin, Phenprocoumon and Acenenocournarin h<uuve found extensive use 
as clinically effective oral anticoagulants in man, whilst Coumachlor and 
also Warfarin are used as rodenticides. 
It is well known that the coumarin anticoagulants are highly bound to 
plasma proteins, (see O'Reilly, 1973 and references therein) and Interest in 
this field has been intense due to possible drug interactions (see chapter 3). 
There have, however, been only a few systematic studies of the binding of 
several coumarin derivatives (O'Reilly, 1971; Garten and Wosilait, 1971) 
and only one involving the use of circular dichroism measurements (Chignell, 
1970). There have been reports concerning the binding of one or two coumarin 
derivatives to albumin by Perrin and Nelson, 1972; Perrin et at., 1975 and 
Witting et al., 1976 for Warfarin, Perrin and Idsvoog, 1971 and Perrin et at., 
1975 for dicoumeral and finally by Perrin and Nelson, 1972 for 4-hydroxy- 
coumarin. 
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In this work four closely related coumarin derivatives and their binding 
to Bovine and Human Serum Albumins were studied, using the techniques 
of UV-visible absorption spectroscopy and circular dlchr, -)ism. No attempt 
was made to quantify the binding, although this can be done from CD data 
(Rosen, 1970) other methods are probably more suitable for the estimation 
of binding parameters and, furthermore, substantial data is available on this 
aspect of these interactions (see O'ReilLy, 1973). Attention was focussed 
upon those experiments giving data which might lead to rt better under- 
standing of the mechanism of the coumarin-albumin inter<lction. 
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5: 2 EXPERIMENTAL APPROACH 
Both Human and Bovine Serum Albumins were used, as supplied by 
Behringwerke (see chapter 2). The coumarins were dissolved in a few 
drops of IN NaOH, to aid solution in sodium phosphate buffer, 67 mM, 
pH 7.4. The pH of the drug-albumin solutions was checked immediately 
before recording spectra. 
The UV-visible spectra were recorded at 200C in 10 mm quartz cells 
as described in chapter 2. Spectra were recorded from at Least three 
separate drug-albumin solutions, from which a mean extinction coefficient 
and an absorbance maxima were calculated. The final d! bumin concentration 
was 3x 10-5 M whilst the drug concentration was 2x 10 -5 M. 
Circular Dichroism measurements were made at 2 70 C in 10 mm 
cylindrical cells, as described in hapter 2, from at least three separate 
drug-albumin solutions. The final albumin concentration was 3x 10-5 M 
and the drug concentration was 6x 10-5 M. The eliptisities reported 
below are difference values, having had the elipticity for for albumin 
subtracted from them . Results are expressed as molar cli pticities, 
calculated with respect to albumin concentration, based upon a molecular 
weight of 69,000. Anisotropy values were calculated as described In 
chapter 2. CD measurements were also made at pH values of 6.6,7.0, 
7.4,7.8 and 8.2. 
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5: 3 FIGURES AND TABLES 
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Figure 5: 1 The absorption spectra of the coumarins, (a) In phosphate 
buffer (67 mM, pH 7.4) and (b) in Ii A solution 
a 
Ac( 
Coumachlor 
0.1A 
a 
Phen procoumon 
fo. 
1A 
b 
a 
Warfarin 
O. 1A 
b 
C1 
360 340 320 300 280 260 
wavelength (nm) 
The concentrations were: coumarin 2x 10-5 M, HSA 3x 10^5 M. 
For (b), HSA was used as a blank. 
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Figure 5: 2 The absorption spectra of the coumarins, (a) in phosphate 
buffer (67 mM, pH 7.4) and (b) in BSA solution 
a 
Ac 
Coumach[or 
0.1A 
a 
Phenprocoumon ýý b 
0.1A 
Warfarin 
O. 1A 
a 
b 
360 340 320 300 280 260 
Wavelength (nm) 
The concentrations were: coumarin 2x 10-5 M, BSA 3x 10-5 M, 
For (b), BSA was used as a blank 
a 
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Figure 5: 3 The difference spectra between bound and unbound forms of 
the coumarin drugs 
BSA 
Acenocoumarin 
Coumachlor 
1 
0.1A 
T 
HSA 
0.1A 
.......... . ....... . 
P n0. 
IA 
Warfarin 
0. IA 
340 320 300 340 320 300 
These spectra were recorded with the sample cuvette containing albumin 
(3 x 10-5 M) and coumarin (2 x 10-5 M) in phosphate buffer, the reference 
cuvette contained coumarin (2 x 10-5 M) only. 
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Figure 5: 4 An example of the UV spectra from which data was taken 
The samples were phenprocoumon (2 x 10- 
5 M) and Human 
Serum Albumin (3 x 10-5 M) in 67 mM sodium phosphate buffer pH 7.4 
4 
wavelength (nm) 
Spectra were recorded as follows: - 
1. Baseline 
2. Coumarin absorption 
3. Albumin absorption 
4. Album in/coumarln absorption 
5. Bound coumarin absorption 
6. Bound/free difference 
Sample: Buffer 
Sample: Coumarin 
Sam pie: Atbumin 
Sam ple: Album In/coumarin 
Sam ple: Album in/coumarin 
Sam ple: Album in/coumarin 
Reference: Buffer 
Reference: Buffer 
Reference: Buffer 
Reference: Buffer 
Reference: Atbumin 
Reference : Coumarin' 
360 340 320 300 280 260 24( 
-222- 
Figure 5: 5 An example of the circular dichroism spectra from which. 
measurements were taken 
b 
J 0.005° 0 
a 
a 
340 320 300 280 260 
wavelength (nm) 
a=3x 10-5 M HSA in sodium phosphate buffer, 67 mM, pH 7.4. 
b=3x 10-5 M HSA with 6x 10-5 M Warfarin in phosphate buffer. 
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Figure 5: 6 CD Difference spectra of the coumarins bound to BSA 
Ac 
Co 
Phe 
Warfarin 
10.0020 
e 
380 360 340 320 300 280 260 
Wavelength (nrn) 
In all cases the concentrations were: BSA 3x 10-5 M, coumarin 6x 10-5 M. 
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Figure 5: 7 CD Difference spectra of the coumarins bound to I-ISA 
Acenocoumarii 
Coumachlor 
Phenprocoumo 
Warfarin 
0.002° 
380 360 340 320 300 \280 /260 
Wave length 
In all cases the concentrations were: coumarin 6x 10-S M, HSA 3x 10-5 M. 
-225- 
Figure 5: 8 CD Difference spectra of 4-hydroxycoumarin in the presence of HSA 
+2,0 
"4 -Hydroxycoumarin 
f 1,0 
n 
0 
25 0 300 35 0 
Wa vele ng th , nm 
_0 ,5 
4-Hydroxycoumarin 6x 10-5 M, HSA 3x 10 5 M. 
Molar eliptizity calculated with respect to HSA concentration. 
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Table 5: 1 Structures and some properties of the coumarin derivatives under study 
Av. d: ily 
Name and 
dose for 
Structure M. W. therapeutic Einding Parameters 
synonyms hypothrom- 
b[naernia 
Mg. 
Acenocoumarin 0O 
S introm n=2.1 ± 0.1 
Nicoumalone OH 
NO2 
I 
CH2 
353.3 5 
= 14.7 + 0.4 x4 -1 Ka _ 
10 M- 
C=O 
C H3 
Coumach[or 
Tomorin 
Cl 342.79 Not normally Unknown 
OH CH 2 
used in human 
1 therapy 
C=0 
1 
Uri 3 
Phen procoumon 0 
Marcumar 
C-0 n=1.9 + 0.2 
OH CH 
12 
280.3 4 
=26.6+0.8x104M-1 K 
CH 3 
a 
Warfarin O 
Coumadin H 
14- C 
n=2.0 ± 0.1 
OH 
CH 
2 
308.32 7 
I K =23.1+0.5x104M 1 C=0 a 
I C H3 
4-Hydroxy- 
coumarln n-0.9 ± 0.1 162.1 .1 1500 
K =7.9±0.3x104M- 
OH a 
The values of daily dose for hypoprothrombinaemia and the binding parameters (which refer to the high 
0 
affinity sites only, at 27 C, pH 7.4, phosphate buffer, crystalline HSA) are taken from O'Reilly, 1973. 
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Table 5: 2 UV Absorption data for the coumarin derivatives free and bound 
to Human and Bovine Serum Albumins 
Free (in phosphate Bound (in BSA) Bound (in HSA) 
buffer pH 7.4 
67 mM 
maximum shoulder maximum shoulder maximum shoulder 
wavelength 308 291 311 291 312 291 
Warfarin 
extinction 12.87 10.50 11.96 10.25 12.13 9.88 
co-efficient 
wavelength 302.5 291.5 304.5 291.5 305 291 
Acenocoumarin 
extinction 19 .38 18.77 17.08 17.00 16.50 16.75 
co-efficient 
wavelength 309 292 313.5 292.5 314 293 
Phenprocoumon 
extinction 14.63 11.19 13.50 10.33 13.54 10.13 
co-efficient 
wavelength 307.5 292 311 292.5 312 292 
Coumachlor 
extinction 13.50 11.03 12.21 10.58 12.54 10.63 
co-efficient 
Extinction co-efficient (mM, 25 
0 C) 
recordings of solutions of drug (2 x 
and absorbance maxima are from 
10-5 M) in phosphate buffer with a buffer 
blank in the case of 'free', drug (2 x 10 " M) in protein (3 x 10 `' M) with a 
-S 
protein blank (3 x 10 M) for 'bound. 
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Table 5: 3 Circular d ichro ism data for the coumarin - Bovine Serum Albumin 
complexes at pH 7.4 
Wavelength Molar Anisotropy 
Compound positions of elipticity factor 
CD maxima nm . [0] x 10-4 gx 105 
305 + . 293 + . 009 + 9.2 
Warfarin 287 + . 531 + . 016 + 21.8 
255 + 1.288 + . 058 
332 - . 126 + . 010 - 6.3 
304 + . 125+ . 017 +3.4 
Phenprocoumon 291 - . 129 + . 019 - 5.2 
275 + . 361 + . 016 
256 + 1.42 ± . 012 
332 - . 426 4- . 007 - 21.6 
Acenocoumarin 286 + 1.57 5+ . 046 + 35.0 
281 + 1.908+ . 014 + 32.5 
316 - . 424+. 014 - 10.9 
Coumachlor 292 - . 334 + . 013 - 9.9 
256 +1 . 405 + . 070 
All figures are difference values obtained by subtraction of the corresponding 
value for BSA alone. Molar elipticity calculated with reference to total drug 
concentration (6 x 10-5 M, BSA 3x 10-5 M). Anisotropy values calculated 
with respect to drug bound. 
Results expressed as mean ± SEM (n = 6). 
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Table 5: 4 Circular dichroism data for the coumarin - Human Serum 
Albumin complexes at pH 7.4 
Wavelength Molar Anisotropy 
Compound positions of eliptlcity factor 
CD maxima nm. [8] x 10-4 gx 105 
312 +. 424+. 019 + 13.6 
Warfarin 268 - . 262 + . 029 - 25.0 
257 + . 418 + . 062 
317 -. 572+. 020 - 15.4 
292 - . 891+. 014 - 31.2 
Phenprocoumon 268 - . 298 + . 014 - 30.3 
257 + 1.031 ± . 048 
330 - . 429 + . 012 - 18.3 
Acenocoumarin 289 -F . 49 8+ . 023 + 10.0 
(268 ) (< . 075) 
325 -. 107+. 017 - 3.7 
Coumachlor 268 - . 262 + . 020 - 15.4 
256 +. 771±. 019 
All figures are difference values obtained by subtraction of the corresponding 
value for HSA alone. Molar elipticity calculated with respect to total drug 
conch (6 x 10-5 M; HSA 3x 10-5 M). Anisotropy values calculated with 
respect to drug bound. Results expressed as Mean ± SEM (n = 6). 
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Table 5: 5 Influence of off on the circulardlchrolsm of the coumarin - BSA complexes 
Compound and MOLAR ELIPTICITY [e] x 10-3 
wavelength 
position of pH 
maxima 8.2 7.8 7.4 7.0 6.6 
Acenocoumartn 
332 - 2.72 ± . 098 - 3.94 ± . 001 - 4.26 ± . 098 - 4.48 ± . 22 - 4.59 ± . 001 
286 + 7.87 ± . 377 + 11.81 ± . 001 + 14.86 ± . 22 + 16.17 ± . 
098 + 17.06 ± . 19 
281 + 9.71 ± . 459 + 14.53 + . 001 + 18.81 ± . 098 + 20.11 + . 098 + 20.67 ± . 328 
Phen procoumon 
332 - 1.69 ± . 055 - 1.51 ± . 108 - 1.41 ± . 108 - 1.58 ± . 056 - 1.64 ± . 001 
304 + 1.08 ± . 108 + . 886 ± . 108 + . 984 ± . 190 + 1.07 ± . 171 + 1.08 + . 108 
291 + 2.46 ± . 190 + 2.07 ± . 056 + 1.57 ± . 056 + 1.74 ± . 056 + 1.42 ± . 144 
286 + 15.03 ± . 22 + 14.83 ± . 098 + 14.27 ± . 190 + 14.04 ± . 220 + 13.45 ± . 095 
Coumachlor 
316 - 2.84 ± . 056 - 3.77 ± . 001 - 3.99 + . 108 - 4.32 ± . 289 - 4.98 ± . 108 
292 - . 984 ± . 108 - 2.40 ± . 108 - 3.06 ± . 108 -3 . 50 ± . 220 -3 . 50 ± . 108 
256 + 15.42 ± . 190 + 13.23 ± . 108 + 12.57 ± . 190 + 12.03 ± . 220 + 11.59 + . 394 
Warfarin 
305 + 3.12 ± . 125 + 2.68 ± . 144 + 2.84 ± . 108 +3 . 12 ± . 095 + 3.17 ± . 108 
287 + 4.98 ± . 358 + 5.14 ± . 108 + 5.14 ± . 108 + 4.87 ± . 057 + 5.25 + . 190 
255 + 12.03 +. 22 + 10.61 ±. 108 + 11.59 ±. 108 + 10.94 ±. 108 11.15+. 001 
The results are expressed as difference values. 
Molar ellpticltles calculated with respect to total drug conc'l (6 x 10-5 M; BSA 3x 10-5 M), 
Mean ± S. E. M. (n = 3) 
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Table 5: 6 Influence of nH on the circular dichroism of the coumarin - HSA comoieres 
Compound and MOLAR ELIPTICITY [81 x 10-3 
wavelength 
position of pH 
maxima 
8.2 7. 8 7.4 7.0 6.6 
Acenocoumarin 
330 - 3.44 ± . 095 - 3.66 ± . 056 - 4.04 ± . 056 - 4.27 ± . 164 - 4.16 ± . 056 
289 + 7.11 ± . 236 + 6.18 + . 055 + 5.25 ± . 108 + 5.58 ± . 190 + 5.52 ± . 144 
Phenprocoumon 
320 - 2.46 ± . 22 - 4.69 ± . 289 - 5.36 ± . 056 - 6.14 ± . 108 - 6.07 ± . 095 
292 - 6.45 ± . 056 - 8.30 ± . 197 - 9.02 + . 095 - 10.00 ± . 190 - 9.84 + . 095 
268 - 3.38 ± . 289 - 4.10 ± . 220 - 2.95 ± . 001 - 3.38 ± . 262 - 2.89 ± . 236 
257 + 7.87 + . 001 + 8.47 ± . 144 + 9.51 + . 328 + : . 144 + 10_00 ± . 220 
Coumachlor 
325 - . 492 + . 164 - . 764 ± . 095 - 1.07 ± . 190 - ;0 + . 001 - . 492 ± . 001 
268 - 2.62 + . 492 - 2.73 + . 377 - 2.84 ± . 525 - 2. RI) ± . 843 - 2.02 ± . 502 
256 + 8.20 ± . 328 + 7.76 ± . 190 + 7.33 ± . 190 + 9.02 ± . 997 + 7.76 + . 377 
Warfarin 
312 + 5.74 ± . 001 + 4.65 ± . 190 + 3.83 ± . 095 + 3.34 ± . 249 + 2.73 ± . 341 
268 - 3.17 ± . 190 - 3.34 + . 620 - 2.19 + . 827 - 2.30 ± . 328 - 2.73 ± . 492 
257 + 5.63 + . 190 + 4.21 ± . 190 + 5.41 ± . 869 + 4.20 + . 502 + 3.88 + . 190 
The results are expressed as difference values. 
Molar ellpttcitles calculated with respect to total drug concentration (6 x 10 P, i; HSA concentrdtJon 3x 10-5 M) 
Mean ±S. E. M. (n=3) 
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Table 5: 7 UV absorption and circular dichroism maxima for the coumarin 
derivatives bound to albumin 
Compound Type of Spectra Wavelength positions of maxima (nm) 
and signs of induced elipticity 
Warfarin UV Bound to HSA 312 291 
CD If " 312+ 268- 257+ 
UV " BSA 311 291. 
CD " 11 305+ 287+ 255+ 
Phenprocoumon UV Bound to HSA 314 293 
CD if if 317 292- 268- 257+ 
UV "" BSA 313.5 292.5 
CD If 11 332-, 304+ 291- 275+ 256+ 
Enantiomers in buffer 311 2J30 268 262 241 
Acenocoumarin UV Bound to HSA 305 291 
CD If 11 330- 289+ (268-) 
UV " BSA 304.5 291.5 
CD 61 332- 28C± 281+ 
Coumachlor UV Bound to HSA 312 292 
CD 325- 268- 256+ 
UV " BSA 311 292.5 
CD " if 316- 292- 256+ 
4-OH Coumarin CD Bound to HSA 310+ 290+ 268- 
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Table 5: 8 The percentage of coumarin bound to albumin and the 
relationship to coumarin partition coefficient 
Albumin Ligand 
Percentage bound 
Mean + SEM (n=6) 
Partition coefficient, 
octanol/phosphate 
buffer (pH 7.4,67 mM) 
Mean ± SEM (n=4) 
Acenocoumarin 77.71 + 0.06 7.3 + 0.10 
Coumachlor 86.67 + 0.05 38.1 + 0.20 
HSA 
Phenprocoumon 83.19 + 0.06 17.3 + 0.35 
Warfarin 77.05 +0ý 04 10.6 + 0.20 
Acenocoumarin 74.79 ± 0.21 7.3 + 0.10 
Coumachlor 86.85 + 0.13 38.1 + 0.20 
BSA 
Phenprocoumon 85.18 + 0.08 17.3 + 0.35 
Warfarin 81.16 + 0.12 10.6 + 0.20 
The percentage of coumarin (6 x 10-5 M) bound to albumin (3 x 10-5 M) 
was determined by half-cell equilibrium dialysis at 250 C. 
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5: 4 RESULTS AND DISCUSSION 
5: 4: 1 ELECTRONIC ABSORPTION SPECTRA 
The electronic absorption spectra of the four coumarins were 
qualitatively similar, as shown in figures 5: 1 and 5: 2. It can be seen that 
these compounds exhibit a relatively intense transition in the region 
300 - 310 nm with a well defined shoulder at 290 - 293 nm. In some 
cases a much weaker shoulder was observable in the region 275 - 280 nm. 
Table 5: 2 lists the absorption maxima and extinction coefficients for the 
four compounds. 
In structures as complex as these, it is difficult to ascribe transitions 
to specific portions of the molecule. However, reference to simpler compounds 
aids the assignment. Brand and Toribara (1972) have ro; )orted the 
absorption spectra of coumarin in phosphate buffer (pl-? 7 . 4,0.1 M). They 
found two intense transitions, one at 277 nm and a second at 308 nm, but 
no sign of a peak at 290 nm. It is almost certain then that the absorption 
(in the region 300 - 310 nm) of the anti-coagulant coumarins under study 
is due to transitions in the main coumarin ring system, the same can be 
said of the weak shoulder at 275 - 280 nm but this is less important. 
The intense absorption of coumarin at 308 nm is due to 7r--> it transitions 
in the conjugated system. The structural difference between coumarin and 
the derivatives under study is the addition of a substituted benzyl moiety. 
In the cases of Warfarin, Phenprocoumon and Coumachior this addition has 
little effect upon the absorption around 308 nm (see table 5: 2). This is to 
be expected since the electrons of the coumarin ring cannot be further 
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delocalised by conjugation with the electrons of the phenyl ring due to 
the intervening secondary methyl linkage. Not only is ordinary resonance 
conjugation unlikely but hyperconjugation, as proposed by Crawford (see 
Crawford, 1953), is also unlikely since a separation of charge involving 
both the coumarin and phenyl rings would require the existence of two 
double bonds to the linking atom (Sangster and Irvine, 19 55). In addition, 
the substituted benzyL moieties of these compounds would not be expected 
to contribute significantly to absorption in the wavelength region of 308 nm. 
In contrast to the other coumarin derivatives, Acenocoumarin has a more 
intense transitioniat the lower wavelength of 302 .5 nm. This change in 
absorption, relative to coumarin, could be due either to some effect upon 
the , electrons of the coumarin ring, or to the presence of an additional 
chromophore. As has been stated, it is unlikely that there can be any 
conjugation between the coumarin and phenyl rings, and the presence of 
the electron withdrawing p-nitro group will not change the situation. Thus, 
it is likely that there is an additional absorbing chronophore in Aceno- 
coumarin. An isolated nitro group has only a weak n-s r transition around 
270 nm, but this is masked in aromatic nitro compounds by it -> it 
transitions (Rao, 1975). Benzene normally has an absorption around 200 nm, 
associated with Tr -ý it transitions, however large bathochronic shifts 
in this absorption can arise with nitro substituted derivatives (Doub and 
Van derbelt, 1947). For example, p-nitro phenol and p--czitro toluene have 
absorption maxima at 317.5 nm and 285 nm respectively. It is possible 
then, that the transitions of the main coumarin ring and of the subsituted 
p-nitro benzyl portions of acenocoumarin overlap to give the Intense transition 
observed at 302 .5 nm. It is interesting to note that Doub and Van derbelt 
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(1947) also reported p-chloro substitution of benzene derivatives (as in 
coumachlor) to produce only small bathochrcrnic shifts in absorption maxima. 
As well as the main peak in the region 300 - 310 nm, all the coumarin 
anticoagulants studied exhibited a well defined shoulder at 291 - 292 nm. 
It has already been stated that coumarin itself has no absorption maxima 
In this region. However, 4-hydroxy coumarin, in acid solution, has an 
absorption spectrum quantitatively identical with that of warfarin (Brand 
and Torlbara, 1972). It seems very likely, then, that the shoulder at 
291 - 292 nm is due to the 4-hydroxy substituent on the coumarin ring. 
The absorption spectrum for warfarin reported here is in good agreement 
with published spectra (Chignell, 1970; Brand and Torlbara, 1972), the 
absorption spectra of the other three compounds are not readily available. 
Table 5: 1 and figure 5: 2 give details of the absorpt i1c)a spectra of the 
coumarins when bound to HSA and BSA. This data was obtained with a 
sample solution of albumin (3 x 10- 
5 
M) with coumarin (2 x 10- 
5 
M), and 
a reference solution of albumin (3 x 10- 
5 
M) alone. The spectra thus 
recorded have been taken to reflect the absorption of bound coumarin. 
This can be justified from several stand points. The drug-albumin ratio 
used was 2: 3, under these circumstances about 90% of the coumarin 
derivatives are bound to albumin. There is, then, little contribution to the 
spectra from free drug. The spectra must also reflect any ligand induced 
changes In albumin absorption, However, over much of the wavelength range 
of interest, albumin has no absorption. It can be seen from figure 5: 4 that 
the absorption of albumin is, in fact, only a little perturbed by coumarin 
derivative binding. 
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Upon binding to albumin, all the derivatives showed a bathochromic 
(red) shift of 2-5 nm in the main absorption peak, with a reduction in 
the intensity of absorption. The shoulder at 291 - 292 rim also showed 
a reduction in intensity, but to a small degree and there was little, if any, 
change in the position of the maxima. Binding to HSA produced a greater 
red shift in the main peak compared to BSA but there were no other consistent 
differences between the two albumins. 
A red shift in ligand absorption maximum, upon binding to albumin, has 
been reported for several drugs Including phenylbutazone (Chignelt, 1969a) 
and flufenamic acid (Chignell, 1969b), and for several c+. l, s (Klotz ei: at., 
1946). Chignell (1969a) suggested that the red shift is due to the movement 
of ligand from polar, aqueous solution, to the more hydrophobic environment 
of the protein binding site. This seems to be in conflict with the well 
known fact that it irr transitions shift to shorter wavelengths with 
decreasing polarity. This phenomena has even been used to distinguish 
Ir --, r transitions from other types. There are, however, many exceptions 
to the ruLe, with benzene being the most notable. The blue shift in protein 
UV absorption upon unfolding or denaturation (Beavers and Holiday, 1952) 
has been attributed to the movement of aromatic residues from the hydro- 
phobic interior of the protein to the polar solvent (Yan ari and Bovey, 1960). 
It seems logical that the binding of an aromatic compound to a protein would 
produce the opposite, i. e. red, shift, which is indeed what is observed with 
these coumarin derivatives. It is interesting to note that coumarin itself 
has an absorption maximum at 308 nm in aqueous media (Brand and Toribara, 
1972) whilst in methanol, which has a lower dielectric constant (24.3 
compared to 78.5 for water), the maximum is at 313 nm (Lang, 1964). 
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The reduction In intensity of the coumarin's absorption upon binding 
is not, perhaps, what would be expected. The red shifts of phenyl- 
butazone and flufenamic acid (Chignell, 1969a, b) are accompanied by 
an increase In intensity, and the movement of an aromatic, absorbing 
species from polar to non-polar solvents normally results in an Increase 
in Intensity of electronic transitions. Several workers have, however, 
reported a reduction in absorption intensity of various tigands upon binding 
to albumin e. g. Thyroxine, (Tritsch, 1968) and azosuiphathiazole (Klotz, 
1960). There does not seem to be a simple mechanistic explanation for 
binding induced changes in absorption intensity. 
The spectral differences between BSA bound and HSA bound coumarin 
derivatives were relatively small. The larger red shift upon binding to 
HSA is possibly a reflection of a greater hydrophobicity of binding sites, 
but little further information can be gained from a comparison of the two 
sets of data. 
The shoulder around 292 nm, which has been attributed to the 4-hydroxyL 
substituent of the coumarin ring, is relatively unaffected by binding to 
albumin. The simplest conclusion would be that the 4-hydroxyl group Is 
not involved in the binding However, the group is acidic in nature, 
deprotonisation being encouraged by the following: - 
o 
ý cý 
oý x 
Such a polar group is unlikely to be situated in an area of high hydro- 
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phobiclty upon binding, but it may be involved in the binding process via 
electrostatic interactions. 
The preceding discussion was based upon the spectra of bound drug 
a second kind of difference spectra were recorded. In this case, the 
sample solution was coumarin (2 x 10-5 M) with albumin (3 x 10-5 M) and 
the reference was coumarin alone (see figure 5-3). As we have 
seen, over much of the absorbance range of the coumarins, albumin shows 
no absorbance and, thus, the difference spectra must redact the changed 
transitions of bound and free drug. The spectra below 285 nm, where 
albumin absorbs significantLy, will be considered later. These difference 
spectra between bound and free drug are comparabLe with those obtained 
using the tandem cuvette techniques of Herskovits (1967). In this system, 
cuvettes with two compartments are used, in the reference cell one half 
is fitted with ligand solution, the other with protein soi.,; tion, whereas the 
two solutions are combined in the sample cell. Differences in the absorption 
of bound and free ligand and/or protein are reflected in the resulting spectra, 
which are often multiphasic. This technique has been used to examine the 
binding of several compounds to albumin including phenylbutazone, (Chignell, 
1969a), fLufenamic acid (Chignell, 1969b), HABA (Baxter, 1964), dicoumerol 
(Perrin and Idsvoog, 1971) and several phenothiazines (Huang and Garay, 
1974). Comparison of spectra obtained in this way, with those in the 
presence of organic solvent or detergent, in place of protein, can give some 
information concerning the nature of the binding site, but the technique is 
generally more useful in quantitative studies. 
The spectra obtained In this study are shown in figure 5: 3. The spectra 
are qualitatively similar for all the derivatives, wi. th both HSA and BSA, 
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being typified by a broad positive maximum In the region 310 - 350 nm and 
a minimum around 300 nm. The magnitude of the spectra in the presence 
of HSA was always greater than the equivalent foi BSA. In common with 
previous observations, this may reflect a greater 1-iydrophobicity of the HSA 
binding sites but the evidence is far from conclusive. The acenocoumarin 
difference spectra were atypical in having only a very small maximum 
around 330 nm with a large minimum at 305 nm. This discrepancy may 
be due to the different nature of the transitions which produce the main 
absorption of acenocoumarin compared to the other derivatives. 
In figure 5: 4 the absorbance specs-:. of the protein alone (scan 3) may 
be compared with the protein's spectra in the presence of ligand, with 
ligand as reference (scan 6). In the region 275 - 285 nm, where the 
absorbance of free and bound ligand is very similar (cf spectra 2 and 5), 
there is a small, but conslstent, difference between the native and liganded 
protein absorbance. These differences are probably due to small confor- 
mational changes with binding, involving changes in the environments of 
some aromatic residues (which contribute most to protein absorption at these 
wavelengths) . 
5: 4: 2 CIRCULAR DICHROISM 
The binding of the coumarin derivatives to albumin produced new cotton 
effects, in addition to the intrinsic effects of the protein . All the coumarins 
produced such changes, with both albumins (see figure 5: 5, a typical 
recording from which data was taken). There have been only limited studies 
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of the coumarin-albumin interaction using C. D. measurements Chignell 
(1970) reported that dicoumerol did produce cotton effects with binding to 
HSA, warfarin, acenocoumarin and 4-hydroxy coumarin did not. In a series 
of simple observations, Perrin and Nelson (1972) demonstrated optical activity 
upon binding with both warfarin and 4-hydroxy coumarin. In later work, 
Perrin and co-workers (Perrin et al., 1975; Wilting et aL., 1975) confirmed 
the production of optical activity with warfarin binding to albumin, but did 
not examine wavelengths below 300 nm. To our knowledc; c;, BSA-eoumarin 
interactions and the binding of Phenprocoumon and Couma. chior to HSA have 
not previously been examined using C. D. techniques. 
There are several possible sources for the new optical activity produced 
with the binding of the coumarins to a[bumin. The most obvious is a change 
in the intrinsic activity of the protein. However, this is unlikely since a 
large conformational change is needed to cause marked changes in protein 
C. D., and we have seen in the previous section that coumarin binding induces 
only small changes in the protein conformation, at least as far as the light 
absorbing residues are concerned. In addition, the wavelength maxima of 
the new cotton effects correspond well with the wavelengths of the coumarins 
absorption maxima. 
Before considering a second source of the new optical activity it is 
pertinent to reiterate the fact that the coumarin derivatives used in this study 
are racaemic mixtures of two enantiomers. Whilst the racemate has no 
optical activity, the individual enantiomers do show cotton effects (see 
next chapter). Thus, if the binding of racemate to albumin affected the 
intrinsic optical activity of one of the enantiomers then new cotton effects 
would be produced . However, it can be seen from figure 5: 8 that 4-hydroxy- 
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coumarin binding to albumin produces new optical activity at wavelengths 
similar to the other derivatives. 4-Hydroxy coumarin does not have an 
asymetric locus and thus the preceding source for optical activity is 
unlikely to be the correct one. The only plausible explanation of the 
new cotton effects Is that the electronic transitions of the coumarin 
derivatives, when bound, are perturbed by an asymetric locus of the protein. 
In other words, the cotton effects are 'extrinsic' or 'induced'. 
There are many qualitative and quantitative differences between the 
induced spectra of the various coumarins when bound to BSA or HSA, as 
can be seen from figures 5: 6 and 5: 7. Simiiarities do exist, however, 
particularly in the wavelengths of the C. D. maxima, whl. ch are displayed 
in table 5: 7. In the region 300 - 350 nm all the interactions induced a 
maximum, and from previous discussion it is reasonable to assume that 
this is due to a perturbation of the Tr --ý ,r transitions of the main coumarin 
ring. The sign and magnitude of the maximum varies with compound and 
protein. Acenocoumarin and Coumachior give negative, and warfarin 
positive, maxima with binding to either protein. Phenprocoumon gives 
a negative maximum with HSA, but binding to BSA produces a biphasic 
spectrum with a negative maximum at 332 nm and a positive maximum at 
304 nm. 
The sign and magnitude of an induced cotton effect depends upon the 
spatial relationship between the perturbed chromophore and the asymetric 
centre (Schellman, 1968). The space around a chromophore Is divided into 
areas of positive and negative contribution to the Induced activity according 
to well defined symmetry rules. Thus, a given asymetric centre may 
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generate positive or negative effects depending upon its spatial relationship 
with the perturbed chromophore. The magnitude of an induced cotton effect 
will depend upon the distance between the chromophore and asymetric locus 
(Schellman, 1968,1969). 
As well as activity above 300 nm, the binding of the coumarins to 
albumin generated several induced bands at shorter wavelengths. With the 
exceptions of the binding of warfarin and coumachlor to HSA, all the inter- 
actions produced an extrinsic C. D. maximum around 290 am. The 
absorption of UV light at this wavelength has been assigned to the 4-hydroxyl 
portion of the coumarin ring, and it seems reasonable tbat the Induced C. D. 
may arise from perturbations of the same chromo phore . The magnitude and 
sign of the band near 290 nm again varied with the nature of the coumarin 
and the protein. Acenocoumarin binding produced the largest effects in 
this region, particularly in combination with BSA when- two maxima at 
2 86 and 2 81 nm can be seen. 
The interaction of the coumarins with HSA produced a small band of 
negative elipticity at 268 nm, a wavelength at which the enantiomers of 
warfarin and phenprocoumon also show a small maximum. The chromophore 
which is perturbed to give this activity must, again, be .i portion of the main 
coumarin ring since 4-hydroxycoumarin also gave a cotton effect at this 
wavelength. The exact nature of the chromophore is unknown. The inter- 
action of acenocoumarin with HSA was again unusual in producing a band 
at 268 nm too small to quantify accurately due to the small signal: noise 
ratio. The lack of visualisation of a 268 nm peak for the BSA-coumarin 
Interaction may reflect some fundamental difference in the binding site or 
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bonding mechanism, compared to HSA. Aiternatlvely, the tack of effect may 
be explained by the fact that the Intrinsic spectra of BSA has a pronounced 
peak at this wavelength where HSA has only a shoulder. This peak of BSA 
may mask the small induced effects which were apparent with HSA. 
The most pronounced induced effects were produced in the region 256- 
257 nm; with the exception of acenocoumarin, all the benzyl coumarin 
derivatives gave positive effects with both albumins. There is no equivalent 
effect in the spectra of the 4-hydroxycoumarin-HSA complex nor in the 
intrinsic spectra of the enantiomers, which perhaps suggests that the binding 
of warfarin, coumachlor and phenprocoumon induce a conformational change 
in aLbumin, which is reflected in this C. D. band. An alternative explanation 
is that these effects are due to perturbations of the transitions of the phenyl 
electrons. The absence of a band for 4-hydroxycoumarin binding is consistent 
with this view. The lack of a2 56/7 nm effect with acenocoumarin may be 
explained by the profound spectral effects of a nitro substituent upon aromatic 
systems, which has already been discussed. The effect of the nitro group 
may be to shift this cotton effect to a higher wavelength, perhaps to the 
286-281 nm region where acenocoumarin binding produces a large maximum. 
From the foregoing discussion, several conclusions may be drawn 
concerning the coumarin-albumin interaction. Perhaps the most important 
conclusion may be gleaned from the simple fact that extrinsic cotton effects 
are produced with binding. Since specific areas around a chromophore 
contribute to negative and positive cotton effects, a simple one point attach- 
ment of ligand and protein will not produce extrinsic optical activity since 
the Ligand Is free to rotate into both areas (Chignell, 1969b) . Thus, the 
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coumarin-albumin complex must be a rigid one with at least two points 
of interaction. 
Several chromophores have been shown to contribute to the extrinsic 
cotton effects. All the derivatives show perturbations in the ,r- ,r 
transitions of the conjugated coumarin ring system on binding to albumin, 
and the involvement of the 4-hydroxyl region of the ring is suggested In 
several of the spectra. The band at 268 nm, formed by interaction with 
BSA is also indicative of the main coumarin ring being involved in the 
binding. The phenyl portion of the side chain may be responsible for 
induced activity in the 286 nm region, but this is not confirmed. The 
remaining part of the side chain (propyl In the case of phenprocoumon, 
butanonyl in the cases of warfarin, acenocoumarin and coumachlor) has 
not been considered, but that is not to say that It is uninvolved In binding. 
A propyl group would not be expected to show any optical properties in the 
wavelength region under study, and the carbonyl group of the butanonyl 
moiety will only have a very weak 7r--> Tr transition around 280 nm. 
Despite the general similarities of the induced optical activities, there 
exist many differences In the sign, intensity and shape of the spectra. 
The differences reflect both the nature of the electronic transitions in the 
ligand and tine spatial arrangement of the chromophores in relation to the 
asymetric centre. A cursory glance at figures 5: 6 and 5: 7 will show that 
theeffects generated upon binding to BSA and HSA are profoundly different, 
the most obvious and consistent difference is seen in the wavelength region 
260-285 nm, where binding to HSA generates negative effects and BSA binding 
produces positive elipticity. These differences presumably reflect the 
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dissimilar natures of the two sets of binding sites. 
The difference in extrinsic spectra for the various cotimarin derivatives 
is best considered by referring to warfarin as a 'standard' . The addition of 
a nitro group to the phenyl ring, to produce acenocoumarin has a profound 
effect upon the induced optical activity. Muller and Wollert (1973a) reported 
that nitro substituted benzodiazepines had different induced optical activity 
compared to other compounds in the series. The hydrophilic nitro group 
of acenocoumarol gives the compound a reduced partitiDn coefficient, 
compared to warfarin (table 5: 8). This reduction in lipophilicity is 
reflected in a smaller percentage of acenocoumarin bound to BSA, than 
warfarin, but there is no significant difference between the two compounds 
for HSA binding. 
The p-chloro subsitutent of coumachlor makes the compound more 
Lipophilic than warfarin. This is reflected in an increased partition 
coefficient and an increase in the percentage of coumachior bound to BSA 
or HSA (table 5: 8). A greater interaction of the side chain of coumachlor 
with the albumin binding site might affect the arrangement of the main ring 
with the asymmetric locus. This would explain why warfarin and coumachlor 
have induced spectra of opposite sign (above 290 nm) for binding with 
both HSA and BSA. In a similar way, the substitution of the butanonyl 
group of warfarin with the less polar propyl group, as in phen procoumon , 
increases lipophilicity. This shows as increased percentage bound 
and partition values of phenprocoumon compared to warfarin. Again, an 
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increase in the binding of the side chain might affect the coumarin ring 
binding, the induced C. D. effects above 290 nm are opposite in sign for 
warfarin and phenprocoumon interactions with HSA. This difference is 
less pronounced for the binding to BSA which might reflect: the relatly^ 
importance of side chain binding for the two albumins. 
One important lesson which should be learnt from these results is how 
subtle modifications of a complex molecule can have a profound effect upon 
the mode of interaction with albumin. Also, the data effectively illustrates 
how albumins from various species can vary in their binding characteristics. 
5: 4: 3 THE INFLUENCE OF pH 
The extrinsic C. D. spectra of the coumarin-albumin complexes were 
examined at various pH values, over the range 6.6 to 8.2. A change In 
the pH of a drug-albumin solution can cause a change in the magnitude or 
character of the interaction for any one of several reasons. If the ligand 
is ionisable, with a PKa in the region of the pH range under study, then 
binding changes may result from the different properties of the ionised and 
unionised forms of ligand. Chemical and structural changes of the protein 
with varying pH may also cause changed ligand interactions. The number 
and ratio of positively and negatively charged amino acid residues will 
change with pH, and if such residues are present at the binding site, the 
binding characteristics of the protein may alter. Albumin is known to 
undergo a structural transition beginning near pH 7.0 with completion at 
pH 9.0. This phenomenon is known as the N_>B transition (Wallerik, 
-248- 
1973) and has been reported to alter the binding properties of the protein 
(Shecter, 1969; White et al. , 1973; Müller and Wollert, 1974). The 
better known N>F transition occurs over the pH range 4 to 2 and is 
thus unlikely to be important in binding studies. 
The C. D. spectrum of albumin does not change over the pH range 
6.6 to 8.2 (Müller and Wollert, 1974) thus, any changes in the spectra of 
the coumarin-albumin complexes must be extrinsic in origin. The wavelength 
positions of the extrinsic spectra did not change with p TH. '. There were, 
however, small alterations in the Intensity of the bands. These alterations 
are shown In tables 5: 5 and 5: 6. The variations with pH were small for 
all the interactions, which is consistent with the opinion that ionic bonds 
play only a small role in the coumarin-albumin complex (see Chapter 3). 
The induced peaks around 290 nm, which have been assigned to the 4-hydroxyl. 
portion of the coumarin ring, were changed, in all cases, with variation in 
pH. There was, however, no consistency in the direction or magnitude of the 
change. The 4-hydroxyl group is ionisable, with a pKa of 5 (for warfarin, 
Lachman, personal communication cited by Perrin and NeLson, 1972). There 
would, then, be significant changes in the amounts of ionised and unionised 
coumarin derivatives over the pH range under study. Different binding 
properties of these two forms would explain the changes in the 290 nm peak. 
A significant change in the induced elipticity above 300 nm was produced 
with pH change, in most of the Interactions. Decreasing pH shifted the bands 
in a negative dlrection., which could be due to increasing protonation of the 
4-hydroxyl moiety moving the coumarin ring towards an area of negative 
contribution to the cotton effects. The positive band at 312 nm for the 
warfarin -HSA complex Is an example of such a negative shift with decreasing 
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PH. O'Reilly (1971) has reported that warfarin has a higher affinity for 
HSA with decreasing pH, so that, in this case, an increase in affinity is 
mirrored by a decrease in elipticity; a surprising finding . However, 
Perrin and Nelson (1972) reported the extrinsic C. D. spectra of the 
warfarin-HSA complex, at 310 nm, to be positive at pH 7.4 but negative 
at pH 5.0. This is consistent with the proposed movement of the coumarin 
ring into a negative contributing area with increasing protonation and is 
compatable with the reduction in positive eli. pticity going t: rom pH 8.2 to 
pH 6.6, which must ref tact a portion of this inversion. :,, cause of the 
small size and the lack of consistency of the pH induced spectraL changes 
no further conclusions can be reasonably drawn from these results. 
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CHAPTER SIX 
THE BINDING OF THE ENANTIOMERS OF WARFARIN 
AND PHENPROCOU MON TO SERUM ALBU MIN 
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6: 1 INTRODUCTION 
The coumarin oral anticoagulants, of the general formula: 
o 
H 
C 
ý-R 
OH R 
1 
possess an asymmetric centre which results in the compounds having 
two isomeric forms, or enantiomers. Both phenprocoumon and warfarin 
exist in two isomeric forms namely the R (+) and S (-) forms, but the 
clinical formulations of the drugs are racemic. Due to their very wide- 
spread use, and because of the serious potentiation of -nticoagulant effect 
with the co-administration of certain common therapeutic agents, the 
metabolism and distribution of coumarin drugs have been intensively 
studied. 
The S(-) optical isomer of both phenprocoumon and warfarin Is a more 
potent anticoagulant than the R (+) enantiomer in man and the rat. There 
are also stereoselective pathways of metabolism and elimination for the 
warfarin Isomers In these two species and a stereospecific distribution of 
phenprocourr. on in man (a full list of references for these facts will be given 
In the discussion). 
We have studied the binding of the enanttomers of phenprocoumon and 
warfarin to bovine and human serum albumin using the equilibrium dialysis 
technique. In order to investigate the mechanisms of stereoselective 
binding, the interactions have also been studied using the techniques of 
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circular dlchroism and fluorescence. Attempts were also made to use 
nuclear magnetic resonance measurements to probe the coumarin-albumin 
complex and although the experiments were largely unsuccessful, data is 
presented which illustrates well the difficulties of examining drug-protein 
interactions using this technique. 
The binding of racemic phenprocoumon and Its enantiomers to hepatic 
cytochrome P450, as determined by substrate induced binding spectra, was 
also examined. Since the coumarin drugs are thought to be metabollsed 
largely by the mixed function oxidase system, it was hoped that any stereo- 
specificity in biotransformation would be reflected in the binding spectra. 
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6: 2 EXPERIMENTAL APPROACH 
The enantiomers of warfarin were kindly donated by Professor 
A. Breckenridge (University of Liverpool, England). Phenprocoumon (PPC) 
enantiomers used in the dialysis and circular dichrolsm measurements 
were gifts of Hoffmann - La Roche (Basle, Switzerland), whilst those used 
in the fluorescence, NMR and microsomal experiments were prepared by a 
modification of the method of West and Link (1965) as described In chapter 
2. Human and bovine serum albumins (crystalline, 100% electrophoretically 
pure) were obtained from Behringwerke (Marburg, Lahn, Germany) for all 
measurements except those involving NMR where BSA (Conn fraction V) was 
used from the Sigma Chemical Co. 
6: 2: 1 DIALYSIS 
The binding of PPC and warfarin (1 .5-6.0 x 10-5 M) to BSA and HSA 
(3 x 10-5 M) in phosphate buffer (67 mM, pH 7.4) at 25° C was measured 
using the half-cell equilibrium dialysis technique (see chapter 3). Drug 
concentrations were determined by the fluorimetric method of Seiler and 
Duckert (1968) as modified by jähnchen et at. (1976). The binding values 
are expressed as percentage bound at the concentrations used in the C. D. 
and fluorescence work. The PPC - HSA interaction was more thoroughly 
Investigated, and the data was analysed by the method of Scatchard (1949). 
Those data points which contribute to the tine equivalent to the high affinity 
binding were analysed by linear regression to obtain the y intercept which 
was taken as the total binding constant (TBC), n1K1 + n2K2. 
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6: 2: 2 CIRCULAR DICHROISM 
The CD measurements were made at 270 C in a Cary 61 spectropotarimeter 
using 10 mm cylindrical cells. Other conditions of measurement are 
detailed in chapter 2. The intrinsic spectra of the enantlomers (6 x 10-5 M) 
were recorded in phosphate buffer (67 mM, pH 7.4) and the spectra of the 
racemates and enantiomers were also determined In the presence of HSA or 
BSA (3 x 10-5 M). Results are expressed as molar elipd. cities 8 (deg. cm-2 . 
dmole-1) calculated with reference to albumin concentration, total drug 
concentration or bound drug concentration. ALL the results in the presence 
of albumin are reported as difference values using the oiipticity of albumin 
at the same wavelengths as a blank, except for those spectra in the lower 
halves of figures 6: 2 to 6: 5 which are 'double difference' spectra, I. e. , the 
Intrinsic eiipticities of both albumin and the isomers have been subtracted. 
6: 2: 3 FLUORESCENCE 
Fluorescence titration of racemic phenprocoumon and its isomers into 
buffer (sodium phosphate, 67 mM, pH 7.4) or albumin solution (1 x 10-5 M) 
was performed In the normal way, as described in chat:, -er 2. The competition 
of phenylbutazone for the binding sites of racemic, R (+) and S (-) 
phenprocoumon and warfarin was examined by the fluorescent probe displacement 
technique. 
ft 
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6: 2: 4 NUCLEAR MAGNETIC RESONANCE 
The NMR spectra of racemic warfarin and racemic phenprocoumon 
(0.2 M in NaOD/D20) were examined using a Varian XL 100 instrument 
by accumulation using the Fourier Transform (FT) facilities. The NMR 
spectra of phenprocoumon (1 x 10- 
3 
M) in the presence of BSA (Conn fraction 
V, 1% to 5% w/v in D20) was also obtained. The effect of protein upon the 
various resonances of phenprocoumon was estimated from the observed line 
I 
broadening sT the reciprocal transverse relaxation time, was taken . 
2 
as iQv when Av IS the observed line width at half peak height. 
6: 2: 5 BINDING SPECTRA 
Hepatic microsomaL suspensions were prepared from rat and hamster 
as outlined in chapter 2. Substrate Induced binding spectra were recorded 
using either the Perkin-Elmer 356 double-beam, double-wavelength spectro- 
photometer or the equivalent machine produced by the American Instrument 
Company. The spectral dissociation constants (Ks) were calculated from 
Lineweaver-Burk diagrams of titrations of phenprocoumon (250 mM in Dimethyl- 
formamide, DMF) into microsomal preparations, by the method of 
AL-Gailany (1975). 
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6: 3 FIGURES AND TABLES 
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Figure 6: 1 Scatchard plots of the interactions of HSA with phenprocournon 
and its enantiomers 
6 
r 
Df 
x 105 M-1 
4, 
2 
 R (+) Phenprocoumon 
S (-) Phenprocoumon 
ºR, S(t) Phenprocoumon 
l2365 
r 
Each point represents mean ± SEM (n =4 or 5). The values of the closed 
symbols were used in regression analyses to give the following equations: - 
S (-) PPC :-r= 723,935-388,667r (R = 0.88, n= 20), TBC = 7.24 x 105 m- 
1 
Df 
r R (+) PPC: D= 
403,392-174,012r (R = 0.84, n= 18), TBC = 4.03 x 105 M-1 
f 
RS (±) PPC :-D= 633,915-297,697r (R = 0.84, n= 19), TBC = 6.34 x 105 M-1 
f 
The total binding constant (TBC) = n1K1 + n2K2, or the y Intercept. 
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Figure 6: 2 Circular dichroism spectra of phenprocoumon and its 
isomers in buffer and in the presence of HSA 
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Lower half: PPC isomers and racemate (6 x 10~5 M) In HSA (3 x 10-5 M) 
solution. The effects of HSA have been subtracted in all cases, plus the 
intrinsic effects in the case of the isomers. The molar elipticity (e) is 
calculated with respect to HSA concentration. Each point Is the mean of 
five determinations. 
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F igure 6: 3 Circular d ichro lsm spectra of warfarin and its isomers 
in buffer and in the presence of BSA 
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Intrinsic effects in the case of the Isomers. Molar elipticity (6) Is calculated 
with respect to BSA concentration. Each point is the mean of five 
determ inat tons . 
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F igure 6: 4 Circular d ichro lsm spectra of phen procoumon and its isomers 
in buffer and in the presence of BSA 
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effects in the cases of the isomers. The molar elipticity (0) is calculated 
with respect to BSA concentration. Each point is the mean of five 
determinations. 
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Figure 6: 5 Circular dichroism spectra of warfarin and its isomers 
in buffer and in the presence of HSA 
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Figure 6: 6 The titration of phosphate buffer and HSA with phenprocoumon 
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Figure 6-7 Dixon plot of the displacement of phenprocoumon from 
HSA by phenylbutazone 
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Figure 6: 8 The variation of reciprocal transverse relaxation times 
of phenprocournon with albumin concentration 
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Figure 6: 9 The NMR spectrum of phen pro coumon 
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Figure 6: 10 The influence of BSA on the NMR spectrum of phenprocoumon 
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6: 4 RESULTS AND DISCUSSION 
The equilibrium dialysis studies of the binding of warfarin and 
phenprocoumon enantiomers to albumin yielded interesting, but confusing, 
results (table 6: 1). Previous studies of the binding of R (+) and S (-) 
warfarin to HSA have shown only very small differences between the two 
enantiomers. O'Reilly (1971,1973) reported the S (-) isomers to have a 
higher association constant than R (+) but no statistical iiformation was 
provided. In a more thorough study, Sellers and Koch-Weser (1975) showed 
a slightly greater binding of S (-) to HSA, compared to the R (+) enantlomer. 
Our results are fully compatible with these findings. We found a lower free S(-) 
concentration at both drug levels studied (1 .5x 10-5 M and 6.0 x 10-5 M, 
HSA concentration 3.0 x 10 
-5 M) , but there was not a statistically significant 
difference from the values of the R (+) isomer. That there is only a very 
slight difference between the binding of the two warfarin enantlomers to 
human albumin is confirmed by the observation that the apparent volume of 
distribution of the drugs, in man, are not significantly different (Hewick 
and McEwen, 1973). 
To our knowledge, the binding of the warfarin enantiomers to BSA has 
not previously been reported. Table 1 shows the rather surprising finding 
that R (+) warfarin Is bound more strongly that S (-) warfarin at both concen- 
trations studied. The difference was only significant, however, at the 
lower drug concentration of 1 .5x 10 
-5 M (BSA 3x 10-' 5 M) . It would be 
interesting to see if the volumes of distribution for the two isomers would 
be different when administered to cattle. Unfortunately, even the splendid 
work of Link and his associates at the Wisconsin AgrL'C! lItural Research Farm 
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(Campbell and Link, 1941; Link, 1943) did not include such an investigation. 
Again, it would be interesting to examine the binding of the Isomers to rat 
albumin, the rat being another species where the volumes of distribution of 
the two enantiomers of warfarin are not significantly different (Hewick, 1972; 
Breckenridge and Orme, 1972). 
In the course of this work, more attention has been focussed upon 
phenprocoumon, since it is less well studied, but nevertheless a much 
prescribed anticoagulant (especially on the continent) . In contrast to 
warfarin, the isomers of PPC were bound to HSA in a most disparate manner. 
Table 6: 1 shows that more S (-) isomer Is bound at al., the concentrations 
studied and the difference is highly significant at low drug concentrations. 
A Scatchard plot of the PPC - HSA interaction was used to calculate the 
total binding constants (TBC, equivalent to n1K1 + n2K2) for the three forms 
of PPG. The total binding constant for racemic PPC (4.03 x 105 M-1) agrees 
welt with that reported by O'Reilly (1971,1973) of 5.05 x 105 M-1 and by 
Foged et at. (1976) of 7.3 x 105 M-1 . The pharmacokinetics of the enan- 
tiomers of phenprocoumon in man have been studied by jähnchen et at. (1976) 
and Hewick and Shepherd (1976). Both studies Involved the administration 
of each form of the drugs to five subjects. jähnchen et at. , found the 
apparent volume of distribution of the S (-) PPC isomer to be smaller in all 
subjects, whilst Hewick and Shepherd reported the same finding for three 
subjects. Asmallervolume of distribution of S (-) PPC is consistent with 
the higher human albumin binding of this isomer. 
The BSA binding of the R (+) Isomer of PPC, like that of warfarin, Is 
more avid than that of the S (-) isomer. However, unlike warfarin, where 
the difference between R (+) and S (-) is far greater for i3SA than HSA, the 
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difference between R (+) PPC and S (-) PPC is significantly !ss for BSA than 
for HSA . 
To summarise the binding data: at low drug concentrations (1 .5x 10- 
5 M), 
HSA binds the S (-) enantiomers more avidly than the R (+) enantiomers. 
The difference is very marked in the case of PPC, but not significant for 
the warfarin isomers . In contrast, BSA binds the R 
(+) enantlomers to a 
greater extent than the S (-), and the difference is more marked for warfarin 
than for PPC . At this drug concentration HSA 
binds a greater amount of 
drug than BSA. At higher drug concentrations (6 x 10- 
5) 
there is apparently 
no stereospecific binding in any of the complexes. Also, BSA binds more 
drug than does HSA. It seems, then, that only the high affinity sites of 
albumin bind the coumarin drugs stereos pecif ica i Ly . 
Stercospecific binding by albumin has been reported . ü. only a few small 
molecules. The enantiomers of tryptophan (McMenamy and Oncley, 1958); 
noradrenaline (Powis, 1975); Oxazepam Hemisuccinate (Müller and Wotlert, 
1975) and two dansyl amino acids (Koga et at., 1975) have differing affinities 
for serum albumin, but little is known of the mechanisms of stereospecific 
albumin binding . 
Circular dlchroism measurements have proved useful in studies of optical 
Isomer binding to albumin (Perrin, 1973; Müller and Wollert, 1975) because 
of the unique sensitivity of the technique to molecular geometry. The CD 
spectra of PPC and warfarin racemate and isomer complexes with HSA and 
BSA are shown in figures 6: 2 to 6: 5. Tables 6: 2 and 6: 3 show the molar 
elipticities and anisotropy factors of the same complexes at the wavelengths 
310 nm, 290 nm and 270 nm. These measurements wc! ro aIL made from spectre 
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recorded at drug concentrations of 6x 10_ 
5M (albumin 3x 10_ 5 M), 
qualitatively identical spectra were obtained at a concentration of 3x 10-5 M. 
The higher concentration was used because the greater intensity of the effects 
allowed more accurate measurements to be made. 
The intrinsic CD spectra of the R (+) and S (-) isomers of both coumarins 
were of equal magnitude, but opposite sign (see tables 6: 2 and 6: 3 and 
figures 6: 2 and 6: 3) which is confirmation of the optical purity of the 
enantiomers. The spectra of PPC and warfarin isomers were qualitatively 
similar, showing main CD maxima at about 310 nm, 290 nm and 240 nm 
with less well defined maxima at 268 nm and 262 nm . The racernlc compounds 
showed no optical activity in the presence of phosphate buffer alone. 
New cotton effects were produced with the albumin binding of all the 
enantiomers. It is worth repeating the logic which leads to the conclusion 
that these new effects must be extrinsic or induced. An alteration in the 
intrinsic spectra of albumin with binding Is unlikely to be the source since 
large changes in protein conformation, tantamount to denaturation, are required 
to produce such significant changes in the CD spectra. In addition, the new 
CD maxima fall at the same wavelengths asthe intrinsic spectra of the 
enantiomers. A change in the perturbations of the druq: 1 onantlomers by its 
own asymmetric carbon atom can be excluded since the symmetrical 4-hydroxy- 
coumarin exhibits similar, new Cotton effects when bound to albumin (see 
figure 5: 8). Changed Cotton effects can arise from binding Induced changes 
in molar extinction coefficients. However, the anisotropy values (which 
are calculated, taking into account absorption changes) differ in the same 
way as the molar elipticities when In buffer and in albumin solution (see 
tables 6: 2 and 6: 3). The only remaining explanation is that the n(3w Cotton 
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effects are due to perturbations of the electronic transitions of the drugs 
bound, by an asymmetric locus of the protein. It was shown in the previous 
chapter that the Induced elipticity in the wavelength regions 310 nm and 
370 nm are due to transitions in the main coumarin ring, whilst those around 
290 nm were shown to originate in transitions of the 4-hydroxyl moiety of the 
compounds. 
Figures 6: 2 to 6: 5 show a gradation in the similarities between the 
Induced spectra of the R (+) and S (-) enantlomers. For PPC bound to HSA 
(figure 6: 2) the induced spectra are of the same sign, shape and at the same 
wavelength positions for each form of the drug. The same can be said of the 
spectra for the various forms of warfarin when bound to BSA (figure 6: 3), 
except the very small negative effects around 290 nm and 270 nm for the R (+) 
enantiomer, at which wavelengths the racemic and S (-) forms have positive 
minima. The induced spectra of the PPC - BSA complexes (figure 6: 4) are, 
again, of similar shape and wavelength position, but in this case, the signs 
of the induced elipticities between 260 and 300 nm are positive for the S (-) 
isomer and negative for the R (+) Isomer (above 300 nm the signs of the 
induced spectra are the same). Finally the Interaction of S (-) warfarin 
and R (+) warfarin with HSA produced very different spectra. To a large 
extent, wavelength positions of peaks and troughs do not coincide, and 
the signs of the spectra are disimilar for much of the wavelength region under 
study. There is only one real similarity between the two spectra, at 270 nm 
where there is a negative peak for each enantiomer. Within experimental 
error (the standard errors are not shown so as not to further complicate the 
diagrams) the induced spectra of the racemates fall between the two Isomers 
in all four cases, as would be expected. 
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This gradation in the spectral relationship between R (+) and S (-) 
enantiomners can be explained by referring to the binding parameters as 
shown in table 6: 1. The largest difference between any of the enantiomers 
is that shown by the PPC - HSA interaction (5.92 ± 0.44% free for S (-), 
9.34 + 0.2 1% for R (+) at 1 .5x 10-5 M drug and 3 .0x 10-5 M HSA). This 
is the interaction which gave the greatest similarities between the induced 
CD spectra of the two enantiomers. At the other end of tht scale, there 
are no significant differences between the percentage bi tiling of the enantiome, rs 
of warfarin with HSA. The CD spectra for these interact! of-s show the 
greatest divergence of all those recorded. The other two sets of data also 
fit weis with this inverse relationship, the CD spectra cff the warfarin enan- 
tiomers bound to BSA are very similar and these interactions show highly 
significant differences in binding. Finally, the PPC - BSA interaction shows 
a small degree of stereospecific binding but n'onounce<: d , d. ifferencer in the 
signs of the induced CD spectra of the enantiomers. 
In chapter 5. it was shown that the induced CD effects in the wavelength 
region 350 - 270 nm are due to perturbations of the 4-hydroxy coumarin ring 
system. Since the induced spectra of the PPC enantiomers bound to HSA are 
very similar, it must be concluded that the orientation of the 4-hydroxycoumarin 
ring is identical In both complexes. If this Is so, the orientation of the 
other substituents at the asymmetric carbon atom (i. e. the phenyl and ethyl 
groups and the single hydrogen) must be different. These substituents 
specifically contribute to the binding mechanism and the binding energy 
(see previous chapter and also O'Reilly, 1971; Chignell, 1970 and Garten 
and Wasilalt, 1971) probably by hydrophobic Interactions with the protein. 
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The arrangement of S (-) side chains with the binding site must allow 
more bonds to be formed, since this isomer exhibits the stronger binding. 
To continue this argument, the enantiomers of warfarin, when bound to HSA.. 
are perturbed to give different CD spectra. This suggests that the 
orientation of the 4-hydroxycoumarin ring cannot be the same for the S (-)- 
HSA complex and the R (+) -HSA complex. If the orientation of the main 
ring is dissimilar, then the side groups may be able to interact With the 
protein in the same manner, for each isomer. This explain why 
there are only very small differences in the binding par-:; ieters for the 
warfarin isomers with HSA. The PPC - BSA and warfarin - BSA complexes 
show intermediate behaviour in both CD spectra and bla(ling parameters 
which presumably reflects the partially different orient itions of side chains 
and coumarin nuclei In these complexes. 
In order to gain further insight into the mechanisms of coumarin isomer 
binding to albumin, the techniques of nuclear magnetic: resonance and 
fluorescence were used. It was hoped that NMR measurements would 
show the relative contributions of the various portions of the coumarin 
molecule to the overall binding process. This approach has been used to 
study the albumin binding of sulphonamides (jardetsky and Wade-jardetsky, 
1965), penicillin (Fisher and jardetsky, 1965) acetyisaLicylic acid (Sykes 
and Hull, 1973) and acetrizoate (Rodrigues de Miranda and Hil bers, 1976). 
Initial experiments were performed using racem is PPC and warfarin at high (0.2 M) 
concentrations, in order to record the basic NMR spectra of the compounds. 
Good results were obtained for PPC (see figure 6: 6), but not for warfarin. 
This was because the compounds were dissolved in a D20 solution of NaOD 
at a high pH (pD) in order to obtain the required concentration. Under these 
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conditions, the protons of the warfarin aliphatic side chain exchange 
freely with deuterium, due to the tautomerism of the ketone functional 
group, with the resulting loss of side chain resonances. Because of this 
reaction, no further NMR measurements were made with warfarin. 
Exploratory experiments with racemic PPC in D2O/NaOD showed that 
the minimum concentration of drug which gave a satisfactory NMR spectra 
was 2x 10-3 M. Since we wished to study the binding of the drug to the 
high affinity sites, a protein concentration of at least 2x 10^3 M (N14°ß w/v 
albumin) would be required. Figure 6: 7 shows the effects of up to 4% albumin 
(BSA in this case, for economic reasons. The NMR spectra of BSA and HSA 
are very similar) on the NMR spectra of 2x 10-3 M racemic PPC. It is 
obvious from these results that it would be impossible to study the binding 
at drug - albumin ratios of about 1: 1 since the spectrum of the protein would 
mask the drug resonances. This is a major drawback of the NMR technique 
for the study of small molecule-albumin interactions. In all the previous 
reports, small molecule has been present in about a 100 fold excess over 
protein. Under these conditions, any Information obtained will probably 
reflect secondary or 'non-specific' binding which makes up the bulk of 
binding complexes a high ligand concentration. Figure 6: 8 shows how the 
reciprocal transverse (spin-spin) relaxation time T2- 
1 
of the methyl and 
aromatic protons of racemic PPC varied with protein concentration over the 
range 0- 4% BSA. Both peaks were broadened at about the same rate, which 
suggests that the side chain as well as the main aromatic rings are involved 
with binding. Otherwise, little information can be derived from the NMR 
measurements. Because of the practical difficulties which arose, the NMR 
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measurements were discontinued. This short study does, however, 
illustrate that nuclear magnetic resonance techniques may be of little value 
if information is required on mixtures where the ligand and macromolecule 
concentrations are of the same order of magnitude. The technique may 
provide useful information on secondary binding, or primary binding where 
the association constant Is small, when excess ligand can be used. 
Phenprocoumon and warfarin are both fluorescent probes for the coumarin 
binding sites (see chapter 3). The interaction between the enantiomers of 
PPC and HSA was studied using the fluorescence measurements. Attention 
was focussed on this particular interaction since the isomers have been. 
shown to bind to different degrees, but CD measurements did not show any 
great dissimilarities. The racemic, S (-) and R (+) forms of PPC have 
Identical fluorescence intensities in buffer (see figure 6: 9) and identical 
excitation and emission maxima of 317 nm and 385 nm respectively. The 
fluorescence enhancement with binding to HSA was also the same for each 
form of PPC, within the limits of experimental error (figure 6: 9). The 
excitation and emission maxima were shifted to 325 nm and 380 nm respectively. 
(The blue shift in emission wavelength was explained in chapter 3, the red 
shift In excitation maximum is equivalent to a similar shift in absorption 
maximum, which was discussed in chapter 5). It is, perhaps, not surprising 
that there was no difference in the fluorescence enhancement of the isomers, 
since the coumarin rings of the two molecules are thought to lie In the 
same orientation. The fluorescence of PPC is probably due largely to 
transitions in the main coumarin ring and, thus, stereospecific fluorescence 
of PPC - HSA would not be expected. Following the same argument, the 
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enantiomers of warfarin might be expected to show different fluorescence 
properties when bound to HSA. Wilson (1974) studied the fluorescence of 
warfarin and its isomers when bound to albumin, but did riot find any 
significant differences between the various forms of the drug. It seems, 
then, that whilst the coumarin rings of S (-) and R (+) warfarin may be 
differently orientated with respect to the asymmetric locus of the protein, 
they are nevertheless in areas of similar hydrophobicity. 
The competition of phenylbutazone and warfarin for albumin binding 
sites is well known (Solomon and Schrogie, 1967). It has been shown that 
the fluorescent probe properties of warfarin can be used to monitor this 
competition (Wilson, 1974). Initial suggestions that the potentiation of 
the anticoagulant effect of warfarin, in man, with concomitant phenylbutazone 
administration could be due to displacement of the coumarin from albumin 
binding sites (Aggeler et at. , 1967) have been modified, because of recent 
pharmacokinetic data. The plasma clearance of S (-) warfarin is slowed by 
phenylbutazone administration, whilst the clearance of the R (+) isomer is 
increased (Lewis et at., 1974; Schary et al ., 1975). It was concluded 
that inhibition of the metabolism of the more potent S (-) isomer is responsible 
for the potentiation effect of phenylbutazone. (The different potencies and 
routes of metabolism of PPC and warfarin Isomers will be discussed further). 
The competition of phenylbutazone and PPC for HSA binding sites was 
examined using the fluorescent probe displacement technique. The results 
are expressed in the form of a Dixon plot in figure 6: 10. The displacement 
appears to be biphasic, the two portions being equivalent to phenylbutazone 
concentrations of 0- 25 x 10 
-6 M and 25 - 150 x 10- 
6M (PPC and HSA 
concentrations were 10 x 10 M). The initial displacement, at low 
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phenylbutazone concentrations, accounts for much of the reduction in 
fluorescence. This is probably due to competition between phenylbutazone 
and PPC for primary binding sites. The reduction in fluorescence at higher 
phenylbutazone concentrations is probably a reflection of competition for 
secondary binding sites. Using low concentrations of phenylbutazone, 
Wilson (1974) showed a competitive inhibition of racemic warfarin binding 
to HSA. It seems, then, that phenylbutazone and the coumarlns not only 
share high affinity binding sites, but also some secondary binding is also 
to communal sites on HSA. There was no difference between R (+) and S (-) 
PPC in the degree of displacement by phenylbutazone. Whether the difference 
between racemic PPC and the Isomers, as shown in figure 6: 10, Is an 
authentic disparity or merely experimental variation remains to be proven 
by further Investigation . 
Our studies of the enantiomers of warfarin and phenprocoumon were 
extended by an examination of the substrate induced binding spectra which 
were produced on the addition of the compounds to rat or hamster hepatic 
microsomes. Warfarin and phenprocoumon are hydroxyLated by the microsomal 
mixed function oxidase system and, In addition, warfarin undergoes side 
chain reduction of the ketonic function by a soluble enzyme system. The 
stereospecific metabolism of warfarin is thought to explain many of the 
pharrnacodynamic differences between the isomers. In man, S (-) warfarin 
is eliminated more rapidly than R (+) (Hewick and McEwen, 1973; Breckenridge 
et at. , 1974). The principal metabolic product of 
S (-) warfarin, Ili man, 
is 7 hydroxywarfarin, with minor quantities of S, S warfarin alcohol, and 
6 hydroxywarfarin. The R (+) Isomer is metabolised mainly to the R, S warfarin 
alcohol, with the remainder as 6 hydroxywarfarin (Lewis et at., 1.974). 
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In the rat, however, R (+) warfarin is eliminated more quickly than S (-) 
(Breckenridge and Orme, 1972; Hewick, 1972). In vitro experiments 
using rat hepatic tissues have shown 7 and 8 hydroxylation to be stereo- 
selective for R (+) warfarin, this isomer was also metabollsed more rapidly 
than S (-) warfarin. In contrast 4'hydroxylatlon was stereoselective for 
the S (-) enantiomer. Reduction of the side chain ketonic function was 
stereoselective for R (+) warfarin and reduction was to the S alcohol (Pohl 
et al. , 1976). These stereospecific pathways of 
drug metabolism are 
reflected in the substrate induced binding spectra of the warfarin enantiomers. 
Previous work in our laboratories has shown that both R (+) and S (-) 
warfarin elicit a reverse type one (R1) binding spectra with rat hepatic 
microsomes but the spectral dissociation constants (KS) were very dissimilar 
at 45.0 x 10-5 M and 16.0 x 10-5 M respectively (Wilson, 1974; see 
table 6: 4). P, xperiments were also performed using hd. ý ; ter hepatic 
microsomes, where there was an even more marked stercospecificity, the 
R (+) isomer eliciting a type 1 spectra and the S (-) a reverse type 1. There 
is, however, no available data concerning the metabolism of warfarin 
enantlomers in this species. 
The available information on phenprocoumon metabolism and elimination 
is far less complete than that for warfarin. The plasma clearance of S (-) 
PPC in man is slightly less than that of R (+) PPC (jahnchen et at., 1976; 
Hewick and Shepherd, 1976) but there is no significant difference in the 
rate of elimination. It has already been suggested that the difference in 
the plasma clearance of the PPC isomers may be due to their protein binding 
characteristics, rather than stereospeclfic metabolism, but there is no 
metabolic evidence to support this theory. In a short study of the urinary 
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excretion of PPC isomers in the rat, Golding and West (1969) found R (+) 
PPC to be eliminated faster than S (-) PPC (as is the case for warfarin in 
the rat) . The 
difference was not large, however, and the recent findings 
that PPC related material is excreted mainly in the faeces (Haddock et al ., 
1975) also casts some doubt upon the significance of the data of Golding 
and West (1969). 
We have investigated the substrate induced binding spectra of rarem is , 
R (+) and S (-) phenprocoumon in order that some tentative prediction of the 
presence of stereospecific microsomal metabolism may be made. At present, 
there is no information available on the metabolism of PP(; isomers, but 
racernic PPC has been studied (Haddock et at., 1975) 
(obviously one of the 
stereoselective reactions of warfarin, the ketonic reduction, cannot take 
place with PPC). Racemic PPC is hydroxylated in the same positions as 
racemic warfarin, but the relative amounts of the hydroxylated metabolites 
are very different. Whilst warfarin is excreted from the rat mainly as 7- 
hydroxywarfarin (Link et al., 1965), the major fecal and urinary metabolites 
of PPC are the 6 and 4' hydroxy derivatives. The addition of each of the 
forms of phen procoumon to rat or hamster hepatic m icro some s elicited 
reverse type one (R1) spectra changes in all cases 
(table 6: 4). From 
Lineweaver-Burk diagrams of the titration of rat microsomes (2 mg. ml-1 
protein) with phenprocoumon 
(5 x 10- 
5M 
to 4x 10- 
4 
M) spectral dissociation 
constants (Ks) were calculated. The Ks values were very similar for each 
of the three forms of phenprocoumon 
(table 6: 4). Since i-lie isomers elicit 
the same type of spectral change, and have similar dissociation constants, 
it seems that they interact with the mixed function oxidase system In similar 
fashions. This suggests that the enantiomers of phenProcoumon may not 
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be stereo selectively hydröxylated. The evidence is by no means conclusive, 
but the conclusion fits well with the known pharmacokinetic parameters of 
the individual isomers. 
It has been suggested that the binding of coumarins to serum albumin 
could be used as a model for the interaction of the drugs with their receptor 
sites (O'ReIE[y, 1969,1971,1973). However, some of the Inadequacies 
of this model have been Illustrated by the binding and activities of the 
isomers of warfarin. The S (-) warfarin isomer is about five times more 
potent than the R (+) isomer, both in man (O'Reilly, 1971,1974) and in 
the rat (Eble et at., 1966; Br--ckenridge and Orme, 1972). This difference 
is not just a function of the metabolism or the distribution of the isomers, 
but the intrinsic anticoagulant activity of the S (-) isomer has been shown 
to be at least double that of R (+) (Nagashima et al ., 1969; Breckenridge 
and Orme, 1972). However, as has been shown in this and previous work 
(table 6: 1; O'Reilly, 1971; Sellers and Koch Wesser, 1975) the enantiomers 
differ only slightly in their binding to human albumin. It seems, then, that 
HSA is not a good model for receptor binding. On the other hand, it is 
possible that the nature of the album in-coumarin interaction should be 
considered, not the magnitude of the complex. We have shown that the 
main coumarin rings of S (-) and R (+) warfarin are in different orientation 
when bound to albumin. It may be that the orientation of the coumarin 
rings at the receptor sites accounts for the difference in potency of the 
two enantiomers. 
In the case of phenprocoumon, the coumarin rings of the two enantiomers 
are thought, by us, to be bound to HSA in similar orientations. Whilst the 
S (-) isomer is more potent in man, (Hewick and Shepherd, 1976) it 
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has been suggested that this is due to differences in distribution between 
the two isomers (Jähnchen et at., 1976). In addition, when considering 
albumin binding as a receptor model, it is apparent that the protein binding 
data must be generated from the same species as that in which anticoagulant 
activity is measured. Thus, we have shown that bovine and human albumins 
interact very differently with the isomers of both phenprocoumon and warfarin. 
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CHAPTER SEVEN 
FINAL DISCUSSION: THE NATURE OF LIGAND-ALBU M' N COMPLEXES 
-287- 
The binding sites of albumin have been the subject of considerable 
research and discussion, but only recently has significant progress been 
made towards understanding the topography of the protein. Recent 
elucidation of the amino acid sequences of bovine and human albumins 
(Brown, 1975; Behrens et at. , 1975) has given substance to previously 
nebulous concepts of the nature of albumin binding sites. The proposed model 
of albumin (Brown, 1975) includes many loops which, when associated in the 
native protein, give rise to several clefts in the molecule. Indeed, if anion 
binding sites are regions of apolar character with adjacent areas of positively 
charged residues (Swaney and Klotz, 1970), then the structure of albumin is 
ideally suited for the binding of organic acids. Several binding areas have 
been isolated, for various compounds, and these have been discussed in 
chapter 1 and are illustrated in figure 1: 6. Note that alt the specific binding 
areas are concerned with ionic molecules or compounds with polar regions. 
Our studies with the coumarin drugs, particularly warfarin, have indicated 
that there is a high affinity binding site, located near the available tryptophan 
of albumin, which is not a primary site for the fatty acids. There appear to 
be two types of high affinity sites, for short and medium chain fatty acids, 
which are not primary binding areas for warfarin. 
It seems, then, that there are several areas of the albumin molecule which 
provide high affinity interactions with organic acids. We have demonstrated 
the existence of three such areas, but there are probably several more. 
Thorp (1972) has suggested that there are three separate primary binding areas 
on human albumin, and proposed that these areas may change conformation to 
suit the ligand present. Sudlow and Colleagues (1975) have shown two 
distinct drug binding sites on albumin, one of which binds warfarin, phenyl- 
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butazone, iophenoxic acid, DNSA and some sulphonamides. The other is 
specific for fiufenamic acid, CPIB, ethacrynic acid and ANS. We have also 
shown displacement of warfarin and phenprocoumon by phenylbutazone, thus 
the coumarin site which we have studied is probably equivalent to one of the 
sites of Sudlow et al . (1975) . 
Whilst these binding sites are specific, they are not exclusive. Primary 
sites for one type of compound can interact with a second compound, if the 
second compound is present in excess and has saturated its own high affinity 
sites. We have shown that the primary site for warfarin can serve as a 
secondary site for fatty acids and vice versa. The prim iry short chain FA 
and medium chain FA sites can each act as secondary sites for the other 
category of fatty acid. 
We have not studied the binding of basic compounds to albumin and there 
is little information available. It is likely that there-: 1-1re specific areas of 
albumin which provide high affinity interactions with b, ýs; ic compounds, but 
probably far fewer in number than the anion binding sites. Kriegistein et al. 
(1972) have reported that the basic phenothiazines bind to a single site on 
albumin. 
In addition to these specific sites, which are involved in the binding of 
charged molecules, albumin appears to possess areas of lipophilic character 
which are able to interact with many organic small molecules. There are 
probably many of these sites, perhaps partially overlapping, with a wide range 
of affinities depending upon the ligand involved. They provide both secondary 
sites for the binding of charged l igands , when in excess of primary site 
concentration, and are also involved in the interactions with uncharged ligands 
The binding parameters of neutral molecules to albumin are characterised by 
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a greater number of 'primary' sites but lower association constants than 
equivalent values for ionic compounds (Steinhardt and Reynolds, 1969). The 
carbamates are typical of neutral ligands for albumin. CL1rbamat es have 4 to 9 
primary sites with associations constants of about 103 M-1 (Wilson, 1974). 
From displacement experiments, it was shown that carbamates and fatty acids 
do not share any primary sites. In addition, carbamatn binding was only 
affected by fatty acid when concentrations were such that FA was bound to 
secondary sites (table 4: 9). 
The nature of a ligand-albumin complex is not only dependent upon the 
type of binding site but also the properties of the ligarid and the types of 
bond which can be formed between the two species. These three determinants 
of binding are intimately related since the structure of ligand determines the 
sites to which it will preferentially bind and the bonds formed depend upon 
both Ligand anu site. The thermodynamic parameters of fatty acids binding 
to BSA (table 4: 5) suggest that their primary binding is a combination of 
electrostatic and hydrophobic interactions. The electrostatic binding is 
roughly constant for all the fatty acids, but hydrophobic interactions, indicated 
by a positive entropy change, become Larger with increasing chain length. 
Secondary binding Is accompanied by positive enthalpy and entropy changes, 
which is typical of hydrophobic bonding. Secondary binding appears to be 
primarily a function of the Lipophilicity of the Ligand, the secondary binding 
of the fatty acids increased linearly with chain length or partition coefficient. 
The interaction of warfarin and HSA is accompanied by negative tH and 
positive AS values (O'Reilly, 1973) which have been interpreted as indicating 
the presence of hydrogen bonding and hydrophobi. c bonding. The importanco 
of hydrophobic bonding in the coumarin-atburnin compic< is shown by our 
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spectral and equilibrium dialysis studies. The lipophilicities of the four 
compounds, as determined by octanol/water partition, correlated well with 
the percentage of drug bound. There was Little influence of pH on the 
extrinsic CD spectra of the coumarins when bound, which suggests that 
electrostatic interactions do not play a major role in bonding. The binding 
of the coumarins to albumin produced changes in the UV absorption and 
fluorescence of the compounds which indicate that the binding sites are 
hydrophobic in nature. 
CD studies of the coumarin derivatives showed that the various compounds 
take up different orientations when bound to albumin. The lipophilicity of the 
side chains is thought to influence the arrangement of the molecule with 
respect to the asymmetric centre of the binding site. The spatial relationship 
between ligand and binding site can be most important, as has been shown in 
our studies on the enantiomers of ph-nprocouinon and wa. [nrin. The isomers 
of these compounds bind differently to albumin, due to different orientations 
at the same binding site. Furthermore, the human and bovine albumins 
differ in their stereospecificity for the isomers. This point illustrates the 
fact that albumins from various species might be generally very similar In 
structure and binding properties, but they can exhibit quite disparate binding 
parameters in certain cases. This should be remembered if the interaction 
with albumin is to be used as a model for other binding reactions, for instance, 
drug-receptor interactions. 
This discussion on albumin binding sites has been performed with the 
supposition that the sites are pre-existing on the molecule. This is the 
approach which was adopted by Scatchard (1949) in his mathematical model 
for ligand binding. All workers who use the Scatchard plot are, perhaps 
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unknowingly, concurring with this theory and the assumptions which are 
implicit in this treatment of data. The assumptions that there is no interaction 
between binding sites, that binding sites are not created or destroyed and 
that the affinities within a class of sites are identical may not be absolutely 
correct, but the Scatchard analysis yields parameters which are readily 
understandable and easy to manipulate. There is the alternative approach 
of Karush (1950) which proposes that the albumin molecule has a high degree 
of confon-natIona! adaptability and that binding sites ar> created and moulded 
to suit the tip acd present. The mathematical anaLys1s -, vhich is commensurate 
with this theory is that of multiple step-wise equilibria proposed by Klotz 
et aI. (1946) and recently championed by Fletcher and iris colleagues (Fletcher 
et at ., 1970,1973). 
This model makes no assumptions of pre-existing sites 
or independence between sites and is probably superior to the Scatchard (1949) 
model since it can be applied to any binding situation . However, the solution 
of the model requires computer analysis and the parameters are often unwieldy, 
being a group of 8 or 10 association constants. 
Alt the binding equilibria studied in this project have been analysied 
using the Sc3tcha d model and, although there are limitations, the data is 
fully cornpatable with this approach. For the binding of ligands to primary 
sites we have found no evidence for distinct conformational changes. Primary 
fatty acid binding had no effect upon albumin fluorescence, although very 
high fatty acid concentrations did quench albumin, probably because of 
confo: rndtiif"al changes. The interaction of albumin with the coumarins 
pro, lu, 7.., c? only very small changes in the UV absorption spectra of the protein 
and no ch: i, nges in CD effects. Since the majority of ligand 
binde ;g to ý31ýý^ý1, ý :n vivo is to primary sites, because of the low small 
rolecui:. ýo ý ýýntrations, it seems unlikely that conform: jtional changes play 
-292- 
a major role in normal binding to albumin. 
The displacement of one [igand by another has also been considered, by 
a number of authors, to be the result of conformational changes when the 
two ligands do not share the same high affinity sites. For example, it has 
been suggested that fatty acids affect the binding of warfarin by alterations 
of the conformation of the drug binding sites (Chakrabati et al. , 1976). 
However their studies, and many other similar investigations, were carried 
out with high ligand concentrations relative to albumin. Under these 
circumstances competition for common secondary sites can result in displacement 
even though the two ligands do not share the same primary sites. We have 
shown that most bound compounds can be shown to be displaced if the correct 
concentrations of protein and competitor are chosen. 
Our investigations with the coumarins and fatty acids have shown the 
usefulness of studying a series of closely related ligands in order to 
understand the mechanisms of binding to albumin. Further studies, using 
other groups of compounds should extend our knowledge of the binding sites 
of albumin. The study of more series of acidic compounds should lead to 
an estimate of the total number of anion binding sites and a better understanding 
of their specificity, whilst work with series of basic compounds would yield 
valuable information in this little studied area. 
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REFERENCES 
Aggeler, P. M., O'Reilly, R. A. , Leong, L. and Kowitz, p. F. 
1967,276,496. 
Agren, A. Acta Pharm. Suec., 1968,5,37. 
N. Engt. 1. Ivied ., 
Ahtee, L., Boullin, D. J., Saarnivaara, L. and Paasonen, M. K. In The 
Phenothiazines and structurally related drugs (Forrest, I. S. , Carr, C. J. 
and Usdin, E. eds. ) 1974, pp. 379-388, Raven Press, New York. 
Ahtee, L., Mattila, M. J. and Vapaatalo, H. I. Biochem. i'harmacol., 1967, 
16,2432. 
Alsen, P., Lcibman, A., Harris, D. C. and Moss, T. l; ocher., 1975,14,2()2, 
Alfsen, A. Compt. Rend. Trav. Lab. Carlsberg, 1963,33 (11), 415. 
Al-Gailany, K. A. S. Ph. D. Thesis, 1975, University o Surrey. 
Am icon Publication No. ß426- 1974, Am icon Ltd., High ', ycombe , Bucks. 
Anai, M., Haraguchi, H. and Takagi, Y. J. Biol. Cherm., 1972,247,193. 
Anderson, S. R. and Weber, G. Biochem., 1969, _8,371.. 
Andersson, L. -O. Biochim. Biophys. Acta, 1966, . 
117,155. 
Andersson, L. -O., Rehnstrom, A. and Eaker, D. L. Eur. J. Biochem., 1971, 
20,371 . 
Anker, H. S. In The Plasma Proteins, 1960, ist Edn., 2, (Putnam, F. W. ed. ) 
pp. 267-307, Academic Press, New York. 
Anton, A. H. and Corey, W. T. Acta Pharmacol., 1971,29, Suppl. 3,134. 
Anton, A. H. and Solomon, H. M. (Ed. ) Ann. N. Y. Acad., c; ci., 1973,226,1. 
Anton, A. H. and Boyle, J. J. Can. J. Physiol. Pharmacol., 1964,42,809. 
Arita, T., Hori, R., Takada, M. and Misawa, A. Chem. Pharrn. Bull., 1971, 
19,937. 
Ashbrook, J. D., Spector, A. A. and Fletcher, J. E. J. BLol. Chem., 1972,247, 
703 8. 
Ashbrook, J. D. , Spector, A. A., Santos, E. C. and Fletcher, J. E. J. Biol. Chem. 
1975,250,2333. 
Attalah, N. A. and Lata, G. F. Biochim . Biophys. Acta ., 1968,168,321. 
-294- 
Barbati-Brodano, G. , Derenzini, 
M. and Fiume, L. Nature, 1974,248,63 . 
Barnett, D. B. and Hancock, B. W. Brit. Med. J., 1975,1,608. 
Baxter, J. H. Arch. Biochem. Blophys., 1964,108,375. 
Beaven, G. H. and Holiday, E. R. Advan. Protein Chem., 1952,7,319. 
Becker, R. S. In Theory and interpretation of fluorescence and phosphorescence, 
1969, Wiley-Interscience, New York. 
Behrens, P. Q., Spiekerman, A. M. and Brown, J. R. Fed. Proc., 1975,34,591. 
Bennhold, H. In Die Eiweisskorper des Blutplasmas (i3ennho[d, H., Kylin, E. , 
and Rusznyak, S. Eds. ) 1938, Steinkopf, Leipzig. 
Bennhold, H. In Transport Function of Plasma Proteins, (Desgrez, P. and 
De Traverse, P. M. , Eds. 
) 1966, pp 1-12, Elsevier, Amsterdam. 
Berson, S. A. and Yalow, R. S. J. CLLn. Invest., 1959,38,1996. 
Bickel, M. H. and Steele, J. W. Chem. Biol. Inter., 1974,8,151. 
Black, M. and Arias, I. M. In Handbook of Fxpcrimental Pharmacology, 28, 
(Gillette, J. R. and Mitchell, J. R., Eds. ) 197':: pp. 258-271, Springer- 
Verlag, Berlin. 
Blake, C. C. P., Geisow, M. J., S. van, I. D., Rerat, C. and Berat, B. 
J. Mol. Biol., 1974,88,1. 
Blanchard, J., Tozer, T. N., Sorby, D. L. and Tuck, L. D. J. Pharm. Scl ., 
1973,62,1545. 
Blanchard, J., Tozer, TN., Sorby, D. L. and Dick, L, D. Mot . Pharmacol. , 
1975,11,133. 
Blaschke, T. F., Meffin, R. J., Melmon, K. L. and Rowý: -1-rnd, M. CL1n. 
Pharmaco1. Thera p., 1975,17,685. 
Blatt, W. F., Feinburg, M. A., Hopfenburg, H. und Su-ravis, C. A. 
Scl., 1965,105,224. 
Blatt, W. F., Hudson, B. G., Robinson, S. M. and Zipiiivan, E. M. 
Nature, 1967,216,511. 
Blatt, W. F., Robinson, S. M. and B1xler, H. J. Anal. Biochem., 1968,26,151. 
Bloom, B., Chaikoff, I. L. and Reinhardt, W. O. Amer. J. Physiol., 1951,166, 
451. 
Bloomfield, V. Biochem., 1966,5,684. 
-295- 
Bochner, F., Hooper, W. D. and Sutherland, J. M. Arch. Neurol. , 1974,31,57. 
Booker, H. E. and Darcey, B. Epilepsia, 1973,14,177. 
Bottari, F., DiColo, G., Nannipieri, E., Saettone, M. F. and Serafini, M. F. 
J. Pharm. Sci., 1975,64,946. 
Boyer, P. D., Ballou, G. A., and Luck, L. M. J. Biol. Chem., 1946,162,199. 
Bradshaw, R. A., Shearer, W. T. and Gurd, F. R. N. J. Biol. Chem., 1968,243, 
3817. 
Brand, J. G. and Toribara, T. Y. Mol. Pharmacol., 1972,8,751. 
Brand, L. and Gohlke, J. R. Ann. Re: -. Biochem., 1972,41,843. 
Brand, L., Gohlke, J. R. and Rao, D. S. Bioehern., 1967,6,3510. 
Brauer, R. W. J. Amer. Med. Ass., 1959,169,1462. 
Bratton, A. C. and viarshall, E. K. J. Biol. Chem., 19391,128,537. 
Breckenridge, A. and Or-, ie, M. L. Ann. N. Y. Acad. Sci., 1971,179,421. 
Breckenridge, A. and Orme, M. L. In Biological effects of drugs in relation 
to their plasma concentrations (eds. Davies, D. S. and Pritchard, B. N. C. ) 
1972, MacMillan, London. 
Breckenridge, A. and Orme M. L. Life Sci., 1972,11,, 337. 
Breckenridge, A., Orme, M. L., Wesseling, H., Lewis, R. J. and Gibbons, R. 
Clin. Pharmacol. Therap., 1974,15,424. 
Bridges, J. W. and Wilson, A. G. E. In Progress in Drug Metabolism (Bridges, J. \ 
and Chasseud, L. F. Eds. ) 1976,1, pp. 193-247, Wiley, Chichester. 
Brinkmann, A. O. and Molen, van der, H. J. ßiochim. Riophys. Acta, 1972,274, 
370. 
Brodie, B. B. Fed. Froc., 1952,11,632. 
Brodie, B. B. Proc. Roy. Soc. Med., 1965,58,946. 
Brodie, B. B. In Transport function of plasma proteins (Desgrez, P. and 
De Traverse, P. M. Eds. ) 1966, pp. 137-146, Elsevier, Amsterdam. 
Brodie, B. B. and Hogben, C. A. M. J. Pharrn. Pharmac., 1957,9,345. 
Brown, J. R. Fed. Proc., 1974,33,1389. 
Brown, J. R. Fed. Proc., 1975,34,591. 
Brown, N. A., King, R. F. G. J., Chilicock, M. E. and Brown, S. B. 
Biochem. J., 1974,137,135. 
-296- 
Burgen, A. V. S. and Metcalfe, J. C. J. Pharm. Pharmacot., 1970,22,153. 
Burke, C. W. Biochim. Biophys. Acta, 1969, . 
176,403. 
Burns, J. J. , Rose, R. K. , Chenkin, T. , 
Goldman, A. , Sci ufert, A. and Brodie, r;, L 
J. Pharmacol. Exp. Ther., 1953,109,346. 
Bush, M. T. and Alvin, J. D. Ann. N. Y. Acad. Sci., 1973,226,36. 
Campbell, H. A., Smith, W. K., Roberts, W. L. and Link, K. P. J. Biol. Chem., 
1941,138,1. 
Campion, D. S. and Olsen, R. J. Pharm. Sci., 1974,63,249. 
Chakrabarti, S., Laliberte, R. and Brodeur, J. Fed. Pro :, 1975,34,742. 
Chakrabarti, S. K. , Laiiberte, R. and Brodeur, J. Bio<c; iem . Pharmacol. , 1976, 
25,2515. 
Chavez, L. G. and Benjamin, D. C. Fed. Proc., 1975. H., 592. 
Chen, M. C. and Lord, R. C. J. Amer. Chem. Soc., 1976,98,990. 
Chen, R. F. J. BIoL. Chem., 1967,242,173. 
Chen, R. F. 1971. Unpublished results quoted by Chi. gnell, 1972. 
Chen, R. F. In Methods in pharmacology (ed. Chigneli; 1972,2, pp. 1-32 
Chen, R. F. Arch. Biochem. Biophys., 1974,160,106. 
Chien, Y. W., Lambert, H. J. and Lin, T. K. J. Pharm Sci. , 1975,64,961 . 
Chignell, C. F. Life Sci., 1968,7,1181. 
Chignelt, C. F. Mo[. Pharmacot., 1969a, 5,244. 
Chignell, C. F. MoLec. Pharmaco1., 1969b, 5,455. 
ChigneLL, C. F. Mo[. PharmacoL., 1970a, 6,1. 
Chigneti, C. F. Advan. Drug. Res., 1970b, 5, S5. 
Chignell, C. F. In Handbook of experimental pharmacology (Brodie, B. B. and 
Gillette, J. R., Eds. ) 1971,28, Pt. 1, pp. 187-211, Springer-Verlag, Berlin. 
Chignell, C. F. In Methods in pharmacology (Schwartz, A. Ed. ) 1972,2, 
pp. 33-62. 
Chignell, C. F. Ann. N. Y. Acad. Sci., 1973,226,44. 
-297- 
Chignell, C. F. In Drug interactions (Morselli, P. L., Garattini, S. and 
Cohen, S. N., Eds. ), 1974, pp. 111-123, Raven Press, London. 
Chignetl, C. F. and Benzinger, T. H. In Methods in pharmacoLogy (Chigneti, 
C .F., Ed. 
) 1972,2, p. 465-490, Appleton-Century-Crofts, New York. 
Chignell, C. F., Vessell, E. S., Starkweather, D. K. and Berlin, C. M. 
Clin. Pharmacol . Ther. , 1971,12,897. 
Churchich, J. E. Biochim. Biophys. Acta, 1972,285,91. 
Cohn, E. J., Hughes, W. L. and Weare, J. H. J. Amer. Chem. Soc., 1947, 
69,1753 . 
Cooke, J. R. and Roberts, L. B. In Microsomes and Drug O. -idations 
(Gillette, J. P.., Conney, A. H., C'osmides, G. J., x_; st: C`, rook, R. W., 
Fouts, J. R. and 1vIannering, C. J. Eds. ) 1969, pp. ] r]-1.66, Academic Press, 
London. 
Cooper, P. F. and Wood, G. C. 1. Pharm. PharmacoI., 1968,20, Suppl. 1505. 
Crawford, J. S. and Davies, P. Brit . j. Pharmacot., 1971,43,344. 
Crawford, J. S., Jones, R. L., Thompson, J. M. and Welts, W. D. E. 
Brit. J. Pharmacol., 1972,44,80. 
Crawford, V. A. J. Chem. Soc., 1973,2058. 
Cruze, C. A. and Meyer, M. C. J. Pharm. Sci.., 1976,65,33. 
Cuatrecasas, P., and Anfinsen, C. B. In Methods in enzymology (jackoby, W. B. 
Ed. ) 1971,22, pp. 345-378, Academic Press, New York. 
DanieL, E. and Weber, G. Biochem. , 1966,5,1893. 
Danon, A. and Sapira, J. D. J. Pharm. Exp. Therap., 1972,182,295. 
Davison, C. In Fundamentals of drug metabolism and drug disposition 
(La Du, B. N. , Mandel, 
I. T. G. and Way, E. I.. , Eds. ) 1971, pp. 63-75, 
Williams and Wilkins, Baltimore. 
Davison, C. and Smith, P. K. J. Pharmacol. Exp. Ther., 1961,133,161. 
De Moor, P., Heirwegh, K., Hereman, J. F. and Decler, k-Raskin, M. 
J. Clin. Invest., 1962,41,816. 
Derenzini, M., Fiume, L., Marinozzi, V., Mattioli, S. S., Montanaro, L. 
and Sperti, S. Lab. Invest., 1973,29,150. 
Dippy, J. F. J. J. Chem. Soc., 1938,1222. 
Dixon, M. Biochem. J., 1953,55,170. 
Dottery, C. T., Emshie-Smith, D. and Muglgletori, D. F. Brit. J. Pharmacot., 
1961,17,488. 
-298- 
Doub, L. and Vandenbelt, J. M. J. Am. Chem. Soc., 1947,69,2714. 
Donnan, F. G. Chem. Rav., 1924,1,73. 
Dunn, B. M. and Chaiken, I. M. Biochem., 1975,14, ': `343. 
Dunn, W. J. J. Pharm. Sci., 1973,62,1575. 
Edsati, J. T. and Wyman, J. Biophys. Chem., 1958,1,591. 
Eble, J. N., West, B. D. and Link, K. P. Blochem. Pharmacol., 1966,15,1003. 
Edelman, G. M. and McClure, W. O. Account. Chem. Rr s., 1968,1,65. 
Ehrlich, P. Ber. Dtsch. Cýem. Ges., 1909,42,17. 
Ehrnebo, M., AgureLl, S., Boreus, L. 0., Gorduri, E. fonroth, U. 
CLin. Pharmacoi. Ther., 1974,16,424. 
Eisback, P. and P-Attic, P. Blochim. Biophys. Acta., , 296,89. 
Ernster, L. and Orrenius, S. Fed. Proc ., 1965,24,1190. 
Fabre, J., MiLck, E., KaLfcpoulos, P. and Merior, G. Schweiz. Med. 
Wochenschr. , 1971,101,625. 
Faerch, T. and Jacobsen, J. 21rch. Biochem. Biophys., ! 75,168,351.. 
Faircicugh, G. F. and Fruton, J. S. Biochern., 1966, '. C73. 
Farese, G., Mager, M. and Blatt, W. F. CIin. Chem., 1970,16,226. 
Farnsworth, W. E. CLiniLine (Amicon), 1974,2,4. 
Feldman, H. A. Anal. Biochem. , 1972,48,317. 
Fischer, J. J. In Methods in Pharmacology (Schwartz, A., Ed. ) 1971,1, 
pp. 431-453, Appleton-Century-Crofts, New York. 
Fischer, J. J. and jardetsky, 0. J. Am. Chem. Soc., 1965,87,3237. 
Fletcher, J. E. and Ashbrook, J. D. Ann. N. Y. Acad. Sci., 1973,226,69. 
Fletcher, J. E., Spector, A. A. and Ashbrook, J. D. Biocliem., 1970,9,4580. 
Foged, L., Husted, S. and Andreasen, F. Acta. Pharm. Tox., 1976,39,312. 
Forster, T. In Fluoroszeruz Organischer Verbindungen, 1951, p. 85, 
Vandenhoeck u . Ruprecht , Gottingen. 
Foster, J. F. In The plasma proteins, Ist Edn., (Putnam, F. W. Ed. ) 1960, 
Academic Press, New York. 
Foster, J. F. , Sogami, T. I. , Petersen, H. A. -end Leonard, W. j, j. riet. Cilý 7ý ., 1965,240,2495. 
-299- 
Froese, A., Sehon, A. H. and Eigen, M. Can. J. Chem., 1962,40,1786. 
Fuller, R. W. and Roush, B. Res. Comm. Chem. Pathol. & Pharm., 1974,8,563. 
Gambhir, K. K. and McMenamy, R. H. Fed. Proc. 1973,33,457. 
Gambhir, K. K., McMenamy, R. H. arid Watson, F. J. ßioi . Chem ., 1975, 
250,6711 . 
Ganshorn, A. and Kurz, H. Arch. Pharmakol. Exp. Patho1., 1968,260,117. 
Garrettson, L. K., Procknal, J. A. and Levy, G. Clin. Pharmacol. Therap., 1975, 
18,214. 
Garten, S. and Wositait, W. b. Mot. Phar-riacot., 197]., 3,751. 
Ghoneim, M. M. and Pandya, H. Anesthesiol., 1975, ', 545. 
Gillette, J. R. Ann. N. Y. Acad. Sci., 1971,179,431. 
Gillette, J. R. Ann. N. Y. Acad. Sci., 1973,226,6. 
Gillette, J. R. In Handbook of Experimental Pharmacology, (Gillette, J. R. and 
Mitchell, J. R. Eds. ) 1975,28, Pt. 3., pp. 35-34, SJ) inger-Verlag, Berlin. 
Girl, S. N. and Peoples, S. A. Proc. Soc. Exp. Biol. Med., 1975,148,540. 
Gitlin, D. and Boesman, M. J. CLin. Invest., 1966,45,1826. 
Goding, L. A. and West, B. D. J. Med. Chem., 1969,12,517. 
Goldstein, A. Pharmacol. Rev ., 1949,1,102. 
Goldstein, A., Aranow, L. and Kalman, S. M. Principles of Drug Action, 
1968, Hoeber, New York. 
Goodman, D. S. J. Am. Chem. Soc., 1958,80,3892. 
Graham, T. PhiL. Trans. R(-)Y. SOC., 1861,151,183. 
Green, N. M. Biochim. Biophys. Acta., 1963,74,542. 
Guarino, A. M., Call, J. B., Starkweater, D. K. and Chi. gnell, C. F. 
Cancer Chemother. Rep., 1973,57,125. 
Gugler, R., Shoeman, D. W. and Azarnoff, D. L. Phauiit col., 1974,12,160. 
Haddock, R. E., Trager, W. F. and Pohl, L. R. J. Med. Chem., 1975,18,519. 
Halfmann, C. J. and Nishida, T. Biochem. , 1972,11,3493. 
Halver, B. Clin. Chem., 1972,18,1488. 
-3 00- 
Hansch, C. Il Farmaco., 1968,23,293. 
Hansen, J. M., Siersbaek-Nielsen, K., Skovsted, L., Kampmann, J. P. and 
LumhoLtz, B. Brit. Med. J., 1975,2,684. 
Hartshorn, E. A. Handbook of drug interactions, 1970, Wiley-Interscience, 
New York. 
Hassall, C., Feetam, C. L., Leach, R. H. and Meynell, M. J. Brit. Med. J., 
1975,2,684. 
Hawkins, D., Pinckard, R. N., Crawford, I. P. and Farr, R. S. J. Clin. Invest., 
1969,48,536. 
Hawkins, J. D. Biochem. j., 1961,80,210. 
Helmer, F., Kiehs, K. and Hansch, C. Blochern., 1968,7,2858. 
Henry, R. A. and Wositait, W. D. Tox. Appl. Pharmacol., 1975,33_, 267. 
Hermann, R. B. J. Phys. Chem., 1971,75,363. 
Hermann, R. B. J. Ph_vs. Chem., 1972,76,2754. 
Herskovits, T. T. In Methods in enzymology (Ed. Colwick, S. P. and 
Kaplan, N. O. ) 1967,2, pp. 748-755, Academic Press, New York. 
Herskovits, T. T. and Laskowski, M. J. Riol. Chem ., 1962,237., 2481. 
Hewick, D. S. j. Pharm. Pharmacol., 1972,24,661. 
Hewick, D. S. and McEwen, J. J. Pharm. Pharmacol., 1973,25,458. 
Hewick, D. S. and Shepherd, A. M. M. J. Pharm. Pharmacot., 1976,28,257. 
Himberg, J. J., julkunen, R. J. K. and Soininen, K. A. ArzrteimitteL-Forschung, 
1976,26,177. 
Hippe, E. and Olesen, H. Biochim. Bic) phys. Acta, 1971 , 243,83. 
Hollis, D. P. In Methods in pharmacology (Chignell, C. F. Ed. ) 1972,2, 
pp. 191-222, Appleton-Century-Crofts, New York. 
Hsu, P. -L., Ma, J. K. H. and Luzzi, L. A. J. Pharm. Sci., 1974,63,570. 
Huang, P. C. and Gabay, S. Biochem. Pliarmaco l. 1974,23,9S7. 
Hughes, W. L. In The proteins, 1st Edn., (Neuratte, B. and Bailey, R. Eds. ) 
1954,2, pp. 633-755, Academic Press, New York. 
Hummel, j. P. and Dreyer, W. J. Biochim. Biophys . Acta . 1962,63,530. 
Ikeda, K. and Hamaguchi, K. J. Biochem., 1969,66,513. 
-301- 
Jacobsen, C. Fur. J. Biochcm., 1972,27,513. 
Jacobsen, C. Int. J. Peptide Pro. Res., 1975,7_, 161.. 
Jahnchen, E., Kreigistein, J., Kunkel, F., Samuels, W. j. and Wollert, U. 
Naunyn-Schmeid. Arch. Pharmaco1., 1971,269,67. 
Jahnchen, E. , Meinertz, T. , Gilfrich, H. J. , Groth, U. d3nd Martini, A. 
Clin. Pharmacol. Ther., 1976,20,329. 
jardetsky, 0. and Wade-jardetsky, N. G. Mo[. Pharmacol., 1965,1,214. 
javidan, S. and Mrtck, R. G. J. Pharm. Sci., 1973a, 62,420. 
javidan, S. and Mrtek, R. G. J. Pharm. Sci., 1973b, 62, 
Javidan, S. and Mrtek, R. G. J. Pharm. Sci., 1975,64,3. 
jayle, M. F. Les Haptoglobines, 1962, Masson, Paris. 
Jonas, A., and Weber, G. Biochem. , 1971,10,133 5. 
Jorgensen, A., Hansen, V. and Over K. F. Acta Pharmacol. Toxicot., 1973, 
33,81. 
julkunen, R. J. K., Kekki, M., Himberg, J. -J. and Wahlstrom, B. 
Acti Pharm. To,., 1975,3D, 90. 
Jun, H. W., Luzzi, L. A. and Ma, J. K. H. J. Pharm . Sci.. , 1975,64,493. 
Kakemi, K. , Arita, T. , 
Hort, R., Konishi, R. and Nisiu. niura, K. 
Chem . Pharm. Bull., 
1969,17,248. 
Kanda, Y., Goodman, D. S., Canfield, R. E. and Morgi, F. J. J. ßiol. Chem., 
1974,249,6796. 
Karush, F. J. Am. Chem. Soc., 1950,72,2705. 
Karush, F. J. ý1m. Chem. ýoc., 1951,73,12, i6. 
Karush, F. and Sonenberg, M. J. Am. Chem. Soc., 1949,71,1369. 
Kauzmann, W. Adv. Protein Chem., 1959,14,1 . 
Keen, P. M. Biochem. Pharmacot., 1966,15,447. 
Keen, P. M. In Handbook of Experimental Pharmacology, (Brodie, B. B. and 
Gillette, J. R. Eds. ) 1971,28, Pt. 1, pp. 213-233, Springer-Verlag, Berlin. 
King, T. P. J. Biol. Chem., 1961,236,5. 
King, T. P. Ann. N. Y. Acad. Sci., 1973,226,94. 
-302- 
Klevens, H. B. J. Phys. CoL[. Chem., 1948,52,130. 
Klotz, I. M. J. Am. Chem. Soc., 1946,68,2299. 
Klotz, I. M. In The Proteins (Neurath, H. and Bailey, K. Eds. ) 1953, l st Ed ., 
1, P. 727, Academic Press, New York. 
Klotz, I. M. Brookhaven Symp. BioL., 1960,13,25. 
Klotz, I. M. Ann. N. Y. Acad. Sci., 1973,226,18. 
Klotz, I. M. Accts. Chem. Res., 1974,7,162. 
Klotz, I. M., Burkhard, R. K. and Urquhart, j. M. J. Am. Chem. Soc., 1952, 
74,202. 
Klotz, I. M. and Hunston, D. L. Blochern. , 1971,10, _ý 165. 
Klotz, I. M. and Hunston, D. L. J. BioL. Chem., 1975,250,3001. 
Klotz, I. M., Triwush, H. and Walker, F. M. J. Am. C 70,2935 
Klotz, I. M., Walker, F. M. and i'ivan, R. B. J. Am. C; ,! m. Soc., 1916,68,19Rý. 
Koch-Weser, J. and SeLLers, E. M. N. EngL. J. Med., 1JI1,281,1141. 
Koch-Weser, J. and Setters, E. M. N. Eng1. j. Mod., Jq76a, 294,311. 
Koch-Weser, J. and Sellers, E. M. N. Engt. J. Med., 1976b, 294,5,6. 
Koga, J., Tanaka, A. and Kuroki, N. Nippon Kagaku Karshi, 1975,8,1093. 
Kostenbauder, H. B. , Jawad, 
M. J. , Perrin, J. H. and Auerhart, j. J. Pharm . Sci. , 1971,60,1658. 
Krasner, J. Biochem. Med., 1973,7,35. 
Krasner, j., Thaler, M. and Yaffe, S. J. Pediat. Res., 1973,7,308. 
Kreiglstein, J. KLin. Wochenschr., 1969,47,1125. 
Kreigistein, J. and Kuschinsky, K. Artzneimlttet Forschung., 1968,18,287. 
Kreigistein, J ., Lier, F., and 
Michaetis, J. Naunyn--Schmeid. Arch. Pharmacoi. 
1972a, 272,121. 
Krieglstein, J-, Meiler, W. and Staab, ]. Biochem . Pharmacol ., M2b, 21, ý: `i; 
Kruger-Thiemer, E. Proc. Illint. Pharmacol. Meeting - 1966,1968,7,63. 
Kruger-Thiemer, E., Bunger, P., DettEi, L., Spring, P., and Wempe, E. 
Chemotherapia, 1965,10,325. 
-303- 
Kunin, C. M., Dornbush, A. C. and Finland, M. J. Clin. Invest., 1959,38,195Ü. 
Kurooka, S. and Yoshimura, Y. J. Biochem., 1973,74,785. 
Lagercrantz, C. and Setaka, M. Acta Chem. Scand. (B)., 1975,29,397. 
Latiberte, R., Chakrabarti, S. and Brodeur, J. J. Pharmacol. Exp. Ther., 1976, 
196,194. 
Lang, L. (Ed. ) Absorption spectra in the UV and Visible region, 1964,2,367, 
Academic Press, Budapest. 
Laurell, C. -B., In The plasma proteins (Putnam, F. W., Ed. ) 1960,1, 
pp. 459-478, Academic Press, New York. 
Laurence, D. J. Biochem. J. 19 52 , 51,160. 
Leo, A., Hansch, C. and Elkins, D. Chem. Rev., 1971,71,532. 
Levi, A. J., Gatmaitan, Z., Arias, I. M. J. CLin. Jnvest., 1969,48,2156. 
Levy, G. Ann. N. Y. Acad. Sci., 1973,226,195. 
Levy, G., Procknal, J. A. and Garrettson, L. K. Clin. Pharmacol. Therap., 1975, 
18,210. 
Lewis, R. J. , Trager, 
W. F. , Chan, K. K. , Breckenridge, A., pane, M. L'E., 
Roland, M., and Schart', W. J. C1in. Invcst., 1974, '; 3,1607. 
Link, K. P. Harvey Lectures, 1943,39,162. 
Link, K. P., Berg, D. and Barker, W. D. Sci., 1965,150,378. 
Litwack, G., Ketterer, B. and Arias, I. M. Nature, 1137.1,234,466. 
Litwack, G., Morey, K. S. and Ketterer, B. In Effect of Drugs on Intracellular 
Control Mechanisms (Rabin, B. R. and Freedman, R. P., Eds. ) 1972, 
pp. 105-130, MacMillan, London. 
Lowry, O. H., Rosenbrough, N. J., Farr, A. L. and Rand iH., R. J. J. Biol. Chem., 
1951,193,265. 
Lowry, T. M. Optical Rotatory Power, 1964, Dover, New York. 
Luck, J. M. and Schmidt, A. S. Std. Med. Bull., 1948,6,133. 
Lund, L., Berlin, A. and Lunde, P. K. M. Ciin. Pharmacol. Ther., 1972,13,196. 
Ma, J. K. H., Hsu, P. -L. and Luzzi, L. A. J. Pharm. Sci., 1974,63,32. 
MacFarlane, A. S. Lancet, 1963,2,131. 
Mahler, H. R. and Cordes, T;. H. Biological Chemistry, 1971,2nd. -Edition, 
pp. 559-560, Harper and Row, New York. 
-304- 
Manian, A. A., Piette, L. H., Holland, D., Grover, T. and Leterrier, F. 
In The phenothiazines and structurally relat4: ed drugs (Forrest, T. S., Carr, 
C. J. and Usdin, E. Eds. ) 1974, pp. 149-161, Raven Pi ss, New York. 
Maren, T., Robinson, B. and Pal. mer, R. F. Biochem. Pharmacol., 1961,6,21. 
Markley, K. S. (Ed. ) Fatty Acids, 1960,2nd Edition, Interscience, New York. 
Marks, V. Teach-in, 1972, (Several articles, Aug., p. 641; Sept., p. 711; 
Nov. p. 861; Dec., p. 909). 
Markus, G. and Karush, F. J. Am. Chem. Soc., 1958,80,89. 
Martin, B. K. Nature, 1965a, 207,274. 
Martin, B. K. Nature, 1965b, 207,959. 
Meloun, B., and Kusnir, J. Fobs. Lett., 1972,27,121. 
Meyer, M. C. and Guttman, D. E. J. Pharm. Sci., 1968,57,895. 
Meyer, M. E. and Guttman, D. E. J. Pharrn. Sci., 1970,59,33. 
Meuwissen, J. A. T. P., Ketterer, B. and Mertens, B. B. E. Digestion, 1972, 
6,293. 
Mfldvan, AS, and Cohn, M. Fed. Proc., 1963,22,595. 
Mora, R., Rebeyrotte, P. acid Potonovski, J. 3ull. Soc. Vhim. Biol., 1955, 
37,957. 
Moriguchi, I., Waoa, S. and Nishizawa, T. Chem. Pharm. Bull., 1968,16,601. 
Moriguchl, I., Fushimi, S., Kaneniwa, N. Chem. Pharm. BuL. I., 1971,19,1272. 
Muller, W., Wollert, U. Naunyn. -Schmied. Arch. Phaniiacol., 1974,283,67. 
Muller, W. E. and Wollert, Ti. Mol. Pharmacol., 1975: x, 11,52. 
Muller, W. E. and Wo llert, U. Naunyn-Schmied . Arch . Phirmacol ., 1975b, 288,17. 
Muller, W. E. and Wollert, TI. Biochem. Pharmacol ., 1976,25,147. 
McArthur, J. N Dawkins, P. D., Smith, M. J. H. and Hamilton, E. B. D. 
Brit. Med. J., 1971,2,677. 
McClure, R. J. and Craven, B. M. J. Mol. Biol., 1974,83,551. 
McMenamy, R. H. Arch. Biochem. Biophys., 1967,122,635. 
McMenamy, R. H., Dintzis, H. M. and Watson, F. J. Piol. Chem., 1971, 
246,4744. 
McMenamy, R. H. and Oncley, J. L. J. Biol . Chem ., 1958,233,1436. 
-305- 
McQueen, E. G. Brit . J. PharmacoL., 
1968,33,312. 
McQueen, E. G. Brit. J. PharmacoL., 1969,36,29. 
Nagashima, R., O'Reilly, R. A. , and Levy, G. Clin. Pharmacol . Ti r. , 1969, 10,22. 
Nagwekar, J. B. and Kostenbauder, H. B. J. Pharm. Sci., 1970,59, '751. 
Nagwekar, J. B. and Muangnoicharoen, N. J. Pharm. Sci. , 1973,62,1439. 
Nambu, N. and Nagai, T. Chem. Pharm. Bull., 1972,20,2463. 
Neurath, H. (Ed. ) The Proteins: composition, structure and function, 
1965,2nd. Edition, 111, Academic Press, New York and London. 
Newbold, B. B. and Kilpatrick, R. Lancet, 1960,1,8"7. 
Nilsen, O. G. Biochem. Pharmacol., 1976,25,1007. 
Nilsen, O. G. and Jacobsen, S. Biochem. Pharmacol.; 1.975,24,995. 
Nishikimi, M. and Yoshino, M. J. Biochem., 1972,72,1237. 
Noel, J. K. F. and Hunter, M. J. J. Biol. Chem., 1972,247,7391. 
Nolte, H. and Buttner, H. Chemotherapy, 1974,20,321. 
Notari, R. E. J. Pharm. Sci., 62,865. 
Oakes, J. Eur. J. Biochem., 1973a, 36,553. 
Cakes, J. Eur. J. Biochem., 1973b, 36,559. 
Odar-Cederlof, I. and Borga, O. Ctin. Pharmacol. Therap., 1976,20,36. 
Odell, G. B. Ann. N. Y. Acad. Sci., 1973,226,225. 
Ohkubo, A. J. Blochem., 1969,65,879. 
Oie, S. and Fristid, K. Phannac. Acta, Helv., 1971, "ý5,632. 
Omuro, T. and Sato, R. J. Biol. Chem., 1964,239,2370. 
O'Reilly, R. A. j. Clln. Invest., 1969,48,193. 
O'Reilly, R. A. MoL. Pharmacol., 1971,7_, 209. 
O'Reilly, R. A. Ann. N. Y. Acad. Sci., 1973,226,293. 
O'Reilly, R. A. Clin. Pharmacol. Therap., 1974,16,348. 
O'Reilly, R. A., Ohms, J. I. and Motley, C. H. J. Biol. Chem., 1969,244,1303. 
Osborne, W. A. J. Physiol., 1906,34,84. 
-306- 
Pearlman, W. H. and Crepy, P. J. Biot. Chem., 1967,242,182. 
Pennock, B. E. AnaL. BLochem., 1973,56,306. 
Perrin, J. H. J. Pharm. Pharmacol., 1973,25,208. 
Perrin, J. H. and Hart, P. A. J. Pharm. Sci., 1970,59,431. 
Perrin, J. H. and Idsvoog, P. J. Pharm. Sci., 1971,60,602. 
Perrin, J. H. and Nelson, D. A. Life Sci., 1972,11,277. 
Perrin, J. H. , Vatlner, J. J. and Nelson, D. A. Biochem. Pharrnacol ., 1975, 24,769. 
Peters, T. Advan. Clin. Chem., 1970,13,3/. 
Peters, T. In The plasma proteins (Putnam, F. W., Ed. ) 1975,1, pp. 133-181, 
Academic Press, New York. 
Peters, T. and Hawn, C. J. Biol. Chem., 1967,242,1566. 
PohL, L. R. , Nelson, 
S. D. , Porter, W. R. , Trager, WI., Fasco, MM . 
j. , 
Baker, F. D. and Fenton, J. W. Blochem. Pharmacot., 1976,25,2153. 
Polet, H. and Steinhardt, J. Biochem., 1968,7,1348. 
Polonovski, J. In Trans Port function of plasma proteii, s (Degrez, P. and 
De Traverse, P. M. Eds. ) 1966, pp. 45-55, Elsevier, Amsterdam. 
Popov, P. G. , Vaptzarova, 
K. I. , Kossekova, G. P. and Nikolou, T. K. 
Compt. rend. Acad. Bulg. Sci., 1971,24,1357. 
Poulik, M. D. and Weiss, M. L. In The plasma proteins (Putnam, F. W. Ed. ) 
1975,2nd -Edition, 
2, Academic Press, New York. 
Powis, G. Biochem. PharmacoL., 1975,24,707. 
Priestly, B. G. and O'ReifLy, W. J. J. Pharm. Pharmýj-: cal.,, 1966,18,41. 
Priore, R. L. and Rosenthal, H. E. AnaL. Biochem., 1975,70,231. 
Putnam, F. W. Ed. The Plasma proteins, 1960, vols. 1 and 2, Academic Press, 
New York. 
Putnam, F. W. In The proteins (Neurath, H. Ed. ) 1965,2nd Edition, 3, 
pp. 153-267, Academic Press, New York. 
Putnam, F. W. (Ed. ) The Plasma proteins, 1975,2nd. Ed., 1, Academic 
Press, New York. 
Rao, C. N. R. UV and Visible spectroscopy, ChemicaL applications, 1975 
3rd Edition, Buttertivorths, London. 
-307- 
Raoul, Y. In Transport Function of plasma proteins (Desgrez, P. and 
De Traverse, P. M., Eds. ) 1966, pp. 99-119, Elsevier, Amsterdam. 
Ray, A., Reynolds, J. A. , Polet, H. and Steinhardt, J. Biochem. , 1966, 
5,2606. 
Raz, A. Blochem. J., 1972,130,631. 
Reed, R. G., Feldhoff, R. C., Clute, O. L. andPeters, T. Biochem., 1975, 
14,4578. 
Reed, R. G. , Gates, T. and Peters, T. Anal. Biochem ., 1975,69,361. 
Reidenberg, M. M. Med. Clin. N. Amer., 1974,58,1103. 
Reidenberg, M. M. and Affri. me, M. Ann. N. Y. Acad. S,; i,,., 1.973,226,115. 
Reldenberg, M. M. , Odar-Ceder[of, I., Von Bahr, C., "3orga, 0. and 
Sjoquist, F. New Engl. J. Med., 1971,285,264. 
Reynolds, J. A., Herbert, S., Polet, H. and Steinhardt, j. Blochern., 1967, 
6,937. 
Reynolds, J. A. , Herbert, 
S. and Steinhardt, J. Blochern. , 1968,7,1357. 
Rieder, j. Arzneimittel Forschung. 1963,13,81. 
Rieder, J. Internal Publication, 1970, Hoffman-La Roche and Co., Basel. 
Robertson, J. S. and Madsen, B. W. J. Pharm. Scl., 1974,63,234. 
Rodrigues de Miranda, J. F., Eikelboom, T. D. and Van Os, G. A. J. 
Mol. Pharrnaco(. 1976,12,454. 
Rodrigues De Miranda, J. F. and Hilbers, C. W. Moi. Pharmacol. 1976,12,279, 
Rolinson, G. N. In Recent advances in medical microbiology (Waterson, A. P. 
Ed. ) 1967, p. 254, London, Churchill. 
Rolinson, G. N. and Sutherland, R. Brit. J. Pharmacol. 1.965,25,638. 
Rosen, A. Biochem. Pharmacol. , 1970,19,2075. 
Rosenburg, R. M. and Klotz, I. M. In A laboratory Manual of Analytical 
Methods of Protein Chemistry (Block, R. S. and Alexander, P., Eds. ) 1960, 
pp. 131-168. 
Rosenthal, H. E. Anal. Blochem., 1967,20,525. 
Rothschild, M. A., Oratz, M. and Schreiber, S. S. N. Fngl. J. Med., 1972, 
286,816. 
-3 08- 
Rothschild, M. A. and Waldman, T. (Eds. ) Plasma protein metabolism: 
Regulation of synthesis, distribution and degradation, 1970, Academic 
Press, New York. 
Ruf, H. H. and Gratzl, M. Biochcm. Biophys. Acta., 1976,446,134. 
Ryan, M. T. Arch . Biochem. Biophys., 1968,126,407. 
Ryan, M. T. and Gibbs, G. Arch. Biochem. Biophys., 1970,136,65. 
Ryan, M. T. and Hanna, N. S. Ana[. Biochem., 1971,40,364. 
Sandberg, A. A. and Slaunwhite, W. R. J. Clin. Endocr., 1956,16,923. 
Sanger, F. Proc. Chc-rn. Soc., 1900,76, (cii_ed by Steiuiicirdt et at., 1971). 
Sangster, R. C. and Irvine, J. W. 
pp. 709-710. 
In The ftuorescence or solids, 1955, 
Santos, E. C. and Spector, A. A. Biochem. , 1972, . 
11,9299 
, 
Santos, E. C. and Spector, A. A. Mol. Pharrnacol., 1g71,10,519. 
Scanu, A. M., Edelstein, C. and Keim, P. In The plasma proteins (Putnam, 
F. W. Ed. ) 1975,2nd Edition, 1, pp. 318-385, Academic Press, New York. 
SCcarll', A. TJJ. , rid WisCla :, C'. Ann . 
rZev 
-B-, -1 t',., 
]1,, 41 
,73. 
Scatchard, G. Ann. N. Y. Acad. Sci., 1949,51,660. 
Schachman, H. K. and Edelstein, S. J. Biochem., 1966,5,2631. 
Schary, W. L., Lewis, R. J. and Rowland, M. Res. Commun. Chem. Pathol. 
Pharm., 1975,10,663. 
Schechter, E. j. Biochem ., 1969,10,274. 
Scheig, R. In Medium chain trigtycerides (Senior, J. R. Ed. ) 1968, pp. 39-49. 
Univ. Penn. Press, Phi! ad ; [pihia. 
Scheltman, J. A. Acc. Chem. Res., 1968,1,144. 
Schellman, j. S., Lumry, R. and Samuels, L. T. J. Ar, 1er. Che_m. Soo., 1954, 
76,2808. 
Schoenemann, P. T., Yesair, D. W., Coffey, J. J. and F-, uiitock, F. J. 
Ann. N. Y. Acad. Scl., 1973,226,162. 
Scho [tan , W. Intern. Cong . Chemotherapy, 1963, Proc. 3rd ., Stuttgart, 261. 
Scho ltan , W. Arzneimittel Forschung, 19 64 , 14,146. 
Schultze, H. E. and Heremans, J. F. Molecular Biology of Human Proteins 
with Special Reference to Plasma Proteins, 1966, I, Lisevier, Amsterdam. 
-309- 
Seiler, K. and Duckert, F. Thromb. Diath. Haemorrh., 1968,19,389. 
Sellers, E. M. and Koch-Weser, J. CLin. Pharmacol. Ther., 1970a, 11,524. 
SeLLers, E. M. and Koch-Weser, J. 
Selters, E. M. and Koch-Weser, J. 
CLin. Res., 1970b, ; 18,344. 
Pharmacot. Res. Commun., 1975,7,331. 
Settle, W. , Hegeman, 
S. and Featherstone, R. M. In Handbook of 
experimental pharmacology (Brodie, B. B., Gillette, J. R., Eds. ) 1971, XXVIII 
pp. 175-186, Springer-Verlag, Berlin. 
Shand, D. G. , Mitchell, J. R. and Oates, J. A. In Handbook of experimental 
pharmacology, (Gillette, J. R. and Mitchell, J. R. Eds. ) 1975,28, Pt. 3, 
pp. 272-307, Springer-'Verlag, £3cJin. 
Shoeman, D. W., Benjamin, D. M. and Azarnof , D. L. Ann. N. Y. AAcad. Sci., 
1973,226,127. 
Silverman, W. A., Anderson, W. A. and Crozier, D. N. Pediatrics, 1956, 
18,614. 
Sjoholm, I. and Ljungstedt, I. J. Biot . Chem ., 1973,248,8434. 
Smith, M. J. H., Dawkins, P. D. and McArthur, J. N. J. Pharm. PharmacoI., 
1971 , 23 , 729 . 
Soetewey, F., Rosseneu-Motreff, M. , Lamote, R. and Teeters, H. 
J. Biochem., 1972,71,705. 
Sogami, M. and Foster, J. F. Bioc'nem. , 1968,7,2172. 
Soler-ArgiLaga, C. and Heimberg, M. Lipids, 1976,11,83. 
Soler-Argilaga, C., Infante, R. and PoLonovski, J. J. Lipid Res., 1975,16,11E 
Solomon, H. M. In Handbook of experimental pharmacology (Eichler, 0., 
Farah, A., Herken, H. and Welch, A. D., Eds. ) 1971,288, Pt. 1 , pp. 234-239. 
Solomon, H. M. and Schrogie, J. J. Biochem. Pharmacol., 1967,16,1219. 
Solomon, H. M., Shrogie, J. J. and Williams, D. Biochem. Pharmacol., 1968, 
17,143. 
Spector, A. A. J. Lipid Res., 1975,16,165. 
Spector, A. A., Fletcher, J. E. and Ashbrook, J. D. Biochem., 1971,10,3229. 
Spector, A. A. and John, K. M. Arch. Biochem. Biophys., 1968,127,65. 
Spector, A. A. , John, K. , arid Fletcher, J. E. J. Lipid Res., 1969,10,56. 
Spector, A. A., Santos, E. C. , Ashbrook, J. U. and Fleloiier, J. E. Ann. N. Y. 
Acad. Sci., 1973,226,247. 
-310- 
Spencer, E. M. and King, T. P. J. Biol. Chem., 1971,246,201. 
Squire, B. G., Moser, P. and O'Konski, C. T. Biochem., 1968,7,4261. 
Steinberg, I. Z. and Schachrnan, H. K. Biochem., 1966,5,3728. 
Steiner, R. F., Roth, J. and Robbins, J. J. Biol. Chem., 1966,241,560. 
Steinhardt, J. , Krijn, J. , and Leidy, J. G. Biochem. , 1971,10,4005. 
Steinhardt, J. , Leidy, J. G. and Mooney, J. P. Biochein. , 1972,11,1809. 
Steinhardt, J. and Reynolds, J. A. In Multiple equilibria in proteins, 1969, 
Academic Press, London and New York. 
Storstein, L. and Janssen, 11. CLin. Pharmacoi. Then:,:. 1976,20,15. 
Sud low, G., Birkett, D. J. and Wade, D. N. 
11,824. 
Mol. Pharmacol ., 1975a, 
Sudlow, G., Birkett, D. J. and Wade, D. N. 
1975b, 2,129. 
Sudlow, G., Birkett, D. J. and Wade, D. N. 
12,1.052. 
Gun . Ex . t'Iiarrnaco[. Physlol. , 
Mol . Pharmacol., 1976, 
Swaney, J. B. and Klotz, I. M. Biochem. , 1970,9,2`70. 
Swidler, G. Handbook of drug interactions, 1971, V ilrýv-Interscience, 
New York and London. 
Sykes, B. D. Biochem. Biophys. Res. Commun., 1970,39,508. 
Sykes, B. D. and Hull, W. E. Ann. N. Y. Acad. Sci., ]973,226,60. 
Tabachnick, M. Arch. Biochem. Biophys., 1964,106,415. 
Tanford, C. J. Mo1. Biol., 1972,67,59. 
Tanford, C. (Ed. ) The Hydrophobic effect, 1973, Wilcy-Interscience, London. 
Taylor, P. W. In Methods in Pharmacology (Chignell, C. F. Ed. ) 1972,2, 
pp. 3 51-3 80, Appleton-Century-Crofts , New York. 
Taylor, R. P. and Chau, V. Fed. Proc., 1975,34,591. 
TeLLer, D. N., Levine, R. J. C. and Deriber, H. C. B. Aijressologie, 1968,9,1. 
Teresi, J. D. and Luck, J. M. J. Bio[. Chem., 1952,194,823. 
Thomas-Morvan, C. Acta Endocrinol., 1976,81,288. 
Thompson, J. M. Brit. J. Ptiarmacot., 1973,47,133. 
-311- 
Thorp, J. M. In Absorption and distribution of drugs (Binns, T. B. Ed. ) 1964, 
pp. 64-76, Livingstone, London. 
Thorp, J. M. Proc. Eur. Soc. Study Drug Tox., 1972,12,98. 
Tildon, J. T. and Ogilvie, J. W. J. Biol. Chem., 1972,247,1265. 
Tilstone, W. J., Nimmo-Smith, R. H., Gray, J. M. B, Welch, R. and Lawson, D. H, 
Postgrad. Med . j. 1976, in press. 
Tipping, E., Ketterer, B., ChristodouIides, L. and Enderby, G. Eur. J. 
Biochem., 1976,67,583. 
Toribara, T. Y., Terepka, A. R. and Dewey, P. A. J. CIin. Invest., 1957, 
36,738. 
Tritsch, G. L. Arch. Bioch ., i. Biophys., 1E63, j2-7, 38 4. 
Turner, M. W. and Hutme, B. The plasma proteins, 1971, PitmanMedicat 
and Scientific p=ublishing Co. Ltd., London. 
Van der Vlies, C. Biochem. Pharmacol., 1.970,19,859. 
Wagner, J. G. J. Pharmacok. Biopharrn., 1973,1,363. 
Wahiquist, M., Wilsson, I. M., Sandberg, F. and AgureLl, S. BLochem. 
Pharmac., 1970,19,2579. 
Wallace, S. and Whiting, B. Brit. j. Clin. Phara ocol., ! _974 1 329. 
Wallerik, K. J. Biol. Chem., 1973,248,2650. 
Wardell, M. W. In Drug interactions (Morse IIi, P. L. , Garattini, S. and Cohen, S. N. Eds. ) 1974, pp. 123-134, Raven Press, London. 
Weber, G. Biochem. J., 1960,75,345. 
Weber, G. and Young, L. B. J. Biot. Chem., 1964,239,1415. 
Weber, W. W. and Cohen, S. M. In Handbook of experimental pharmacology 
(Gillette, J. R. and Mitchell, J. R. Eds. ) 1975,28, Pt. 3, pp. 213-233, 
Springer-Verlag, Berlin. 
Weder, H. G., Schildknecht, J., Lutz, R. A. and Kesselring, P. Eur. j. 
Blochern. , 1973,42,475. 
Weder, H. G. and Bickel, M. H. J. Pharm. Sci., 1970,59,1563. 
Weder, H. G., Schildknecht, J., and Kesselring, P. Am. Labor., 1971,10,15. 
West, B. D. and Link, K. P. J. Heteroý: vc[. Chrýrri., 1965,2,93. 
Westphal, U. Steroid-protein interactions, 1971, Springer-Verlag, Berlin 
and New York. 
-312- 
Westphal, U. and Knoefel, P. K. In Absorption, distribution, transformation 
and excretion of drugs (Knoefel, P. K. Ed. 
), 1972, pp. 56-76, Thomas, U. S. A. 
White, A., Handler, D. and Smith, E. L. Principles of biochemistry, 1968, 
McGraw-Hill, New York and London. 
White, D. D., Stewart, S. and Wood, G. C. Febs. Lett., 1973,33,305. 
Widman, M., Nilsson, I. M., Nilsson, J. L. G., AgurelL, S., Borg, H. and 
Grandstrand, B. J. Pharm. Pharmacol., 1973,25,453_ 
WiegLand, Von U-W., Weder, H. G. , Haller, R. Arzneimittel-Forschung, 
1975,25,1008. 
Williams, E. J., I-Lrskovits, T. T. and Laskowski, M. i: l. Cher;., 1955, 
240,3574. 
Wilson, W. D. and Foster, J. F. Biochemistry (U. S. A. ) 1971,10,1772. 
Wilson, A. G. E. Ph. D. Thesis, l971, University of "-trey. 
Wilting, J., Van der Houwen, O. A. G. J., Perrin, J. H. and Braams, R. 
Pharmaceut. Weekbi., 19/6,110,1264. 
Windorfer, A., Kuenzer, W. and Urbanek, R. Eur. J. CI;, 1. Pharrnacol., 1974, 
7,227. 
Wiseman, E. H. and Nelson, E. J. Pharrn. Sci., 1964,53,992. 
Wishina, A. Fed. Proc., 1964,23,160. 
Wishina, A. and Pinder, T. W. Biochem., 1964,3,1377. 
Wong, K. P. and Foster, J. F. Biochem. , 1969,8,401)(',. 
Yanari, S. and Bovey, F. A. J. Biol. Chem., 1960,235,2818. 
Zakrzewski, K. and Goch, H. Biochem., 1968,7,1835. 
Zia, H. and Price, J. C. J. Pharm. Sci., 1975,64,117 ?. 
Zia, H. and Price, J. C. J. Pharm. Sci., 1976,65,226. 
Zubrod, C. B., Kennedy, T. J. and Shannon, J. A. J. Cli ,. invest, 1948,27,114. 
